Compounds as masp-2 inhibitor, pharmaceutical composition and preparation method and use thereof

Abstract

This invention relates to compounds with inhibitory activity on the complement lectin pathway, their preparation methods, and their applications. Specifically, this invention relates to a compound represented by general formula (I'), its pharmaceutically acceptable salt, its preparation method, and its application as a MASP-2 inhibitor, particularly in the preparation of medicaments for treating IgA nephropathy, TA-TMA, aHUS, lupus nephritis, and other diseases.

Description

Compounds, pharmaceutical compositions as MASP-2 inhibitors and preparation methods and uses thereof This application claims to be submitted to the State Intellectual Property Office of China on January 28, 2022. The patent application number is 202210116158. priority of the earlier application, the entire text of which is incorporated into this application by reference. The present invention belongs to the field of medicine, and specifically relates to compounds as MASP-2 inhibitors, pharmaceutical compositions and their preparation methods and uses. In addition to Ig molecules in blood or body fluids, another type of macromolecules involved in immune effects is also found, called complement molecules. Its chemical composition is a group of immunoglobulins with enzymatic activity, accounting for approximately 10% of the total serum globulin. Complement molecules are extremely unstable and most are heat-sensitive and lose activity in 30 minutes at 56°C. Early immunological research found that this substance is essential in immune hemolytic reactions and bacteriolytic reactions, so it is called complement. Research in recent years has proven that complement consists of 11 serum proteins, which are named C1...C9 according to the order of their discovery. Among them, C1 is composed of three subunits: Clq, Clr, and Cls, collectively called the complement system. The complement system can be initiated through three independent and intersecting pathways: the classical pathway, the alternative pathway, and the lectin pathway. The three initiation pathways of the complement system include the classic pathway: C1q, C1r, C1s, C4, C2, C3, C5, C6-9; the mannan-binding lectin pathway (MBL pathway): MBL, MASP1-2, C4, C2 , C3, C5, C6-9 and alternative pathway (alternative pathway): C3, factor B, factor D, factor P (properdin), C5, C6-9. The lectin pathway is initiated through mannose-binding lectin (MBL), collectin 11 (CL-K1), and ficolins (Ficolin-1, Ficolin-2, and Ficolin-3) in the form of pathogen-associated molecular patterns (PAMPs). (D-mannose, N-acetyl-D-glucosamine or acetyl) binding, after binding to the target molecule, MBL, CL-K1 and ficolins interact with MBL-related serine protease 1 and 2 (MASP-1 and MASP-2) form a complex and cleave C4 and C2 to form C3 convertase (C4b2a), which subsequently initiates the complement cascade leading to opsonization, phagocytosis and destruction of target microorganisms through the formation of the membrane attack complex lysis. Mannose-binding lectin-associated serine protease 2 (MASP-2) is an effector enzyme of the lectin pathway of the complement system. Currently, the most rapidly researched projects on the complement lectin pathway are all related to antibodies. For example, the MASP-2-targeted monoclonal antibody Narsoplimab (OMS-721) has been granted breakthrough drug designation in the United States for the treatment of high-risk HSCT-TMA patients, the prevention of complement-mediated thrombotic microangiopathy (TMA), and the treatment of HSCT-TMA. Orphan drug designation, granted in the EU for the treatment of hematopoietic stem cell transplantation (HSCT). Currently, Narsoplimab is also in Phase III clinical development and is being developed for IgA nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS). Previously, the drug was granted orphan drug and breakthrough drug qualifications for the treatment of IgAN in the United States, fast track qualification for the treatment of aHUS, and orphan drug qualification for the treatment of IgAN in the EU. MASP‑2-dependent complement initiation has been suggested to contribute to the pathogenesis of many acute and chronic disease states. Therefore, there is an ongoing need for small molecule compounds suitable for the treatment of patients with diseases and conditions associated with the MASP‑2 complement pathway. In order to improve the above technical problems, the present invention provides a compound represented by formula (I'), its racemate, stereoisomer, tautomer, nitrogen oxide or its pharmaceutically acceptable salt : (I’) where: Cy 3 Selected from or ; Z is selected from CR 2 or N; R 1 ,R 2 and R 3 independently selected from H, halogen, -NH 2 ,-OH,-NO 2 ,-CN,C 1-6 Alkyl, C 1-6 Aminoalkyl or C 1-6 Alkoxy; X is selected from CR 4 orN;R 4 Selected from H, Halogen, C 1-6 Alkyl or C 1-6 Alkoxy; Y is selected from -CH 2 -,-C(C 1-3 alkyl) 2 -, -NH-, -O- or -S-; m is selected from 0, 1, 2 or 3; each R is the same or different and independently selected from H, halogen, C 1-6 Alkyl or C 1-6 Alkoxy; p is selected from 0, 1, 2, 3 or 4; R 5 Selected from H, C 1-6 Alkyl, C 2-6 Alkynyl, C 1-6 Haloalkyl or C 3-6 Cycloalkyl; R 5’ Choose from H or C 1-6 Alkyl; or R 5 and R 5’ Together with the carbon atoms they are attached to form C 3-6 Cycloalkyl; R 6 Choose from H or C 1-6 Alkyl; or R 5 and R 6 Together with the C and N atoms to which they are attached, they form a 3-12 membered heterocycloalkyl group which is unsubstituted or optionally substituted by 1, 2 or 3 R 5a replaced; each R 5a Same or different, independently selected from halogen, C 1-6 Alkyl, -OH, -NO 2 , -CN, side oxygen group (=O), C 2-6 Alkenyl, C 2-6 Alkynyl, C 1‑6 Haloalkyl, C 1-6 Alkoxy or C 1-6 Haloalkoxy; or R on the same carbon or two adjacent carbons 5a Together with the carbon atoms they are attached to form C 3-6 Cycloalkyl, the C 3-6 Cycloalkyl is unsubstituted or optionally substituted by 1, 2 or 3 halogens; Cy 1 Selected from unsubstituted or optionally 1, 2, 3 or 4 R 7 Substituted following groups: 5-8 membered heterocyclyl or 5-6 membered heteroaryl; each R 7 The same or different, independently selected from H, pendant oxygen (=O), halogen or C 1-6 Alkyl; L is selected from -(CR a R b ) q -or-(CR a R b ) q -O-, q is selected from 0, 1 or 2, each R a and R b Same or different, independently selected from H, halogen or C 1-6 Alkyl, or R a and R b Together with the carbon atoms they are attached to form C 3-6 Cycloalkyl; Cy 2 Selected from unsubstituted or optionally 1, 2, 3 or 4 R 8 Substituted following groups: C 6‑10 Aryl, 5-10-membered heteroaryl, C 3‑10 Cycloalkyl or 5-12 membered heterocyclyl; each R 8 Same or different, independently selected from -CN, halogen, C 1‑6 Alkyl, C 1‑6 Alkoxy, C 1‑6 Haloalkyl, C 1‑6 Haloalkoxy, C 3‑10 Cycloalkyl, C 6‑10 Aryl or 5-10 membered heteroaryl. According to an embodiment of the present invention, the compound represented by formula (I') has the structure represented by the following formula (I): (I) where: R 1 ,R 2 and R 3 independently selected from H, halogen, -NH 2 ,-OH,-NO 2 ,-CN,C 1-6 Alkyl, C 1-6 Aminoalkyl or C 1-6 Alkoxy; X is selected from CR 4 orN;R 4 Selected from H, Halogen, C 1-6 Alkyl or C 1-6 Alkoxy; Y is selected from -CH 2 -,-C(C 1-3 alkyl) 2 -, -NH-, -O- or -S-; m is selected from 0, 1, 2 or 3; each R is the same or different and independently selected from H, halogen, C 1-6 Alkyl or C 1-6 Alkoxy; p is selected from 0, 1, 2, 3 or 4; R 5 Selected from H, C 1-6 Alkyl, C 2-6 Alkynyl, C 1-6 Haloalkyl or C 3-6 Cycloalkyl; R 6 Choose from H or C 1-6 Alkyl, or R 5 and R 6 Together with the C and N atoms to which they are attached, they form a 3-12 membered heterocycloalkyl group which is unsubstituted or optionally substituted by 1, 2 or 3 R 5a replaced; each R 5a Same or different, independently selected from halogen, C 1-6 Alkyl, -OH, -NO 2 , -CN, side oxygen group (=O), C 2-6 Alkenyl, C 2-6 Alkynyl, C 1‑6 Haloalkyl, C 1-6 Alkoxy or C 1-6 Haloalkoxy; or R on the same carbon or two adjacent carbons 5a Together with the carbon atoms they are attached to form C 3-6 Cycloalkyl, the C 3-6 Cycloalkyl is unsubstituted or optionally substituted by 1, 2 or 3 halogens; Cy 1 Selected from unsubstituted or optionally 1, 2, 3 or 4 R 7 Substituted following groups: 5-8 membered heterocyclyl or 5-6 membered heteroaryl; each R 7 The same or different, independently selected from H, pendant oxygen (=O), halogen or C 1-6 Alkyl; L is selected from -(CR a R b ) q -or-(CR a R b ) q -O-, q is chosen from 0, 1 or 2, each R a and R b Same or different, independently selected from H, halogen or C 1-6 Alkyl, or R a and R b Together with the carbon atoms they are attached to form C 3-6 Cycloalkyl; Cy 2 Selected from unsubstituted or optionally 1, 2, 3 or 4 R 8 Substituted following groups: C 6‑10 Aryl, 5-10-membered heteroaryl, C 3‑10 Cycloalkyl or 5-12 membered heterocyclyl; each R 8 Same or different, independently selected from -CN, halogen, C 1‑6 Alkyl, C 1‑6 Alkoxy, C 1‑6 Haloalkyl, C 1‑6 Haloalkoxy, C 3‑10 Cycloalkyl, C 6‑10 Aryl or 5-10 membered heteroaryl. According to an embodiment of the present invention, the compound represented by formula (I') has the structure represented by the following formula (I): (I) where: R 1 ,R 2 and R 3 independently selected from H, halogen, -NH 2 ,-OH,-NO 2 ,-CN,C 1-6 Alkyl or C 1-6 Alkoxy; X is selected from CR 4 orN;R 4 Selected from H, Halogen, C 1-6 Alkyl or C 1-6 Alkoxy; Y is selected from -CH 2 -, -NH-, -O- or -S-; m is selected from 0, 1, 2 or 3; each R is the same or different and independently selected from H, halogen, C 1-6 Alkyl or C 1-6 Alkoxy; p is selected from 0, 1, 2, 3 or 4; R 5 and R 6 independently selected from H or C 1-6 Alkyl, or R 5 and R 6 Together with the C and N atoms to which they are attached, they form a 3-12 membered heterocycloalkyl group; Cy 1 Selected from unsubstituted or optionally 1, 2, 3 or 4 R 7 Substituted following groups: 5-6 membered heterocyclyl or 5-6 membered heteroaryl; each R 7 Same or different, independently selected from H, halogen or C 1-6 Alkyl; L represents -(CR a R b ) p -, p is selected from 0, 1 or 2, each R a and R b Same or different, independently selected from H, halogen or C 1-6 Alkyl, or R a and R b Together with the carbon atoms they are attached to form C 3-6 Cycloalkyl; Cy 2 Selected from unsubstituted or optionally 1, 2, 3 or 4 R 8 Substituted following groups: C 6‑10 Aryl, 5-10-membered heteroaryl, C 3‑10 Cycloalkyl or 5-12 membered heterocyclyl; each R 8 Same or different, independently selected from CN, halogen, C 1‑6 Alkyl, C 1‑6 Alkoxy, C 1‑6 Haloalkyl, C 1‑6 Haloalkoxy, C 3‑10 Cycloalkyl, C 6‑10 Aryl or 5-10 membered heteroaryl. According to an embodiment of the invention, when Cy 1 Through the chiral carbon atoms on its ring and -C(=O)NR 6 - When connected, the compound represented by formula (I’) has the structure represented by the following formula (II): (II), where, R 5 Selected from C 1-6 Alkyl, C 2-6 Alkynyl, C 1-6 Haloalkyl or C 3-6 Cycloalkyl; m, p, X, Y, R, R 1 ,R 2 ,R 3 ,R 6 ,L,Cy 1 and Cy 2 As defined herein. According to an embodiment of the invention, when Cy 1 Through the chiral carbon atoms on its ring and -C(=O)NR 6 - When connected, the compound represented by formula (I) has the structure represented by the following formula (II): (II), where, R 5 for C 1-6 Alkyl; m, p, X, Y, R, R 1 ,R 2 ,R 3 ,R 6 ,L,Cy 1 and Cy 2 As defined herein. According to an embodiment of the present invention, the compound represented by formula (I’) has a structure represented by any of the following formulas (I-a) ~ (I-j’): (I-a)、 (I-b)、 (I-c), (I-d’)、 (I-e)、 (I-f), , (I-g’)、 (I-h’)、 (I-i’)or (I-j’), where R 5 Selected from C 1-3 Alkyl, C 2-3 Alkynyl, C 1-3 Haloalkyl or C 3-4 Cycloalkyl; R 5a independently selected from halogen, C 1-3 Alkyl, -OH, -NO 2 , -CN, side oxygen group (=O), C 1‑3 Haloalkyl, C 1-3 Alkoxy or C 1-3 Haloalkoxy; or R on the same carbon or two adjacent carbons 5a Together with the carbon atoms they are attached to form C 3-6 Cycloalkyl, the C 3-6 Cycloalkyl is unsubstituted or optionally substituted by 1, 2 or 3 halogens; n is 0, 1, 2 or 3; m, X, R 1 ,R 2 ,R 3 ,R 7 , L and Cy 2 As defined herein. According to an embodiment of the present invention, the compound represented by formula (I) has a structure represented by any of the following formulas (I-a) ~ (I-j): (I-a)、 (I-b)、 (I-c), (I-d)、 (I-e)、 (I-f)、 (I-g)、 (I-h)、 (I-i) or (I-j), where, R 5 for C 1-3 Alkyl; m, X, R 1 ,R 2 ,R 3 ,R 5 ,R 7 , L and Cy 2 As defined herein. According to an embodiment of the present invention, the compound represented by formula (I’) has a structure represented by any of the following formulas (I-l) to (I-u’): (I-l)、 (I-m)、 (I-n)、 (I-o’)、 (I-p), (I-q)、 (I-r’)、 (I-s’), (I-t’)or (I-u’), where R 5 Selected from C 1-3 Alkyl, C 2-3 Alkynyl, C 1-3 Haloalkyl or C 3-4 Cycloalkyl; R 5a independently selected from halogen, C 1-3 Alkyl, -OH, -NO 2 , -CN, side oxygen group (=O), C 1‑3 Haloalkyl, C 1-3 Alkoxy or C 1-3 Haloalkoxy; or R on the same carbon or two adjacent carbons 5a Together with the carbon atoms they are attached to form C 3-6 Cycloalkyl, the C 3-6 Cycloalkyl is unsubstituted or optionally substituted by 1, 2 or 3 halogens; n is 0, 1, 2 or 3; m, X, R 1 ,R 2 ,R 3 ,R 7 , L and Cy 2 As defined herein. According to an embodiment of the present invention, the compound represented by formula (I) has a structure represented by any of the following formulas (I-l) to (I-u): (I-l)、 (I-m)、 (I-n)、 (I-o)、 (I-p), (I-q)、 (I-r)、 (I-s), (I-t)or (I-u), where R 5 for C 1-3 Alkyl; m, X, R 1 ,R 2 ,R 3 ,R 5 ,R 7 , L and Cy 2 As defined herein. According to an embodiment of the present invention, the compound represented by formula (I’) has a structure represented by any of the following formulas (I-v) ~ (I-z’): (I-v)、 (I-w)、 (I-x)、 (I-y)、 (I-z)、 (I-v’)、 (I-w’)、 (I-x’)、 (I-y’)or (I-z’), where R 5 Selected from methyl, ethyl, ethynyl, propynyl, -CH 2 F.-CHF 2 ,-CF 3 Or cyclopropyl; R 5a independently selected from halogen, methyl, ethyl, -CH 2 F.-CHF 2 ,-CF 3 Or methoxy; or R on the same carbon or two adjacent carbons 5a Together with the carbon atoms to which they are connected, they form cyclopropyl or cyclobutyl, which are unsubstituted or optionally substituted by 1, 2 or 3 halogens; n is 0, 1, 2 or 3; m, X, R 1 ,R 2 ,R 3 ,R 7 , L and Cy 2 As defined herein. According to embodiments of the invention, Cy 3 Selected from the structural formulas shown below: , , , or . According to embodiments of the invention, Cy 3 Selected from the structural formulas shown below: , , , , , , , , or . According to embodiments of the invention, Cy 3 Selected from the structural formulas shown below: , , , , , , , , , , , , , , , , , , , , , , , or . According to an embodiment of the invention, R 5 Selected from H, C 1-3 Alkyl, C 2-3 Alkynyl, C 1-3 Haloalkyl or C 3-4 Cycloalkyl; R 5’ Choose from H or C 1-3 Alkyl; or R 5 and R 5’ Together with the carbon atoms they are attached to form C 3-4 Cycloalkyl. According to an embodiment of the invention, R 5 Selected from H, methyl, ethyl, ethynyl, propynyl, -CH 2 F.-CHF 2 ,-CF 3 Or cyclopropyl; R 5’ Selected from H, methyl or ethyl; or R 5 and R 5’ Together with the carbon atom to which they are attached, they form a cyclopropyl group. According to an embodiment of the invention, R 1 ,R 2 and R 3 Independently selected from H, F, Cl, Br, -NH 2 , -OH, -CN, methyl, ethyl, -CH 2 NH 2 Or methoxy. According to an embodiment of the invention, R 1 Selected from H, F, Cl, Br, -NH 2 Or methyl. According to an embodiment of the invention, R 2 Selected from H, F, Cl, Br, -CN, methyl, ethyl or methoxy. According to an embodiment of the invention, R 3 Selected from H, F, -NH 2 , -OH, -CH 2 NH 2 Or methoxy. According to an embodiment of the invention, X is selected from CR 4 orN;R 4 Selected from H, halogen, methyl or ethyl. According to an embodiment of the invention, Y is selected from -CH 2 -, -C(CH 3 ) 2 -, -NH- or -O-; m is selected from 0, 1 or 2. According to an embodiment of the invention, each R is the same or different and is independently selected from H, halogen, C 1-3 Alkyl or C 1-3 Alkoxy; p is selected from 0, 1 or 2. According to an embodiment of the invention, R 5 Selected from H, methyl or ethyl. According to an embodiment of the invention, R 6 Selected from H, methyl or ethyl. According to an embodiment of the invention, R 5 and R 6 Together with the C and N atoms to which they are attached, they form a 4-, 5- or 6-membered heterocycloalkyl group, which is unsubstituted or optionally substituted by 1, 2 or 3 R’s 5a replaced; R 5a Independently selected from F, Cl, Br, methyl or ethyl; or R on the same carbon or two adjacent carbons 5a Together with the carbon atoms to which they are attached, they form cyclopropyl or cyclobutyl, which are unsubstituted or optionally substituted by 1, 2 or 3 halogens. According to an embodiment of the invention, R 5 and R 6 Together with the C and N atoms to which they are attached, they form a 4-, 5- or 6-membered heterocycloalkyl group. According to an embodiment of the invention, R 5 and R 6 Together with the C and N atoms to which they are attached, they form the following structure: , , , , , , , , , , or ;The structure formed is preferably selected from: , , , , , , , , , , , , or . According to embodiments of the invention, L is absent or selected from -C(R a )(R b )-, -O- or -C(R a )(R b )-O-, R a and R b are independently H, halogen, methyl or ethyl, or R a and R b Together with the carbon atom to which they are attached, they form cyclopropyl or cyclobutyl. According to an embodiment of the invention, L is absent or selected from -CH 2- ,-CH(CH 3 )-,-CF 2 -, -O-, -CH 2 -O-, -CH(CH 3 )-O-or ; According to an embodiment of the present invention, Cy 1 Selected from unsubstituted or substituted by 1 or 2 R 7 The following substituted groups: tetrahydropyrrolyl, 2,5-dihydro-1H-pyrrolyl, pyrrolyl, piperidinyl, 1,2,3,6-tetrahydropyridyl, 1,2,5,6 - Tetrahydropyridyl, piperazinyl, 4-azaspiro[2.5]octyl, 1,2-dihydropyridyl or 1,4-dihydropyrazinyl; each R 7 The same or different, independently selected from H, pendant oxygen (=O), F, Cl or CH 3 . According to embodiments of the invention, Cy 1 Selected from the structures shown below: , , , , , , , , , , , , or ; Preferably selected from: , , , , , , , , , , , , , , , , , , , , or . According to embodiments of the invention, Cy 2 Selected from unsubstituted or optionally 1, 2, 3 or 4 R 8 Substituted following groups: C 6‑10 Aryl, 5-9-membered heteroaryl, or 6-11-membered heterocyclyl; each R 8 Same or different, independently selected from -CN, F, Br, Cl, -CH 2 F.-CHF 2 ,-CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, methoxy, ethoxy, phenyl, pyridyl or trifluoromethoxy. According to embodiments of the invention, Cy 2 Selected from unsubstituted or optionally 1, 2, 3 or 4 R 8 Substituted following groups: C 6‑10 Aryl, 6-9-membered heteroaryl or 6-11-membered heterocyclyl; each R 8 Same or different, independently selected from F, Br, Cl, CH 2 F. CHF 2 ,CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, methoxy, ethoxy, phenyl, pyridyl or trifluoromethoxy. According to embodiments of the invention, Cy 2 Selected from unsubstituted or substituted by 1, 2, 3 or 4 R 8 Substituted following groups: phenyl, naphthyl, pyrrolyl, pyridyl, benzothiazolyl, piperidinyl, 6-azaspiro[2.5]octyl, 7-azaspiro[3.5]nonyl , 8-azaspiro[4.5]decyl or 3-azaspiro[5.5]undecyl; each R 8 Same or different, independently selected from F, Br, Cl, CH 2 F. CHF 2 ,CF 3 , methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, methoxy, ethoxy, phenyl, pyridyl or trifluoromethoxy. According to embodiments of the invention, Cy 2 Selected from the structures shown below: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or . According to embodiments of the invention, Cy 3 Selected from the structures shown below: , , , or ; R 1 ,R 2 and R 3 Independently selected from H, F, Cl, Br, -NH 2 ,-OH,-CN,C 1-3 Alkyl or C 1-3 Aminoalkyl; R 4 Selected from H, Halogen or C 1-3 Alkyl; Y is selected from -CH 2 -, -C(CH 3 ) 2 -, -NH-, -O- or -S-; m is selected from 0, 1 or 2; each R is the same or different and independently selected from H, halogen or C 1-3 Alkyl; p is selected from 0, 1 or 2; R 5 Selected from H, C 1-3 Alkyl, C 2-3 Alkynyl, C 1-3 Haloalkyl or C 3-4 Cycloalkyl; R 5’ Choose from H or C 1-3 Alkyl; or R 5 and R 5’ Together with the carbon atoms they are attached to form C 3-4 Cycloalkyl; R 6 Choose from H or C 1-3 Alkyl; or, R 5 and R 6 Together with the C and N atoms to which they are attached, they form a 4-, 5- or 6-membered heterocycloalkyl group, which is unsubstituted or optionally substituted by 1, 2 or 3 R’s 5a replaced; R 5a Independently selected from F, Cl, Br, methyl or ethyl; or R on the same carbon or two adjacent carbons 5a Together with the carbon atoms to which they are attached, they form cyclopropyl or cyclobutyl, which are unsubstituted or optionally substituted by 1, 2 or 3 halogens; L is absent or selected from -C(R a )(R b )-, -O- or -C(R a )(R b )-O-, R a and R b independently selected from H, halogen or C 1-3 Alkyl, or R a and R b Together with the carbon atom to which they are attached, they form a cyclopropyl group; Cy 1 Selected from unsubstituted or substituted by 1 or 2 R 7 The following substituted groups: tetrahydropyrrolyl, 2,5-dihydro-1H-pyrrolyl, pyrrolyl, piperidinyl, 1,2,3,6-tetrahydropyridyl, 1,2,5,6 -Tetrahydropyridyl, piperazinyl, 4-azaspiro[2.5]octyl, 1,2-dihydropyridyl or 1,4-dihydropyrazinyl; each R 7 Identical or different, independently selected from H, side oxygen (=O), F or Cl; Cy 2 Selected from unsubstituted or substituted by 1, 2, 3 or 4 R 8 Substituted following groups: phenyl, naphthyl, pyrrolyl, pyridyl, benzothiazolyl, piperidinyl, 6-azaspiro[2.5]octyl, 7-azaspiro[3.5]nonyl , 8-azaspiro[4.5]decyl or 3-azaspiro[5.5]undecyl; each R 8 Identical or different, independently selected from -CN, F, Cl, -CH 2 F.-CHF 2 ,CF 3 , methyl, ethyl, n-propyl, isopropyl, tert-butyl, methoxy, phenyl, pyridyl or trifluoromethoxy. According to an embodiment of the invention, R 1 ,R 2 and R 3 Independently selected from H, F, Cl, Br, -NH 2 , -OH or C 1-3 Alkyl; X is selected from CR 4 or N; R 4 Selected from H, Halogen or C 1-3 Alkyl; Y can be selected from -CH 2 - or -NH-; m is selected from 0, 1 or 2; each R can be the same or different and independently selected from H, halogen or C 1-3 Alkyl; p can be selected from 0, 1 or 2; R 5 Can be selected from H or C 1-3 Alkyl; R 6 Can be selected from H or C 1-3 Alkyl; or, R 5 and R 6 Together with the C and N atoms to which they are attached, they form a 4-, 5- or 6-membered heterocycloalkyl group; L may be absent or selected from -C(R a )(R b )-, R a and R b Independently of each other, H, Halogen or C 1-3 Alkyl, or R a and R b Together with the carbon atom to which they are attached, they form a cyclopropyl group; Cy 1 Can be selected from unsubstituted or substituted by 1 or 2 R 7 The following substituted groups: tetrahydropyrrolyl, 2,5-dihydro-1H-pyrrolyl, pyrrolyl, piperidinyl, 1,2,3,6-tetrahydropyridyl, 1,2,5,6 -Tetrahydropyridyl or piperazinyl; R 7 Selected from H, F or Cl; Cy 2 Can be selected from unsubstituted or 1, 2, 3 or 4 R 8 The following substituted groups: phenyl, naphthyl, pyridyl, benzothiazolyl, piperidinyl, 6-azaspiro[2.5]octyl, 7-azaspiro[3.5]nonyl, 8- azaspiro[4.5]decyl or 3-azaspiro[5.5]undecyl; each R 8 Can be the same or different, independently selected from F, Cl, CF 3 , methyl, isopropyl, tert-butyl, methoxy, phenyl, pyridyl or trifluoromethoxy. According to embodiments of the invention, Cy 3 Selected from the structures shown below: , , , or ; R 1 Selected from H, F, Cl, -NH 2 or methyl; R 2 Selected from H, F, Cl, -CN or methyl; R 3 Selected from H, F, -NH 2 , -OH, -CH 2 NH 2 or methoxy; R 4 Selected from H or F; Y selected from -CH 2 -, -C(CH 3 ) 2 -, -NH- or -O-; m is 1 or 2; R is selected from H, methyl or ethyl; R 5 Selected from H, methyl, ethyl, ethynyl, propynyl, -CH 2 F.-CHF 2 ,-CF 3 Or cyclopropyl; R 5’ Selected from H, methyl or ethyl; or R 5 and R 5’ Together with the carbon atoms to which they are attached they form a cyclopropyl group; R 6 is H; or, R 5 and R 6 Together with the C and N atoms to which they are attached, they form the following structure: , , , , , , , , , , or ;The structure formed is preferably selected from: , , , , , , , , , , , , or ; L can be absent or selected from -CH 2 -, -CH(CH 3 )-,-CF 2 -, -O-, -CH 2 -O-or ;Cy 1 Can be chosen from the structures shown below: , , , , , , , , , , , or ; Preferably selected from: , , , , , , , , , , , , , , , , , , , , or ; and / or Cy 2 Can be chosen from the structures shown below: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or . According to an embodiment of the invention, R 1 Can be selected from H or F; R 2 Can be selected from H, F, Cl or methyl; R 3 Can be selected from -NH 2 , -OH or methoxy; X can be selected from CR 4 orN;R 4 Selected from H or F; Y can be selected from -CH 2 -; m is 1 or 2; R can be selected from H; R 5 Can be selected from H or methyl; R 6 Can be selected from H; or, R 5 and R 6 Together with the C and N atoms to which they are attached, they form the following structure: , or ;The structure formed is preferably selected from: , or ; L can be absent or selected from -CH 2 -, -CH(CH 3 )-,-CF 2 -or ;Cy 1 Can be chosen from the structures shown below: , , , , , , or ; Preferably selected from: , , , , , , , , , or ; and / or Cy 2 Can be chosen from the structures shown below: , , , , , , , , , , , , , , , , , , , , , , , , , , , or . According to an embodiment of the present invention, the compound represented by formula (I') is selected from the structures shown below: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or ; Preferably, the compound represented by formula (I') is selected from the following structures: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or . The present invention also provides a method for preparing the compound represented by formula (I'), which includes the following steps: Compound I-A' and compound I-B' undergo a condensation reaction to generate compound I-1', and then compound I-1' is deprotected. Obtain the compound represented by formula (I'); Or compound I-C’ and compound I-D’ undergo a condensation reaction to generate compound I-1’, and then compound I-1’ is deprotected to obtain a compound represented by formula (I’); Among them, R 5 ,R 5’ ,R 6 ,L,Cy 1 ,Cy 2 and Cy 3 Independently of each other have the definitions set forth herein; Cy is Cy 1 A group in which the active group is protected by PG; PG is a protecting group, such as an amino protecting group, such as tert-butoxycarbonyl. The present invention also provides a method for preparing a compound represented by formula (I), which includes the following steps: compound I-A and compound I-B undergo a condensation reaction to generate compound I-1, and then compound I-1 is deprotected to obtain a compound represented by formula (I). ; Or a condensation reaction occurs between compound I-C and compound I-D to generate compound I-1, and then compound I-1 is deprotected to obtain a compound represented by formula (I); Among them, R 1 ,R 2 ,R 3 ,R 5 ,R 6 ,R,X,Y,L,Cy 1 ,Cy 2 , m and p independently of each other have the definitions set forth herein; Cy is Cy 1 A group in which the active group is protected by PG; PG is a protecting group, such as an amino protecting group, such as tert-butoxycarbonyl. The invention also provides a compound represented by formulas (I-A) to (I-G), its racemate, stereoisomer or its hydrochloride: (I-A)、 (I-C)、 (I-E)、 (I-F) or (I-G), where R 1 ,R 2 ,R 3 ,R 5 ,R 6 , R, X, Y, m and p independently have the definitions described herein; Preferably, the compound represented by formula (I-A) is selected from the following compounds: , , , , , , , , , or . The present invention also provides a pharmaceutical composition, which contains a therapeutically effective amount of the compound represented by formula (I'), its racemate, stereoisomer, tautomer, nitrogen oxide or their pharmaceutically acceptable Accept at least one of the salts. According to an embodiment of the present invention, the pharmaceutical composition further includes at least one pharmaceutically acceptable excipient. These pharmaceutical compositions can be prepared in a manner well known in the pharmaceutical art and they can be administered by a variety of routes, depending on whether local or systemic treatment is desired and the area to be treated. May be administered topically (e.g., transdermal, cutaneous, ocular, and mucosal including intranasal, vaginal, and rectal delivery), pulmonary (e.g., by inhalation or insufflation of a powder or aerosol, including by nebulizer; intratracheal, intranasal), Oral or parenteral administration. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, such as intrathecal or intracerebroventricular administration. Administration may be parenteral as a single bolus or may be administered, for example, by a continuous infusion pump. Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids, powder formulations, and powders. Conventional pharmaceutical carriers, water, powder or oily bases, thickening agents, and the like may be necessary or desirable. In preparing the pharmaceutical compositions of the present invention, the active ingredients are usually mixed with auxiliary materials, diluted with auxiliary materials or packed into such carriers in the form of capsules, sachets, paper or other containers. When an excipient is used as a diluent, it can be a solid, semi-solid or liquid material that serves as a solvent, carrier or medium for the active ingredient. Accordingly, the pharmaceutical composition may be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (solid or dissolved in a liquid vehicle); ointments, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders containing, for example, up to 10% by weight of the active compound. Some examples of suitable excipients include lactose, glucose, sucrose, sorbitol, mannitol, starch, acacia, calcium phosphate, alginate, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone , cellulose, water, syrup and methylcellulose. The auxiliary materials can also be selected from: lubricants such as talc, sodium stearate, magnesium stearate, sodium oleate, sodium benzoate, sodium acetate, sodium chloride and mineral oil; wetting agents; emulsifiers and suspending agents; Preservatives such as methyl benzoate and hydroxypropyl benzoate; sweeteners and flavoring agents. The compositions of the present invention may be formulated to provide immediate, sustained or delayed release of the active ingredient after administration to the patient using methods known in the art. The compositions may be formulated in unit dosage form, each dosage containing about 5 to 1000 mg, more usually about 100 to 500 mg of active ingredient. The term "unit dosage form" refers to physically discrete unit dosage units suitable for use in human patients and other mammals, each unit containing a predetermined quantity of activity calculated to produce the desired therapeutic effect in admixture with a suitable pharmaceutical excipient. substance. The effective dosage of the active compound can range over a wide range and is usually administered in a pharmaceutically effective amount. However, it is understood that the actual amount of compound administered will generally be determined by the physician based on relevant circumstances, including the condition being treated, the route of administration chosen, the actual compound administered; the age, weight, and response of the individual patient; the nature of the patient's symptoms; Severity etc. For the preparation of solid compositions, such as tablets, the principal active ingredients are mixed with pharmaceutical excipients to form a solid preformulation composition containing a homogeneous mixture of the compounds of the invention. When these preformulated compositions are referred to as homogeneous, it is meant that the active ingredient is generally evenly distributed throughout the composition such that the composition can be readily divided into equally effective unit dosage forms such as tablets, pills and capsules. The solid preformulation is then divided into unit dosage forms of the above type containing, for example, about 0.1 to 1000 mg of the active ingredient of the invention. Tablets or pills of the present invention may be coated or compounded to provide dosage forms that provide the advantage of long-acting action. For example, tablets or pills contain internal and external dosage components, the latter being a coated form of the former. The two components can be separated by an enteric layer, which serves to prevent disintegration in the stomach, allowing intact passage of the inner component through the duodenum or delayed release. A variety of materials may be used for such enteric layers or coatings, including various polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate. Liquid forms for oral or injectable administration into which the compounds and pharmaceutical compositions of this invention may be incorporated include aqueous solutions, suitably flavored syrups, aqueous or oily suspensions; and edible oils such as cottonseed oil, sesame oil, Flavored emulsions of coconut oil or peanut oil; and elixirs and similar medicinal vehicles. Pharmaceutical compositions for inhalation or insufflation include solutions, suspensions, and powders dissolved in pharmaceutically acceptable water or organic solvents or mixtures thereof. Liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described above. In certain embodiments, the pharmaceutical compositions are administered by the oral or nasal respiratory route to achieve local or systemic effects. The composition can be atomized by using an inert gas. The nebulized solution can be inhaled directly from the nebulizing device, or the nebulizing device can be connected to a mask curtain or intermittent positive pressure ventilator. Pharmaceutical compositions in the form of solutions, suspensions or powders may be administered orally or nasally from a device that delivers the formulation in an appropriate manner. The amount of compound or pharmaceutical composition administered to a patient is not fixed and depends on the drug administered, the purpose of administration such as prevention or treatment; the patient's condition, the mode of administration, etc. In therapeutic applications, a patient suffering from a disease may be administered an amount of the composition sufficient to cure or at least partially inhibit symptoms of the disease and its complications. The effective dose will depend on the disease state treated and the judgment of the attending clinician, which judgment will depend on such factors as the severity of the disease, the age, weight, and general condition of the patient. The pharmaceutical composition administered to the patient may be in the form of a pharmaceutical composition as described above. These compositions can be sterilized by conventional sterilization techniques or can be filtered. The aqueous solution may be used as is in packaged form or may be lyophilized and the lyophilized preparation mixed with a sterile aqueous vehicle prior to administration. The pH of the compound preparation is usually 3 to 11, more preferably 5 to 9, and most preferably 7 to 8. It will be appreciated that the use of certain of the foregoing excipients, carriers or stabilizers may result in the formation of pharmaceutical salts. Therapeutic dosages of the compounds of the present invention may be determined based, for example, on the specific use of the treatment, the manner in which the compound is administered, the health and condition of the patient, and the judgment of the prescribing physician. The proportions or concentrations of the compounds of the present invention in pharmaceutical compositions may not be fixed and depend on a variety of factors, including dosage, chemical properties (eg, hydrophobicity), and route of administration. For example, the compounds of the present invention can be provided for parenteral administration in a physiologically buffered aqueous solution containing about 0.1 to 10% (w / v) of the compound. Some typical dosage ranges are about 1 μg / kg to about 1 g / kg body weight per day. In certain embodiments, the dosage range is about 1 mg / kg to about 2000 mg / kg body weight / day, preferably about 50 mg / kg to about 500 mg / kg body weight / day. The dosage will likely depend on such variables as the type and extent of the disease or condition, the general health of the particular patient, the relative biological potency of the compound selected, the formulation of the excipients, and their route of administration. Effective doses can be obtained by extrapolation of dose-response curves derived from in vitro or animal model testing systems. The present invention also provides compounds represented by formula (I'), their racemates, stereoisomers, tautomers, nitrogen oxides or their pharmaceutically acceptable salts and the above pharmaceutical compositions in the preparation of medicines. the use of. According to an embodiment of the present invention, the medicament is used for preventing and / or treating diseases related to the complement lectin pathway. According to an embodiment of the invention, the drug is a MASP-2 inhibitor. The present invention also provides compounds represented by formula (I'), their racemates, stereoisomers, tautomers, nitrogen oxides or their pharmaceutically acceptable salts and the above pharmaceutical compositions, which are useful in treating and / or for use in preventing diseases associated with the complement lectin pathway. The present invention also provides a method for treating and / or preventing diseases related to the complement lectin pathway, which includes administering to the patient a therapeutically or preventively effective amount of the compound represented by formula (I′), its racemate, stereoisomer, and mutual At least one of isomers, nitrogen oxides or their pharmaceutically acceptable salts and the above pharmaceutical compositions. According to an embodiment of the present invention, the disease related to the complement lectin pathway is selected from thrombotic microangiopathy (TMA), kidney disease, respiratory distress syndrome caused by coronavirus infection, hematological disease, type I or type II diabetes Resulting complications, cardiovascular diseases or conditions, inflammatory gastrointestinal conditions, pulmonary conditions, ophthalmic diseases or conditions, ocular angiogenic diseases or conditions, disseminated intravascular coagulation (DIC) or other complement-mediated coagulation Disorders, angiogenesis-dependent cancers or tumors, peripheral nervous system and / or central nervous system disorders or injuries, sepsis or conditions caused by sepsis, inflammatory response caused by tissue or organ transplantation, ischemia-reperfusion Injury, graft-versus-host disease, diffuse alveolar hemorrhage (DAH), veno-occlusive disease (VOD), skin disorder, endocrine disorder, atherosclerosis or autoimmune disease; the thrombotic microangiopathy is selected from thrombotic microangiopathy Thrombocytopenic purpura (TTP), refractory TTP, Upshaw Schulman syndrome (USS), hemolytic uremic syndrome (HUS), atypical hemolytic syndrome (aHUS), non-factor H-dependent atypical hemolytic syndrome, aHUS secondary to infection, plasma therapy-resistant aHUS, TMA secondary to cancer, TMA secondary to chemotherapy, TMA secondary to transplantation, or TMA associated with hematopoietic stem cell transplantation (HSCT-TMA); the renal disease is selected from IgA nephropathy , mesangial proliferative glomerulonephritis, membranous glomerulonephritis, membranoproliferative glomerulonephritis, acute post-infectious glomerulonephritis, C3 glomerulopathy, cryoglobulinemic glomerulonephritis, Pauciimmune necrotizing crescentic glomerulonephritis, lupus nephritis or Henoch-Schonlein purpura nephritis; the respiratory distress syndrome caused by coronavirus infection is selected from influenza A virus, influenza B virus or type C Respiratory distress syndrome caused by influenza virus and respiratory distress syndrome caused by SARS-COV-2, SARS-COV or MERS-COV; the hematological disease is selected from paroxysmal nocturnal hemoglobinuria (PNH), cold agglutination syndrome, disseminated intravascular coagulation or autoimmune hemolytic anemia; the inflammatory gastrointestinal disorder is selected from the group consisting of pancreatitis, Crohn's disease, ulcerative colitis, irritable bowel syndrome or inflammatory bowel disease ( IBD); the peripheral nervous system and / or central nervous system disorder or injury is selected from multiple sclerosis (MS), myasthenia gravis (MG), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), Guillain-Barre syndrome, post-stroke reperfusion, degenerative disc, traumatic brain injury, Parkinson's disease (PD), Alzheimer's disease (AD), Miller-Fehr syndrome, traumatic brain injury and / or hemorrhage , traumatic brain injury, demyelination or meningitis; the autoimmune disease is selected from systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis, polymyositis or psoriasis. According to an embodiment of the present invention, the disease related to the complement lectin pathway is selected from the group consisting of renal disease, thrombotic microangiopathy (TMA), atypical hemolytic syndrome (aHUS), thrombotic microangiopathy (TMA), ischemic regeneration Perfusion injury, aHUS secondary to infection, ophthalmic disease, inflammatory gastrointestinal disease, pulmonary disease, inflammatory reaction due to organ or tissue transplant surgery, hematological disease, complications due to type I or type II diabetes, including kidney The disease is selected from immunoglobulin A nephropathy (IgA nephropathy), C3 glomerulopathy, lupus nephritis, glomerulonephritis, and the like. beneficial effects The compounds of the present invention can be used to prevent and / or treat diseases related to the complement lectin pathway, and to prepare drugs for diseases related to the complement lectin pathway. The compound has good inhibitory activity against MASP-2 and has excellent pharmacokinetic and pharmacodynamic activities. Definitions and explanations of terms Unless otherwise stated, the definitions of groups and terms recorded in the specification and patent scope of this application include their definitions as examples, exemplary definitions, preferred definitions, definitions recorded in tables, and the definitions of specific compounds in the examples. Definitions, etc., can be arbitrarily combined and combined with each other. Such combinations and combined group definitions and compound structures should be understood to be within the scope described in the specification and / or patent scope of this application. The term "C n‑m ” and “C n ‑C m ", where n and m are integers, representing a group containing n to m carbon atoms. Examples include C 1‑6 ,C 1‑3 wait. The term is intended to explicitly expose every member of the scope, i.e. C n ,C n+1 ,C n+2 ...C m‑2 ,C m‑1 ,C m . For example, C 1‑6 Intended to disclose C 1 ,C 2 ,C 3 ,C 4 ,C 5 and C 6 . "C n‑m ” means the same as “C n ‑C m "same. The term "n-member," where n is an integer, usually describes the number of ring atoms in which n is the number. The term "n‑m member", where n and m are integers, describes a range in which the number of ring atoms is n to m. For example, piperidinyl is an example of a 6-membered heterocycloalkyl ring, pyrazolyl is an example of a 5-membered heteroaryl ring, and pyridinyl is an example of a 6-membered heteroaryl ring. Unless otherwise stated, the numerical ranges described in this specification and the patent application are equivalent to at least recording each specific integer value therein. For example, the numerical range "1-20" is equivalent to recording each integer value in the numerical range "1-20", that is, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 , 13, 14, 15, 16, 17, 18, 19 and 20. Depending on their molecular structure, the compounds of the present invention may be chiral (possessing one or more stereocenters) and, unless otherwise stated, all stereoisomers such as enantiomers and diastereomers are Expected. These compounds may thus exist in racemic or optically active form. The compounds of the present invention include isomers or mixtures and racemates in which each chiral carbon is in R or S configuration. The compounds of the present invention or intermediates thereof can be separated into enantiomeric compounds by chemical or physical methods known to those skilled in the art, or used in synthesis in this form. In the case of racemic amines, the diastereoisomers are prepared from the mixture by reaction with optically active resolving reagents. Examples of suitable resolving agents are optically active acids, such as the R and S forms of tartaric acid, diacetyl tartaric acid, dibenzoyl tartaric acid, mandelic acid, malic acid, lactic acid, appropriate N-protected amino acids ( For example, N-benzoyl proline or N-benzenesulfonyl proline) or various optically active camphorsulfonic acids. With the help of optically active resolving reagents (such as dinitrobenzoylphenylglycine immobilized on silica gel, cellulose triacetate or other carbohydrate derivatives or chiral derivatized methacrylate polymers ), column chromatography enantiomeric resolution can also be advantageously performed. Suitable eluents for this purpose are aqueous or alcoholic solvent mixtures, for example, hexane / isopropanol / acetonitrile. The corresponding stable isomers can be separated according to known methods, for example by extraction, filtration or column chromatography. In some embodiments, compounds of the invention have ( R)‑Configuration. In other embodiments, the compound has ( S)‑configuration. In compounds with more than one chiral center, unless otherwise stated, each chiral center in the compound may independently be ( R) or ( S). The compounds described herein may also include tautomeric forms. Tautomeric forms result from the exchange of a single bond with an adjacent double bond and the concomitant migration of a proton. Tautomeric forms include proton transfer tautomers, which are isomeric protonation states with the same empirical formula and overall charge. Examples of proton-transfer tautomers include keto-enol pairs, amide-imido acid pairs, lactam-lactam imine pairs, enamine-imine pairs, and heterocyclic systems in which a proton may occupy a Ring forms with two or more positions, such as 1H‑ and 3H‑imidazole, 1H‑, 2H‑ and 4H‑1,2,4‑triazole, 1H‑ and 2H‑isoindole and 1H‑ and 2H‑ pyrazole. Tautomeric forms may be in equilibrium or sterically locked into one form by appropriate substitution. This disclosure is intended to include all such tautomers of the compounds described. The compounds described herein may also include all isotopes of atoms present in intermediate or final compounds. Isotopes include those atoms that have the same atomic number but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium. The term "pharmaceutically acceptable salts" refers to salts of compounds of the invention prepared with relatively non-toxic, pharmaceutically acceptable acids or bases. When the compounds of the present invention contain relatively acidic functional groups, base addition salts can be obtained by contacting the prototype of such compounds with a sufficient amount of a pharmaceutically acceptable base in a pure solution or a suitable inert solvent. . Pharmaceutically acceptable base addition salts include, but are not limited to: lithium salts, sodium salts, potassium salts, calcium salts, aluminum salts, magnesium salts, zinc salts, bismuth salts, ammonium salts, and diethanolamine salts. When the compounds of the present invention contain relatively basic functional groups, acid addition salts can be obtained by contacting the prototype of such compounds with a sufficient amount of a pharmaceutically acceptable acid in pure solution or a suitable inert solvent. . The pharmaceutically acceptable acid includes inorganic acid, and the inorganic acid includes but is not limited to: hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, carbonic acid, phosphoric acid, phosphorous acid, sulfuric acid, etc. The pharmaceutically acceptable acids include organic acids, and the organic acids include but are not limited to: acetic acid, propionic acid, oxalic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid , fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, salicylic acid, tartaric acid, methanesulfonic acid, isonicotinic acid, oleic acid, tannic acid, Pantothenic acid, hydrogen tartrate, ascorbic acid, gentisic acid, fumaric acid, gluconic acid, sugar acid, formic acid, ethanesulfonic acid, pamoic acid (i.e. 4,4'-methylene-bis(3-hydroxy-2- Naphthoic acid)), amino acids (such as glutamic acid, arginine), etc. When the compound of the present invention contains relatively acidic and relatively basic functional groups, it can be converted into a base addition salt or an acid addition salt. For details, see Berge et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science 66: 1-19 (1977), or Handbook of Pharmaceutical Salts: Properties, Selection, and Use (P. Heinrich Stahl and Camille G. Wermuth, ed., Wiley-VCH, 2002). In some embodiments, the "pharmaceutically acceptable salt" is the hydrochloride salt. The term "halogen" or "halo" refers to fluorine, chlorine, bromine and iodine. The term "C 1-10 "Alkyl" refers to a straight-chain or branched saturated monovalent hydrocarbon group having 1 to 10 carbon atoms. For example, straight and branched chain alkyl groups having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms are represented. "C 1-6 "Alkyl" refers to a straight or branched chain alkyl group having 1, 2, 3, 4, 5 or 6 carbon atoms. "C 1-3 "Alkyl" refers to a straight-chain or branched alkyl group having 1, 2 or 3 carbon atoms. The alkyl group includes, but is not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, 2-methylbutyl base, 1-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, neopentyl, 1,1-dimethylpropyl, 4-methylpentyl, 3-methyl Pentyl, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl base, 1,1-dimethylbutyl, 2,3-dimethylbutyl, 1,3-dimethylbutyl or 1,2-dimethylbutyl, etc. or their isomers. The term "alkoxy" refers to a group having the formula "-O-alkyl", where alkyl is as defined above. "C 1-6 "Alkoxy" refers to an alkyl group having 1 to 6 carbon atoms. The alkoxy group includes, but is not limited to, methoxy, ethoxy, propoxy (for example, n-propoxy and isopropoxy), tert-butoxy, and the like. The term "haloalkyl" refers to an alkyl group as defined above substituted by one or more halogens as defined above. The haloalkyl group includes but is not limited to monofluoromethyl, difluoromethyl, trifluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl , 3-bromo-2-fluoropropyl, 1-bromomethyl-2-bromoethyl, etc. The term "haloalkoxy" refers to an alkoxy group as defined above, the alkyl portion of which is substituted by one or more halogens as defined above. The haloalkoxy group includes but is not limited to trifluoromethoxy group, difluoromethoxy group, pentafluoroethoxy group, etc. The term "C 2-6 "Alkenyl" refers to a straight-chain or branched monovalent hydrocarbon group containing 2 to 6 carbon atoms and containing at least one carbon-carbon double bond. The alkenyl group includes but is not limited to vinyl, n-propenyl, isopropenyl, n-butenyl, sec-butenyl, etc. The term "C 2-6 "Alkynyl" refers to a straight-chain or branched monovalent hydrocarbon group containing 2 to 6 carbon atoms and containing at least one carbon-carbon triple bond. The alkynyl group includes, but is not limited to, ethynyl, 1-propynyl, 2-propynyl, 3-butynyl, 2-pentynyl and 1-butynyl. The term "C 1-6 "Aminoalkyl" refers to C substituted by one or more amine groups 1-6 alkyl. "C 1-3 "Aminoalkyl" refers to one or more amino groups substituted C 1-3 Alkyl, the aminoalkyl includes but is not limited to aminomethyl -CH 2 NH 2 , aminoethyl -CH 2 CH 2 NH 2 . The term "C 3-10 "Cycloalkyl" refers to a saturated monovalent or multivalent monocyclic, bicyclic or tricyclic hydrocarbon group having 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms. The bicyclic and tricyclic hydrocarbon groups include bridged rings, fused rings and spiro rings. The C 3-10 The cycloalkyl group can be selected from C 3-6 Cycloalkyl or C 3-4 Cycloalkyl. The C 3-10 The cycloalkyl group can be a monocyclic hydrocarbon group, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl or cyclodecanyl, or a bicyclic hydrocarbon group, such as bornyl , hexahydroindolyl, decahydronaphthyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl, 6,6-dimethyldi Cyclo[3.1.1]heptyl, 2,6,6-trimethylbicyclo[3.1.1]heptyl, bicyclo[2.2.2]octyl, or tricyclic hydrocarbon group, such as adamantyl. The term "3-12 membered heterocycloalkyl" refers to a saturated monovalent or multivalent monocyclic, bicyclic or tricyclic ring system containing 3 to 12 ring atoms, and its ring atoms contain 1, 2, 3 or 4 Heteratoms independently selected from O, S and N, where N and S may also optionally be oxidized to various oxidation states to form nitrogen oxides, -S(=O)- or -S(=O) 2-status. The "3-12-membered heterocycloalkyl" is selected from 3-6-membered heterocycloalkyl or 6-11-membered heterocycloalkyl. The heterocycloalkyl group can be attached to the rest of the molecule through any carbon atom or nitrogen atom (if present) on its ring. The heterocycloalkyl group may include, but is not limited to: azetidinyl, pyrrolidinyl, piperidinyl, piperidinyl, 6-azaspiro[2.5]octyl, diazaspiro[3, 5]nonyl, 2,6-diazaspiro[3,4]octyl, 7-azaspiro[3.5]nonyl, 8-azaspiro[4.5]decane or 3-aza Spiro[5.5]undecyl, etc. The term "3-12 membered heterocyclyl" refers to a saturated or unsaturated non-aromatic monovalent or polyvalent ring system, for example, it is a monocyclic ring containing 4, 5, 6 or 7 ring atoms, including A bicyclic ring with 7, 8, 9, 10, 11 or 12 ring atoms or a tricyclic ring system containing 10, 11 or 12 ring atoms, and its ring atom contains at least one, such as 1, 2, 3, 4 , 5 or 6 heteroatoms independently selected from O, S and N, wherein N and S can also be optionally oxidized to various oxidation states to form nitrogen oxides, -S(=O)- or - S(=O) 2 -status. The bicyclic and tricyclic ring systems include fused rings, bridged rings or spiro rings. The 3-12-membered heterocyclyl can be selected from "3-10-membered heterocyclyl", "5-12-membered heterocyclyl" or "6-11-membered heterocyclyl"; the term "3-10-membered heterocyclyl" "Group" means a saturated or unsaturated non-aromatic ring or ring system containing 3 to 10 ring atoms, and the ring atoms containing at least one heteroatom selected from O, S and N. The term "5-12 membered heterocyclyl" refers to a saturated or unsaturated non-aromatic ring or ring system containing 5 to 12 ring atoms, and the ring atoms containing at least one heteroatom selected from O, S and N . The term "6-11 membered heterocyclyl" refers to a saturated or unsaturated non-aromatic ring or ring system containing 6 to 11 ring atoms, and the ring atoms containing at least one heteroatom selected from O, S and N . In some embodiments, the heterocyclyl group can be heterocycloalkyl. The heterocyclyl group can be connected to the rest of the molecule through any carbon atom or nitrogen atom (if present) on its ring. For example, when the 3-12-membered heterocyclyl group is selected from piperidinyl, it can be a piperidinyl ring. The nitrogen atom on and the carbon atom on its paraposition are connected to other groups. The heterocyclyl group may include, but is not limited to: 4-membered rings, such as azetidinyl, oxetanyl; 5-membered rings, such as tetrahydrofuranyl, dioxolyl, pyrrolidinyl, Imidazolidinyl, pyrazolidinyl, pyrrolinyl; or 6-membered ring, such as tetrahydropyranyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl or trithianiyl Alkyl; or 7-membered ring, such as diazepanyl. Optionally, the heterocyclyl group may be benzo-fused. The heterocyclyl group may be bicyclic, such as but not limited to 6-azaspiro[2.5]octyl, diazaspiro[3,5]nonyl, 2,6-diazaspiro[3, 4]octyl, 7-azaspiro[3.5]nonyl, 8-azaspiro[4.5]decane or 3-azaspiro[5.5]undecyl, hexahydrocyclopenta[c] Pyrrole-2(1H)-yl ring, hexahydropyrro[1,2-a]pyrazin-2(1H)-yl ring, 4-azaspiro[2.5]octyl ring, 1,2-dihydro Pyridyl and 1,4-dihydropyrazinyl. Heterocyclyl may be partially unsaturated, i.e. it may contain one or more double bonds, such as, but not limited to, dihydrofuryl, dihydropyranyl, 2,5-dihydro-1H-pyrrolyl, 4H- [1,3,4]thiadiazinyl, 1,2,3,5-tetrahydroxazolyl or 4H-[1,4]thiazinyl, alternatively, it can be benzo-fused, such as but Not limited to dihydroisoquinolyl. The term "C 6-10 "Aryl" refers to a monovalent aromatic monocyclic, bicyclic or tricyclic hydrocarbon ring containing 6, 7, 8, 9 or 10 carbon atoms, especially a ring with 6 carbon atoms ("C 6 Aryl"), such as phenyl; or a ring with 9 carbon atoms ("C 9 Aryl"), such as indanyl or indenyl, or a ring with 10 carbon atoms ("C 10 Aryl"), such as naphthyl. When the C 6-10 When an aryl group is substituted, it may be mono- or poly-substituted. Moreover, there is no restriction on the substitution position, for example, it may be ortho, para or meta substitution. The term "5-10 membered heteroaryl" refers to a monovalent heteroaryl group containing 5 to 10 ring atoms, and the ring atoms containing 1, 2, 3, 4 or 5 heteroatoms independently selected from N, O and S. or multivalent monocyclic, bicyclic or tricyclic aromatic ring systems. The term "5-8 membered heteroaryl" refers to a monovalent or multivalent monocyclic, bicyclic or tricyclic aromatic ring system containing 5, 6, 7 or 8 ring atoms, in particular, it contains 5 or 6 Carbon atoms, and it contains 1-3, preferably 1 or 2 heteroatoms independently selected from N, O and S. Such bicyclic and tricyclic ring systems include fused rings. In some embodiments, it may be benzo-fused. When the 5-10 membered heteroaryl group is substituted, it may be mono- or poly-substituted. Moreover, there is no restriction on the substitution position. For example, the hydrogen connected to the carbon atom on the heteroaryl ring may be substituted, or the hydrogen connected to the heteroatom on the heteroaryl ring may be substituted. The heteroaryl group may include, but is not limited to: pyridyl, pyrazinyl, pyrimidinyl, triazinyl, pyridazinyl, thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, indole , benzothiazole, benzofuran, or benzimidazole. The term "spiro ring" refers to a ring system in which two rings share one ring-forming atom. The term "fused ring" refers to a ring system in which two rings share two ring-forming atoms. The term "bridged ring" refers to a ring system that shares two or more ring-forming atoms. The compounds of the invention may exist in the form of solvates (eg hydrates), wherein the compounds of the invention comprise as structural elements of the crystal lattice of said compounds a polar solvent, in particular such as water, methanol or ethanol. The amount of polar solvent, especially water, may be present in stoichiometric or non-stoichiometric ratios. The term "patient" refers to any animal including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, pigs, cattle, sheep, horses or primates, most preferably As a person. The term "therapeutically effective amount" refers to the amount of an active compound or drug that a researcher, veterinarian, physician, or other clinician is seeking to elicit a biological or medical response in a tissue, system, animal, individual, or human, and includes one of the following or more of: (1) Prevention of disease: e.g., prevention of a disease, disorder, or condition in an individual who is susceptible to the disease, disorder, or condition but who has not yet experienced or developed the pathology or symptoms of the disease. (2) Inhibition of disease: e.g., inhibition of a disease, disorder, or condition (i.e., preventing further progression of pathology and / or symptoms) in an individual who is experiencing or developing pathology or symptoms of the disease, disorder, or condition. (3) Disease amelioration: e.g., alleviation of a disease, disorder, or condition (i.e., reversal of the pathology and / or symptoms) in an individual who is experiencing or developing the pathology or symptoms of the disease, disorder, or condition. The therapeutically effective dose can be estimated initially from cell culture assays, or the initial dose can be estimated from in vivo data. Using these preliminary guidelines, one of ordinary skill in the art can determine effective doses in humans. In addition, the toxicity and therapeutic efficacy of the compounds described herein can also be determined by standard pharmaceutical procedures in cell culture or experimental animals, for example, by determining LD 50 and ED 50 . One of ordinary skill in the art will understand that the resolved chiral compounds can be distinguished by the order of retention times in the chiral column chromatography. If the absolute configuration of a compound is listed in the examples, it does not mean a one-to-one correspondence with the compound number, but only illustrates the two existence forms of the absolute configuration. The absolute configuration corresponding to the compound number is based on the absolute configuration objectively corresponding to the specific retention time. The technical solution of the present invention will be further described in detail below with reference to specific embodiments. It should be understood that the following examples are only illustrative and explain the present invention, and should not be construed as limiting the scope of the present invention. All technologies implemented based on the above contents of the present invention are covered by the scope of protection intended by the present invention. Unless otherwise stated, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods. Unless otherwise stated, the terms used in the following specific experimental descriptions refer to the following reagents: AH 4 : Sodium borohydride; PPh 3 : Triphenylphosphine; DIAD: diisopropyl azodicarboxylate; m-CPBA: m-chloroperoxybenzoic acid; PyBOP-PF 6 : Tripyrrolidinyl phosphonium bromide hexafluorophosphate; EDCI: 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; HOBT: 1-hydroxybenzotriazole; DIEA: N,N-diisopropylethylamine; LiHMDS: lithium bis(trimethylsilyl)amide; LiEt 3 BH: lithium triethylborohydride; BF 3 . Et 2 O: Boron trifluoride etherate complex; Pd(Ph 3 P) 4 : Tetrakis(triphenylphosphine)palladium; Rh(PPh 3 ) 3 Cl: tris(triphenylphosphine)rhodium chloride; Et 3 SiH: triethylsilane; LAH: lithium aluminum tetrahydrogen; Et 2 Zn: diethyl zinc; KHF 2 : Potassium hydrogen fluoride; PBr 3 : Phosphorus tribromide; SEM-Cl: 2-(trimethylsilyl)ethoxymethyl chloride; Cu(OAc) 2 : Copper acetate; EtOAc: ethyl acetate; TEA: triethylamine; THF: tetrahydrofuran; TBAF: tetrabutylammonium fluoride; T 3 P: 1-propylphosphoric acid cyclic anhydride; <Preparation Example> Example 1, (2R,4S)-N-((2S)-1-((2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amine Synthesis of methyl)-1-side oxypropan-2-yl)-4-(4-fluorobenzyl)pyrrolidine-2-methamide (compound L001) hydrochloride 1.1 Synthesis of compound L001-1 Dissolve L001-a (4.0 g, 30.40 mmol) in methanol (60 mL) at room temperature, cool to 0°C, and add sodium borohydride (3.4 g, 91.20 mmol) in batches. After the reaction solution was stirred at 0°C for 0.5 hours, the temperature was raised to 25°C and the reaction was continued for 2 hours. The reaction solution was quenched with water (10 mL) and concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica column chromatography to obtain compound L001-1 (3.8 g, yield 93.60%). 1.2 Synthesis of compound L001-2 Dissolve L001-1 (3.8 g, 28.11 mmol), triphenylphosphine (8.8 g, 33.74 mmol) and L001-b (4.6 g, 33.74 mmol) in tetrahydrofuran (40 mL) at room temperature, and cool to 0°C. , slowly add diisopropyl azodicarboxylate (6.82 g, 33.74 mmol) dropwise under nitrogen protection. After the dropwise addition was completed, the temperature of the reaction solution was raised to room temperature and the reaction was continued for 2 hours. The reaction solution was concentrated directly, and the residue was diluted with water (100 mL). The pH value of the aqueous phase was adjusted to 3~4 with dilute hydrochloric acid aqueous solution (1 M), and then washed with ethyl acetate (50 mL×3). The pH of the aqueous phase was adjusted to 8~9 with saturated sodium bicarbonate aqueous solution, and then extracted with dichloromethane (50 mL×3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L001-2 (3.6 g, yield 48.45%). LC-MS: [M+H] + = 265.05. 1.3 Synthesis of compound L001-3 Dissolve L001-2 (3.6 g, 13.62 mmol) in dichloromethane (70 mL), add m-chloroperoxybenzoic acid (3.06 g, 17.71 mmol) in batches at 0°C, and raise the temperature to 25°C for 2 hours. The reaction solution was diluted with dichloromethane (200 mL) and washed with saturated aqueous sodium bicarbonate solution (50 mL×3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L001-3 (3.7 g, crude product), which could be used directly in the next step. LC-MS: [M+H] + = 280.95. 1.4 Synthesis of compound L001-4 Dissolve L001-3 (2.6 g, 9.28 mmol) in dichloromethane (50 mL) at room temperature, and add L001-c (2.0 g, 12.06 mmol) and tripyrrolidinyl phosphonium bromide hexafluorophosphate (7.8 g) in sequence. , 16.70 mmol) and N,N-diisopropylethylamine (3.0 g, 23.19 mmol). The reaction solution was stirred at room temperature for 12 hours. The reaction solution was directly concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain compound L001-4 (2.0 g). LC-MS: [M+H] + = 430.00. 1.5 Synthesis of compound L001-5 Dissolve L001-4 (2.0 g, 4.66 mmol) in ethanol (20 mL), add hydrazine hydrate (20 mL, 85%), and stir at 25°C for 12 hours. The reaction solution was concentrated under reduced pressure, and the residue was diluted with water (20 mL) and extracted with dichloromethane (20 mL×3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L001-5 (1.5 g, crude product), which could be used directly in the next step. LC-MS: [M+H] + = 300.05. 1.6 Synthesis of compound L001-6 Dissolve L001-5 (1.5 g, 5.01 mmol) in tetrahydrofuran (20 mL) at room temperature. After adding concentrated hydrochloric acid (20 mL, 37%), the reaction solution was heated to 70°C and stirred for 1 hour. The reaction solution was concentrated under reduced pressure, and the residue was added with ethyl acetate / methanol (20 mL, 10 / 1 (v / v)) and stirred at room temperature for 1 hour. The mixture was filtered, and the filter cake was dried under reduced pressure to obtain the hydrochloride of compound L001-6 (600 mg, yield 64.52%). LC-MS: [M+H] + = 150.20. 1.7 Synthesis of Compound L001-7 Dissolve L001-d (1.5 g, 8.08 mmol) in N,N-dimethylformamide (20 mL), and add 1-(3-dimethylaminopropyl)-3-ethylcarbodioxide in sequence. Amine hydrochloride (1.7 g, 8.89 mmol) and 1-hydroxybenzotriazole (1.2 g, 8.89 mmol) were reacted at 25°C for 10 minutes, and then N,N-diisopropylethylamine (5.2 g, 40.40 mmol) and L001-6 (1.5 g, 8.08 mmol) in N,N-dimethylformamide solution (10 mL), continue the reaction at 25°C for 30 minutes. The reaction solution was poured into water (30 mL), and extracted with ethyl acetate (30 mL×3). The organic phase was washed with saturated aqueous ammonium chloride solution (20 mL×3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the intermediate. Dissolve the intermediate (1.5 g, 4.68 mmol) in dichloromethane (20 mL), add hydrogen chloride in 1,4-dioxane solution (20 mL, 4 M), and react at 25°C for 30 minutes. The reaction solution was directly concentrated under reduced pressure, and the residue was added to dichloromethane (10 mL) and stirred at room temperature for 30 minutes, then filtered, and the filter cake was dried under reduced pressure to obtain compound L001-7 hydrochloride (1.3 g), which was directly used in the next reaction. . LC-MS: [M+H] + = 221.15. 1.8 Synthesis of compound L001-8 Dissolve L001-e (1.0 g, 3.13 mmol) in tetrahydrofuran (15 mL) at room temperature, then cool to -70°C, and slowly add lithium bis(trimethylsilyl)amide (3.8 mL, 3.80 mmol, 1 M tetrahydrofuran solution), stir at -70°C for 0.5 hours after the dropwise addition. Then L001-f (0.7 g, 3.76 mmol) was slowly added dropwise. After the dropwise addition was completed, the reaction solution was continued to stir at -70°C for 2 hours. The reaction solution was quenched with saturated aqueous ammonium chloride solution (10 mL) at -70°C. After the system temperature rose to room temperature, it was extracted with ethyl acetate (20 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L001-8 (800 mg, yield 59.70%). 1.9 Synthesis of Compound L001-9 L001-8 (800 mg, 1.87 mmol) was dissolved in tetrahydrofuran (10 mL) at room temperature. The reaction solution was cooled to -70°C, and lithium triethylborohydride (2 mL, 2.0 mmol, 1M tetrahydrofuran solution) was slowly added dropwise under nitrogen protection. After the dropwise addition, the reaction was continued at -70°C for 0.5 hours. The reaction solution was quenched with saturated aqueous sodium bicarbonate solution (10 mL) at -70°C, and then extracted with ethyl acetate (10 mL×3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L001-9 (800 mg, crude product). LC-MS: [M-OH] + = 412.05. 1.10 Synthesis of compound L001-10 Dissolve L001-9 (800 mg, 1.86 mmol) in dichloromethane (15 mL) at room temperature, cool the reaction solution to -70°C, and slowly add triethylsilane (259 mg, 2.34 mmol) and triethylsilane (259 mg, 2.34 mmol) under nitrogen protection. Boron fluoride etherate complex (332 mg, 2.34 mmol) was added dropwise and stirred at -70°C for 0.5 hours. Triethylsilane (259 mg, 2.34 mmol) and boron trifluoride etherate complex (332 mg, 2.34 mmol) were added, and the reaction solution continued to stir at -70°C for 1 hour. The reaction solution was quenched by adding saturated sodium bicarbonate aqueous solution (10 mL) at -70°C, and extracted with dichloromethane (20 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L001-10 (500 mg, yield 64.94%). 1.11 Synthesis of compound L001-11 Dissolve L001-10 (500 mg, 1.21 mmol) in methanol (20 mL) at room temperature, add wet palladium on carbon (100 mg, 10% palladium content), replace with hydrogen three times, and stir at room temperature under a hydrogen atmosphere for 4 Hour. The reaction solution was directly filtered, and the filtrate was concentrated under reduced pressure to obtain compound L001-11 (410 mg, crude product), which could be directly used in the next step. LC-MS: [M-tBu+H] + = 268.05. 1.12 Synthesis of compound L001-12 hydrochloride Dissolve L001-11 (70 mg, 0.22 mmol) in N,N-dimethylformamide (2 mL) at room temperature, and add 1-(3-dimethylaminopropyl)-3-ethylcarbodiamine Imine hydrochloride (50 mg, 0.26 mmol) and 1-hydroxybenzotriazole (35 mg, 0.26 mmol), react at 25°C for 10 minutes, then add N,N-diisopropylethylamine (141 mg , 1.09 mmol) and L001-7 (67 mg, 0.26 mmol) in N,N-dimethylformamide (2 mL). The reaction system was continued to react at 25°C for 30 minutes. The reaction solution was poured into water (10 mL), and extracted with ethyl acetate (10 mL×3). The combined organic phases were washed with saturated aqueous ammonium chloride solution (10 mL×3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by high-performance liquid phase preparative column chromatography (acidic conditions) to obtain compound L001-12 hydrochloride (50 mg, yield 61.52%). LC-MS: [M+H] + = 526.10. 1.13 Synthesis of Compound L001 Hydrochloride Dissolve L001-12 hydrochloride (50 mg, 0.10 mmol) in dichloromethane (2 mL), add hydrogen chloride in ethyl acetate solution (2 mL, 4 M), and stir at room temperature for 2 hours. If a solid is formed, the reaction solution is filtered, and the filter cake is dissolved in deionized water (10 mL) and freeze-dried to obtain compound L001 hydrochloride (24.3 mg). 1 H NMR (400 MHz, DMSO- d 6 ): δ 10.52(s, 1H), 8.89(s, 1H), 8.50 - 8.64(m, 2H), 8.03(s, 2H), 7.71 - 7.64(m, 1H), 7.48 - 7.28(m, 3H) , 7.20 - 7.11(m, 2H), 6.84(d, J= 8.0 Hz, 1H), 5.17 - 5.12(m, 1H), 4.38(s, 1H), 4.32 - 4.19(m, 1H), 3.36 - 3.26(m, 1H), 3.09 - 2.98(m, 1H) , 2.94 - 2.86(m, 2H), 2.79 - 2.59(m, 2H), 2.49- 2.40(m, 2H), 2.10 - 2.02(m, 1H), 1.98 - 1.86(m, 3H), 1.23(d, J= 8.0 Hz, 3H); LC-MS: [M+H] + = 426.10. Example 2, (2R,4S)-4-([1,1'-biphenyl]-4-ylmethyl)-N-((2S)-1-((2-amino-6,7 -Dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)-1-pendantoxypropan-2-yl)pyrrolidine-2-methamide (compound L002) and (2R ,4S)-4-([1,1'-biphenyl]-4-ylmethyl)-N-((S)-1-(((S)-2-amino-6,7-di Hydrogen-5H-cyclopenta[b]pyridin-5-yl)amine)-1-side oxypropan-2-yl)pyrrolidine-2-methamide (compound L002-IS-01 or L002 -IS-02) and (2R,4S)-4-([1,1'-biphenyl]-4-ylmethyl)-N-((S)-1-(((R)-2- Amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)-1-pentanoxypropan-2-yl)pyrrolidine-2-methamide ( Synthesis of compound L002-IS-02 or L002-IS-01) 2.1 Synthesis of compound L002-1 Dissolve L001-e (2.0 g, 6.20 mmol) in tetrahydrofuran (25 mL) at room temperature and cool to -78°C. Lithium bis(trimethylsilyl)amide (7.0 mL, 7.0 mmol, 1 M tetrahydrofuran solution) was added dropwise under nitrogen protection. After the dropwise addition was completed, stirring was continued at -78°C for 0.5 hours. Then L002-a (1.8 g, 7.44 mmol) was added dropwise. After the dropwise addition was completed, the reaction solution was continued to stir at -78°C for 2 hours. At this temperature, water (50 mL) was added to the reaction solution to quench it. After the system temperature rose to room temperature, it was extracted with ethyl acetate (40 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L002-1 (1.8 g, yield 58%). 2.2 Synthesis of compound L002-2 Dissolve L002-1 (1.8 g, 3.71 mmol) in tetrahydrofuran (30 mL) at room temperature, cool the reaction solution to -78°C, and slowly add lithium triethylborohydride (4.1 mL, 4.10 mmol, 1 M tetrahydrofuran solution). After the dropwise addition was completed, the reaction was carried out at -78°C for 0.5 hours. At this temperature, water (30 mL) was added to the reaction solution to quench it. After the system temperature rose to room temperature, it was extracted with ethyl acetate (30 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L002-2 (1.4 g, crude product), which was directly used in the next reaction. 2.3 Synthesis of compound L002-3 Dissolve L002-2 (1.4 g, crude product) in dichloromethane (20 mL) at room temperature, cool to -78°C, and slowly add triethylsilane (400 mg, 3.44 mmol) and trifluoride under nitrogen protection. Boron diethyl ether complex (488 mg, 3.44 mmol). The reaction solution was stirred at -78°C for 0.5 hours. Then triethylsilane (400 mg, 3.44 mmol) and boron trifluoride etherate complex (488 mg, 3.44 mmol) were added, and the reaction solution continued to stir at -78°C for 2 hours. Add saturated aqueous sodium bicarbonate solution (30 mL) to the reaction solution at -78°C to quench it. After the system temperature rises to room temperature, extract with ethyl acetate (30 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L002-3 (900 mg, yield 50.68%). LC-MS: [M+H] + = 472.59. 2.4 Synthesis of compound L002-4 Dissolve L002-3 (900 mg, 1.91 mmol) in ethanol (15 mL) at room temperature, add wet palladium on carbon (100 mg, 10% palladium content), and stir under a hydrogen atmosphere for 3 hours. The reaction solution was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure to obtain compound L002-4 (780 mg, crude product), which was directly used in the next reaction. LC-MS: [M-tBu+H] + = 326.15. 2.5 Synthesis of compound L002-5 Dissolve L002-4 (400 mg, crude product) in N,N-dimethylformamide (5 mL), and add 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide Hydrochloride (223 mg, 1.16 mmol) and 1-hydroxybenzotriazole (157 mg, 1.16 mmol), stir at 25°C for 10 minutes, then add N,N-diisopropylethylamine (677 mg, 5.25 mmol) and L001-7 (324 mg, 1.26 mmol) in N,N-dimethylformamide (5 mL), and the reaction was continued at 25°C for 0.5 hours. The reaction solution was poured into water (20 mL), and extracted with ethyl acetate (15 mL×3). The combined organic phases were washed with saturated aqueous ammonium chloride solution (20 mL×3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L002-5 (500 mg, yield 81.97%). LC-MS: [M+H] + =584.05. 2.6 Synthesis of compound L002 Dissolve L002-5 (500 mg, 0.85 mmol) in dichloromethane (5 mL), add hydrogen chloride in ethyl acetate solution (5 mL, 4 M), and react at 25°C for 0.5 hours. The reaction solution was directly concentrated under reduced pressure, and the residue was purified by high-performance liquid phase preparative column chromatography (alkaline conditions) and freeze-dried to obtain compound L002 (200 mg, yield 48.28%). 1 H NMR (400 MHz, DMSO- d 6 ): δ 8.20 - 8.13(m, 2H), 7.64(d, J= 8.0 Hz, 2H), 7.57(d, J= 8.0 Hz, 2H), 7.45(t, J= 8.0 Hz, 2H), 7.34(t, J= 8.0 Hz, 1H), 7.27(dd, J= 8.0, 4.0 Hz, 2H), 7.16 – 7.12(m, 1H), 6.22(d, J= 8.0 Hz, 1H), 5.84(s, 2H), 5.14 – 5.03(m, 1H), 4.28 – 4.16(m, 1H), 3.69 – 3.58(m, 1H), 3.09 – 3.04(m, 1H) , 2.93 – 2.83(m, 1H), 2.79 – 2.54(m, 5H), 2.37 – 2.27(m, 1H), 2.22 – 2.13(m, 1H), 1.84 – 1.62(m, 3H), 1.21-1.18( m, 3H); LC-MS: [M+H] + = 484.15. 2.7 Synthesis of compounds L002-IS-01 and L002-IS-02 Compound L002 (200 mg) was subjected to high performance liquid phase column chromatography (alkaline, CHIRAL ART Amylose-C NEO, 30*250 mm, 10 μm, mobile phase, A: n-hexane (0.1% diethylamine), B: Isopropyl alcohol, flow rate: 30 mL / min), the compounds L002-IS-01 (retention time in the spectrum Rt = 6.184 min, 69.9 mg) and L002-IS-02 (retention time in the spectrum Rt = 7.442 min) were separated. , 80.6 mg). L002-IS-01: 1 H NMR (400 MHz, DMSO- d 6 ): δ 8.19-8.12(m, 2H), 7.67 - 7.61(m, 2H), 7.57(d, J= 8.0 Hz, 2H), 7.45(t, J= 8.0 Hz, 2H), 7.34(t, J= 8.0 Hz, 1H), 7.26(d, J= 8.0 Hz, 2H), 7.11(d, J= 8.0 Hz, 1H), 6.24(d, J= 12.0 Hz, 1H), 5.83(s, 2H), 5.09(q, J= 8.0 Hz, 1H), 4.22(p, J= 8.0 Hz, 1H), 3.64(dd, J 1 =8.0, J 2 = 4.0 Hz, 1H), 2.86(dd, J 1 = 10.0, J 2 = 6.8 Hz, 1H), 2.80 - 2.51(m, 5H), 2.37 - 2.29(m, 1H), 2.20 - 2.13(m, 1H), 1.82 - 1.63(m, 3H), 1.35 - 1.23(m, 1H ), 1.19(d, J= 8.0 Hz, 3H); LC-MS: [M+H] + = 484.15. L002-IS-02: 1 H NMR (400 MHz, DMSO- d 6 ): δ 8.16(t, J= 8.0 Hz, 2H), 7.64(d, J= 8.0 Hz, 2H), 7.57(d, J= 8.0 Hz, 2H), 7.45(t, J= 8.0 Hz, 2H), 7.34(t, J= 8.0 Hz, 1H), 7.27(d, J= 8.0 Hz, 2H), 7.15(d, J= 8.0 Hz, 1H), 6.23(d, J= 8.0 Hz, 1H), 5.84(s, 2H), 5.07(q, J= 8.0 Hz, 1H), 4.21(p, J= 8.0 Hz, 1H), 3.64(dd, J 1 = 8.0, J 2 = 4.0 Hz, 1H), 2.89(dd, J 1 =8.0, J 2 = 4.0 Hz, 1H), 2.78 - 2.55(m, 5H), 2.38 - 2.27(m, 1H), 2.22 - 2.19(m, 1H), 1.83 - 1.61(m, 3H), 1.27 - 1.21(m, 1H ), 1.19(d, J= 8.0 Hz, 3H); LC-MS: [M+H] + = 484.15. Example 3, (2R,4S)-N-(2S)-1-(2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino) Synthesis of -1-Pendant oxypropan-2-yl)-4-(4-chlorobenzyl)pyrrolidine-2-methamide (compound L003) hydrochloride 3.1 Synthesis of compound L003-1 Dissolve L001-e (1.0 g, 3.13 mmol) in anhydrous tetrahydrofuran (10 mL). Under a nitrogen atmosphere, cool the reaction system to -78°C, and then slowly add lithium bis(trimethylsilyl)amide dropwise. (3.4 mL, 3.44 mmol, 1 M solution in tetrahydrofuran) and stirred at this temperature for 0.5 h. Then L003-a (804 mg, 3.91 mmol) was added dropwise to the reaction solution, keeping the reaction temperature at -78°C. After the dropwise addition, stirring was continued for 2 hours. At this temperature, add saturated aqueous sodium bicarbonate solution (15 mL) to the reaction solution to quench it, extract with ethyl acetate (30 mL×3), dry the combined organic phases over anhydrous sodium sulfate, filter, and reduce the filtrate to Pressure concentration. The residue was purified by silica gel column chromatography to obtain compound L003-1 (310 mg, yield 22.4%). LC-MS: [M-Boc+H] + = 344.00. 3.2 Synthesis of compound L003-2 L003-1 (310 mg, 0.70 mmol) was dissolved in tetrahydrofuran (4 mL). Under a nitrogen atmosphere, the reaction solution was cooled to -78°C, and lithium triethylborohydride (0.77 mL, 0.77 mmol, 1 M tetrahydrofuran solution) was slowly added dropwise. After the dropwise addition was completed, the reaction solution was continued to stir at -78°C for 2 hours. At this temperature, add saturated sodium bicarbonate (10 mL) aqueous solution to the reaction solution to quench, extract with ethyl acetate (20 mL×3), dry the combined organic phases over anhydrous sodium sulfate, filter, and reduce the filtrate to Pressure concentration. The residue was purified by silica gel column chromatography to obtain compound L003-2 (260 mg, yield 83.6%). LC-MS: [M-OH] + = 427.95. 3.3 Synthesis of compound L003-3 Dissolve L003-2 (260 mg, 0.58 mmol) in dichloromethane (10 mL), cool the reaction system to -78°C under a nitrogen atmosphere, and slowly add triethylsilane (75 mg, 0.64 mmol) and Boron trifluoride diethyl ether complex (98.7 mg, 0.70 mmol). After the dropwise addition was completed, the reaction solution continued to stir at -78°C for 2 hours. At this temperature, add saturated sodium bicarbonate (10 mL) aqueous solution to the reaction solution to quench, and extract with ethyl acetate (20 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was decompressed. concentrate. The residue was purified by silica gel column chromatography to obtain compound L003-3 (200 mg, yield 80.6%). LC-MS: [M+H] + = 430.05. 3.4 Synthesis of compound L003-4 L003-3 (100 mg, 0.23 mmol) was dissolved in methanol (3 mL) and water (3 mL), then sodium hydroxide (18.6 mg, 0.46 mmol) was added, and stirred at room temperature for 16 hours. The reaction solution was diluted with water (5 mL), extracted with ethyl acetate (5 mL), the organic phase was discarded, the pH of the aqueous phase was adjusted to 5-6 with formic acid, and then extracted with ethyl acetate (15 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L003-4 (90 mg, crude product), which could be used directly in the next step. 3.5 Synthesis of compound L003-5 Combine L003-4 (90 mg, crude), 1-hydroxybenzotriazole (39 mg, 0.29 mmol), N,N-dimethylformamide (2 mL) and 1-(3-dimethylamino Propyl)-3-ethylcarbodiimide hydrochloride (55 mg, 0.29 mmol) was added to the reaction flask, and stirred at room temperature for 0.5 hours. At the same time, L001-7 (92 mg, 0.31 mmol) and N,N-diisopropylethylamine (134.2 mg, 1.04 mmol) were dissolved in N,N-dimethylformamide (2 mL), and stirred at room temperature for 0.5 Hour. Then this solution was added to the reaction solution, and stirring was continued for 0.5 hours. The reaction solution was diluted with water (20 mL), and extracted with ethyl acetate (30 mL×3). The organic phases were combined and washed with saturated brine (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by high-performance liquid phase column chromatography (acidic conditions) to obtain compound L003-5 (58.0 mg, yield 40.1%). LC-MS: [M+H] + = 542.00. 3.6 Synthesis of Compound L003 Hydrochloride L003-5 (58 mg, 0.11 mmol) was dissolved in dichloromethane (2 mL) and hydrogen chloride in ethyl acetate (2 mL, 4 M) was added. The reaction solution was stirred at room temperature for 0.5 hours, and solid precipitated. The solid was filtered, and the filter cake was washed with dichloromethane (15 mL), dissolved in deionized water (15 mL), and freeze-dried to obtain compound L003 hydrochloride (36 mg, yield 76.1%). 1 H NMR (400 MHz, DMSO- d 6 ): δ 10.45-10.37(m, 1H), 8.86(d, J= 6.4 Hz, 1H), 8.57-8.55(m, 2H), 7.94(s, 2H), 7.66(dd, J 1 = 8.0 Hz, J 2 = 4.0 Hz, 1H), 7.33(dd, J 1 = 8.0, J 2 = 4.0 Hz, 4H), 6.81(d, J= 8.0 Hz, 1H), 5.14(d, J= 4.0 Hz, 1H), 4.42 - 4.17(m, 2H), 3.27(s, 1H), 3.09 - 2.82(m, 3H), 2.77 - 2.64(m, 2H), 2.48 - 2.35(m, 2H) , 2.06 - 1.90(m, 3H), 1.24 - 1.22(m, 4H); LC-MS: [M+H] + = 442.00. Example 4, (2R,4S)-N-((2S)-1-((2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amine Synthesis of methyl)-1-side oxypropan-2-yl)-4-(4-methylbenzyl)pyrrolidine-2-methamide (compound L004) hydrochloride 4.1 Synthesis of compound L004-1 Add L001-e (1 g, 3.13 mmol) into the reaction flask under a nitrogen atmosphere, add tetrahydrofuran (10 mL) to dissolve and place it in a -78°C cold bath. Add bis(trimethylsilica) while maintaining the temperature at -78°C. base) lithium amide (3.2 mL, 3.20 mmol, 1 M solution in tetrahydrofuran) and stirred for 0.5 h. Then L004-a (576 mg, 3.13 mmol) was added, and the reaction was continued at -78°C for 2 hours. A small amount of insoluble matter is generated. Filter to remove the insoluble matter. The filtrate is diluted with water (50 mL) and extracted with ethyl acetate (50 mL×3). The combined organic phase is dried with anhydrous sodium sulfate and filtered. The filtrate is concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L004-1 (650 mg, yield 49%). LC-MS: [M-Boc+H] + = 324.05. 4.2 Synthesis of compound L004-2 Add L004-1 (600 mg, 1.42 mmol) into the reaction flask, under nitrogen atmosphere, add tetrahydrofuran (5 mL) to dissolve and place it in a -78°C cold bath. Add lithium triethylborohydride while maintaining the temperature at -78°C. (1.42 mL, 1.42 mmol) and stirred for 0.5 hours. The reaction solution was quenched by adding water (50 mL), and extracted with ethyl acetate (50 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L004-2 (810 mg, crude product). LC-MS: [M-OH] + = 408.05. 4.3 Synthesis of compound L004-3 Add L004-2 (600 mg, 1.41 mmol) to the reaction flask under nitrogen atmosphere, add methylene chloride (5 mL) to dissolve and place it in a -78°C cold bath. Add triethylsilane while maintaining the temperature at -78°C. (163.9 mg, 1.41 mmol) and boron trifluoride etherate complex (200 mg, 1.41 mmol), stir for 0.5 hours. Triethylsilane (164 mg, 1.41 mmol) and boron trifluoride etherate complex (200 mg, 1.41 mmol) were added, and stirring was continued at -78°C for 2 hours. At this temperature, the reaction solution was quenched by adding water (50 mL), and extracted with ethyl acetate (50 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L004-3 (402 mg, yield 70%). LC-MS: [M+H] + = 410.00. 4.4 Synthesis of compound L004-4 Add L004-3 (402 mg, 0.98 mmol) into the reaction bottle, add methanol (5 mL) to dissolve, then add wet palladium on carbon (30 mg, 10% palladium content), and react at room temperature for 3 hours in a hydrogen atmosphere. . After the reaction solution was filtered through diatomaceous earth, the filtrate was concentrated under reduced pressure to obtain compound L004-4 (267 mg, crude product), which could be used directly in the next step. LC-MS: [M-tBu+H] + = 264.05. 4.5 Synthesis of compound L004-5 Combine L004-4 (100 mg, 0.31 mmol), 1-hydroxybenzotriazole (47 mg, 0.34 mmol), N,N-dimethylformamide (3 mL), N,N-diisopropyl Ethylamine (170 mg, 1.24 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (65 mg, 0.34 mmol) were added to the reaction flask, and the reaction was carried out at room temperature for 0.5 Hour. Then compound L001-7 (82 mg, 0.37 mmol) was added, and the reaction was continued for 1 hour at room temperature. Add water (40 mL) to dilute, and extract with ethyl acetate (30 mL×3). The combined organic phases were washed with saturated sodium chloride (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by high-performance liquid phase preparative column chromatography (acidic conditions) to obtain compound L004-5 (57.8 mg, yield 35.5%). LC-MS: [M+H] + = 522.10. 4.6 Synthesis of compound L004 hydrochloride Dissolve L004-5 (57.8 mg, 0.11 mmol) in dichloromethane (2 mL), add hydrogen chloride in ethyl acetate solution (1 mL, 4 M), and stir at room temperature for 0.5 hours. If a solid precipitates, the solid is filtered, and the filter cake is washed with ethyl acetate (10 mL). The filter cake was dissolved in water (3 mL) and freeze-dried to obtain compound L004 hydrochloride (40.2 mg, yield 81.1%). 1 H NMR (400 MHz, DMSO- d 6 ): δ 10.45-10.37(m, 1H), 8.86(d, J= 6.4 Hz, 1H), 8.57-8.55(m, 2H), 7.94(s, 2H), 7.66(dd, J 1 = 8.0 Hz, J 2 = 4.0 Hz, 1H), 7.33(dd, J 1 = 8.0, J 2 = 4.0 Hz, 4H), 6.81(d, J= 8.0 Hz, 1H), 5.14(d, J= 4.0 Hz, 1H), 4.42 - 4.17(m, 2H), 3.27(s, 1H), 3.09 - 2.82(m, 3H), 2.77 - 2.64(m, 2H), 2.48 - 2.35(m, 2H) , 2.06 - 1.90(m, 3H), 1.24 - 1.22(m, 4H); LC-MS: [M+H] + =422.15. Example 5, (2R,4S)-N-((2S)-1-((2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amine base)-1-Pendant oxypropan-2-yl)-4-(4-(trifluoromethyl)benzyl)pyrrolidine-2-methamide (compound L005) hydrochloride and (2R,4S )-N-((S)-1-(((R)-2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)-1 -Pendant oxypropan-2-yl)-4-(4-(trifluoromethyl)benzyl)pyrrolidine-2-methamide (compound L005-IS-01 or compound L005-IS-02) salt acid salt and (2R,4S)-N-((S)-1-(((S)-2-amino-6,7-dihydro-5H-cyclopenta[b]pyridine-5- base)amino)-1-side oxypropan-2-yl)-4-(4-(trifluoromethyl)benzyl)pyrrolidine-2-methamide (compound L005-IS-02 or compound L005-IS-01) Synthesis of hydrochloride 5.1 Synthesis of compound L005-1 L001-e (2.0 g, 6.26 mmol) was added to tetrahydrofuran (20 mL) at room temperature, the reaction solution was cooled to -78°C, and lithium bis(trimethylsilyl)amide (6.80 mL) was added dropwise under nitrogen protection. 6.80 mmol, 1 M solution in tetrahydrofuran). After the dropwise addition was completed, stirring was continued at -78°C for 0.5 hours. A tetrahydrofuran solution (10 mL) of L005-a (1.64 g, 6.88 mmol) was added dropwise to the reaction solution. After the addition was completed, the reaction solution was continued to stir at -78°C for 2 hours. An aqueous solution of ammonium chloride (10 mL) was added at -78°C to quench the reaction system. The reaction system was warmed to room temperature and then extracted with ethyl acetate (50 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L005-1 (1.2 g, yield 50.6%). LC-MS: [M-Boc+H] + = 377.95. 5.2 Synthesis of compound L005-2 Dissolve L005-1 (1.1 g, 2.30 mmol) in tetrahydrofuran (15 mL) at room temperature, cool to -78°C, and add lithium triethylborohydride (2.5 mL, 2.5 mmol, 1 M tetrahydrofuran solution) dropwise under nitrogen protection. ). After the dropwise addition was completed, stirring was continued at -78°C for 0.5 hours. Saturated aqueous sodium bicarbonate solution (10 mL) was added to the reaction solution at -78°C for quenching. The reaction solution was raised to room temperature and then extracted with ethyl acetate (30 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L005-2 (500 mg, crude product), which could be used directly in the next step. LC-MS: [M-OH] + = 461.95. 5.3 Synthesis of compound L005-3 L005-2 (500 mg, 1.04 mmol) was dissolved in dichloromethane (5 mL) at room temperature, and the reaction solution was cooled to -78°C. Triethylsilane (312 mg, 2.70 mmol) and boron trifluoride etherate complex (384 mg, 2.70 mmol) were added dropwise to the reaction solution under nitrogen protection. After the addition was completed, stir at -78°C for 1 hour. At -78°C, saturated aqueous sodium bicarbonate solution (10 mL) was added to the reaction solution for quenching. After the system temperature rose to room temperature, it was extracted with ethyl acetate (30 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L005-3 (450 mg, crude product), which could be used directly in the next step. LC-MS: [M-tBu+H] + =407.95. 5.4 Synthesis of compound L005-4 L005-3 (450 mg, crude product) was dissolved in methanol (5 mL), and wet palladium on carbon (200 mg, 10% palladium content) was added. Stir at 20°C for 1 hour under hydrogen atmosphere. The reaction solution was filtered, and the filtrate was concentrated under reduced pressure to obtain compound L005-4 (300 mg, crude product), which was used directly in the next step. 5.5 Synthesis of compound L005-5 L005-4 (127 mg, crude product), L001-7 (100 mg, 0.34 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (88 mg, 0.46 mmol), 1-hydroxybenzotriazole (69 mg, 0.46 mmol) and triethylamine (93 mg, 0.92 mmol) were dissolved in N,N-dimethylformamide (2 mL) and stirred at room temperature for 1 Hour. The reaction solution was diluted with water (20 mL), and extracted with dichloromethane (20 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain crude product. The crude product was purified by high-performance liquid phase preparative column chromatography (acidic conditions) to obtain compound L005-5 (150 mg). LC-MS: [M+H] + =576.10. 5.6 Synthesis of Compound L005 Hydrochloride Dissolve L005-5 (150 mg, 0.19 mmol) in dichloromethane (1 mL), add hydrogen chloride in 1,4-dioxane solution (1 mL, 4 M) dropwise, stir at room temperature for 1 hour, and a white solid will appear. Precipitate. The reaction solution was filtered, and the filter cake was washed with dichloromethane (3 mL). The filter cake was dissolved in deionized water (10 mL) and freeze-dried to obtain compound L005 hydrochloride (52.0 mg, yield 57.4%). 1 H NMR (400 MHz, DMSO- d 6 ): δ 10.54 – 10.52(m, 1H), 8.87(dd, J= 7.2, 4.0 Hz, 1H), 8.73 – 8.42(m, 2H), 8.04(s, 2H), 7.66(dt, J= 8.8, 7.2 Hz, 3H), 7.49(d, J= 8.0 Hz, 2H), 6.82(d, J= 8.0 Hz, 1H), 5.13(d, J= 7.2 Hz, 1H), 4.50 – 4.10(m, 2H), 3.26(s, 1H), 3.10 – 2.97(m, 1H), 2.96 – 2.71(m, 4H), 2.52(d, J= 7.2 Hz, 1H), 2.06(dt, J= 8.8, 6.8 Hz, 1H), 1.99 – 1.83(m, 2H), 1.21(d, J= 7.2 Hz, 3H); LC-MS: [M+H] + =476.05. 5.7 Synthesis of compounds L005-IS-01 hydrochloride and L005-IS-02 hydrochloride L005 hydrochloride (52.0 mg, 0.11 mmol) was separated and purified by supercritical fluid column chromatography (SFC) (column chromatography: Daicel Chiralpak AD, 50×25 mm, 10 μm, mobile phase, A: carbon dioxide, B: ethanol , flow rate: 70g / min), two compounds L005-IS-01 (retention time Rt =1.660min, 7.7 mg) and L005-IS-02 (retention time Rt =1.989min, 9.8 mg) were obtained. L005-IS-01: 1 H NMR (400 MHz, DMSO- d 6 ): δ 8.13(d, J= 7.6 Hz, 2H), 7.62(d, J= 8.0 Hz, 2H), 7.40(d, J= 8.0 Hz, 2H), 7.12(d, J= 8.4 Hz, 1H), 6.21(d, J= 8.4 Hz, 1H), 5.82(s, 2H), 5.05(dd, J= 14.4, 7.6 Hz, 1H), 4.32 - 4.08(m, 1H), 3.61 - 3.59(m, 1H), 2.82 - 2.66(m, 1H), 2.65 - 2.62(m, 5H), 2.37 - 2.12( m, 2H), 1.85 - 1.52(m, 3H), 1.20 - 1.17(m, 4H); LC-MS: [M+H] + =476.05. L005-IS-02: 1 H NMR (400 MHz, DMSO- d 6 ): δ 8.16 - 8.10(m, 2H), 7.62(d, J= 8.4 Hz, 2H), 7.39(d, J= 8.0 Hz, 2H), 7.08(d, J= 8.0 Hz, 1H), 6.21(d, J= 8.4 Hz, 1H), 5.81(s, 2H), 5.07(dd, J= 14.8, 7.6 Hz, 1H), 4.24 - 4.15(m, 1H), 3.62 - 3.59(m, 1H), 2.78 - 2.53(m, 6H), 2.58 - 2.30(m, 2H), 1.70 - 1.62( m, 2H), 1.19(t, J= 8.8 Hz, 4H); LC-MS: [M+H] + =476.05. Example 6, (2R,4R)-N-((S)-1-(((R)-2-amino-6,7-dihydro-5H-cyclopenta[b]pyridine-5 -yl)amino)-1-pentanoxypropan-2-yl)-4-phenylpyrrolidine-2-methamide hydrochloride (compound L006-IS-01 or L006-IS-02) and ( 2R,4R)-N-((S)-1-(((S)-2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino Synthesis of )-1-Pendant oxypropane-2-yl)-4-phenylpyrrolidine-2-methamide hydrochloride (compound L006-IS-02 or L006-IS-01) 6.1 Synthesis of compound L006-1 Add L006-a (1 g, 4.12 mmol) into the reaction flask under nitrogen atmosphere, add tetrahydrofuran (10 mL) to dissolve, and place it in a -78°C cold bath. Keep the temperature at -78°C and slowly add bis(trimethyl) Silica-based lithium amide (4.9 mL, 4.90 mmol, 1 M tetrahydrofuran solution). After the addition was completed, the reaction was continued at this temperature for 1 hour. A solution of N-(5-chloro-2-pyridyl)bis(trifluoromethanesulfonamide) (2 g, 5.10 mmol) in tetrahydrofuran (4 mL) was then slowly added dropwise at -78°C. After the addition is completed, continue the reaction at this temperature for 1 hour. The reaction solution was heated to -20°C and reacted for 16 hours. The reaction solution was quenched with saturated aqueous sodium bicarbonate solution (50 mL), and extracted with ethyl acetate (50 mL×3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L006-1 (1.1 g, yield 71%). 6.2 Synthesis of compound L006-2 L006-1 (600 mg, 1.60 mmol), phenylboronic acid (235 mg, 1.93 mmol), tetrakis(triphenylphosphine)palladium (185 mg, 0.16 mmol) and potassium carbonate (664 mg, 4.81 mmol) were added to the reaction In the bottle, under nitrogen atmosphere, add 1,4-dioxane (10 mL) and water (2 mL) to dissolve. The reaction solution was placed in an 80°C oil bath for 16 hours. The reaction solution was cooled to room temperature, diluted with water (50 mL), and extracted with ethyl acetate (50 mL × 3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was decompressed. concentrate. The residue was purified by silica gel column chromatography to obtain compound L006-2 (420 mg, yield 87%). LC-MS: [M+H] + = 304.10. 6.3 Synthesis of compound L006-3 Add L006-2 (420 mg, 1.36 mmol) and lithium hydroxide monohydrate (873 mg, 20.78 mmol) into the reaction flask, add tetrahydrofuran (4 mL), methanol (2 mL) and water (2 mL) to dissolve. The reaction solution was stirred at room temperature for 2 hours. The pH value of the reaction solution was adjusted to 5~6 with dilute hydrochloric acid (1 M), diluted with water (10 mL), and extracted with ethyl acetate (20 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L006-3 (350 mg, yield 87.1%). LC-MS: [M-tBu+H] + = 234.05. 6.4 Synthesis of compound L006-4 Add L006-3 (350 mg, 1.21 mmol), tris(triphenylphosphine)rhodium chloride (113 mg, 0.12 mmol), triethylamine (123 mg, 1.21 mmol) and methanol (10 mL) to the reaction flask in a hydrogen atmosphere, and stirred at room temperature for 2 days. The reaction solution was filtered, and the pH of the filtrate was adjusted to 10 with sodium hydroxide aqueous solution (1M). Extract with ethyl acetate (40 mL), wash the organic phase once with saturated aqueous sodium bicarbonate solution (20 mL) and discard. Combine all aqueous phases, adjust the pH to about 5-6 with dilute hydrochloric acid (0.5 M), and then extract with ethyl acetate (20 mL×3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L006-4 (209 mg, yield 73.2%). LC-MS: [M-Boc+H] + = 192.10. 6.5 Synthesis of compounds L006-5-IS-01 and L006-5-IS-02 Combine L006-4 (100 mg, 0.34 mmol), 1-hydroxybenzotriazole (53 mg, 0.38 mmol), N,N-dimethylformamide (3 mL), N,N-diisopropyl Ethylamine (177 mg, 1.37 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (73 mg, 0.38 mmol) were added to the reaction flask and stirred at room temperature. 0.5 hours, then add L001-7 (91 mg, 0.41 mmol), and continue the reaction at room temperature for 1 hour. The reaction solution was diluted with water (50 mL), and extracted with ethyl acetate (30 mL×3). The combined organic phases were washed with saturated aqueous sodium chloride solution (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was prepared by high-performance liquid phase column chromatography (acidic conditions) to obtain compounds L006-5-IS-01 (retention time: Rt = 18.349min, 20 mg) and L006-5-IS-02 (retention time: Rt = 20.877min, 30 mg). LC-MS: [M+H] + = 494.10. 6.6 Synthesis of compound L006-IS-01 hydrochloride Dissolve the obtained L006-5-IS-01 (retention time: Rt = 18.349min, 20 mg) in dichloromethane (2 mL), add hydrogen chloride in ethyl acetate solution (1 mL, 4 M), and stir at room temperature. 1 hour. If a solid precipitates, the reaction solution is filtered, and the filter cake is washed with ethyl acetate (10 mL). The solid was dissolved in deionized water (5 mL) and freeze-dried to obtain compound L006-IS-01 hydrochloride (13.5 mg). 1 H NMR (400 MHz, CH 3 OH- d 4 ): δ 7.85 - 7.75(m, 1H), 7.38 - 7.28(m, 5H), 6.85 - 6.80(m, 1H), 5.33 - 5.29(m, 1H), 4.63 - 4.49(m, 1H), 4.37 - 4.30(m, 1H), 3.84 - 3.76(m, 1H), 3.68 - 3.47(m, 1H), 3.36 - 3.31(m, 1H), 3.17 - 3.09(m, 1H), 3.02 - 2.88(m, 2H ), 2.66 - 2.56(m, 1H), 2.22 - 1.99(m, 2H), 1.42(d, J= 7.2 Hz, 3H); LC-MS: [M+H] + =394.10. 6.7 Synthesis of Compound L006-IS-02 Hydrochloride Dissolve the obtained L006-5-IS-02 (retention time: Rt = 20.877min, 30 mg) in dichloromethane (2 mL), add hydrogen chloride in ethyl acetate solution (1 mL, 4 M), and stir at room temperature. 1 hour. If a solid precipitates, the reaction solution is filtered, and the filter cake is washed with ethyl acetate (10 mL). The solid was dissolved in deionized water (5 mL) and freeze-dried to obtain compound L006-IS-02 hydrochloride (22.2 mg). 1 H NMR (400 MHz, CH 3 OH- d 4 ): 1 H NMR (400 MHz, CH 3 OH- d 4 ): δ 7.86 - 7.78(m, 1H), 7.38 - 7.28(m, 5H), 6.85 - 6.82(m, 1H), 5.35 - 5.30(m, 1H), 4.63 - 4.46(m, 1H), 4.39 - 4.28(m, 1H), 3.86 - 3.76(m, 1H), 3.69 - 3.48(m, 1H), 3.38 - 3.35(m, 1H), 3.19 - 3.11(m, 1H), 3.05 - 2.97(m, 1H ), 2.67 - 2.50(m, 3H), 2.11 - 1.99(m, 1H), 1.42(d, J= 7.2 Hz, 3H); LC-MS: [M+H] + =394.10. Example 7, (2R,4R)-N-((2S)-1-((2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amine Synthesis of methyl)-1-side oxypropan-2-yl)-4-(4-fluorophenyl)pyrrolidine-2-methamide (compound L007) hydrochloride 7.1 Synthesis of compound L007-1 L006-1 (450 mg, 1.2 mmol), p-fluorophenylboronic acid (202 mg, 1.44 mmol), tetrakis(triphenylphosphine)palladium (129 mg, 0.12 mmol) and potassium carbonate (497 mg, 3.6 mmol) were mixed at room temperature. ) was added to 1,4-dioxane (10 mL) and water (2 mL). Under nitrogen protection, react at 80°C for 16 hours. The reaction solution was cooled to room temperature, diluted with water (50 mL), and extracted with ethyl acetate (50 mL×3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L007-1 (361 mg, yield 94%). LC-MS: [M+H] + = 322.05. 7.2 Synthesis of compound L007-2 Add L007-1 (361 mg, 1.12 mmol) and lithium hydroxide monohydrate (708 mg, 16.86 mmol) into the reaction flask, add tetrahydrofuran (4 mL), methanol (2 mL) and water (2 mL) to dissolve, Stir at room temperature for 2 hours. The pH value of the reaction solution was adjusted to 5~6 with dilute hydrochloric acid (1 M), diluted with water (10 mL), and extracted with ethyl acetate (20 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L007-2 (325 mg, yield 94%), which could be used directly in the next step. LC-MS: [M-tBu+H] + = 252.05. 7.3 Synthesis of compound L007-3 L007-2 (325 mg, 1.06 mmol), tris(triphenylphosphine rhodium chloride) (102 mg, 0.11 mmol) and triethylamine (107 mg, 1.06 mmol) were added to the reaction flask, methanol (10 mL ) was dissolved, replaced with a hydrogen atmosphere, and stirred at room temperature for 4 days. The reaction solution was filtered, and the filtrate was adjusted to pH = 10 with sodium hydroxide aqueous solution (1 M), extracted with ethyl acetate (40 mL), and the organic phase was washed once with saturated sodium bicarbonate aqueous solution (20 mL) and discarded. The combined aqueous phase was adjusted to pH 5-6 with dilute hydrochloric acid (0.5 M), and then extracted with ethyl acetate (20 mL×3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L007-3 (crude product), which can be directly used in the next step. LC-MS: [M-tBu +H] + = 254.00. 7.4 Synthesis of compound L007-4 Combine L007-3 (100 mg, 0.32 mmol), 1-hydroxybenzotriazole (49 mg, 0.36 mmol), N,N-dimethylformamide (2 mL), N,N-diisopropyl Ethylamine (167 mg, 1.29 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (68 mg, 0.36 mmol) were added to the reaction flask and stirred at room temperature. 0.5 hours, then add L001-7 (86 mg, 0.39 mmol), and continue the reaction at room temperature for 1 hour. The reaction solution was diluted with water (50 mL), and extracted with ethyl acetate (30 mL×3). The combined organic phases were washed with saturated aqueous sodium chloride solution (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by HPLC preparative column chromatography (acidic conditions) to obtain compound L007-4 (40 mg). LC-MS: [M+H] + =512.05. 7.5 Synthesis of compound L007 hydrochloride Dissolve L007-4 (40 mg, 0.078 mmol) in dichloromethane (2 mL), add hydrogen chloride in ethyl acetate solution (1 mL, 4 M), and stir at room temperature for 1 hour. If a solid precipitates, the reaction solution is filtered, and the filter cake is washed with ethyl acetate (5 mL), dissolved in deionized water (5 mL), and freeze-dried to obtain compound L007 hydrochloride (5.2 mg). 1 H NMR (400 MHz, CH 3 OH- d 4 ): δ 7.87 - 7.73(m, 1H), 7.64 - 7.55(m, 1H), 7.37(dd, J= 8.8 Hz, 5.2 Hz, 1H), 7.21 - 7.08(m, 2H), 6.86 - 6.74(m, 1H), 5.36 - 5.32(m, 1.5H), 4.59 - 4.48(m, 1.5H), 4.37 - 4.29(m, 1H), 3.80 - 3.69(m, 1H), 3.35 - 3.33(m, 1H), 3.16 - 3.13(m, 1H), 3.06 - 3.00(m, 1H), 2.91 - 2.84(m, 0.5H), 2.68 - 2.62(m, 1H), 2.21 - 1.95(m, 2.5H), 1.47 - 1.41(m, 3H); 19 F NMR (400 MHz, CH 3 OH- d 4 ): δ -113.09, -116.89; LC-MS: [M+H] + = 412.15. Example 8, (2R,4R)-N-((2S)-1-((2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amine Synthesis of methyl)-1-side oxypropan-2-yl)-4-(4-(trifluoromethyl)phenyl)pyrrolidine-2-methamide (compound L008) hydrochloride 8.1 Synthesis of compound L008-1 L006-1 (450 mg, 1.2 mmol), p-trifluoromethylbenzeneboronic acid (274 mg, 1.44 mmol), tetrakis(triphenylphosphine)palladium (139 mg, 0.12 mmol) and potassium carbonate (496.5 mg, 3.6 mmol) into the reaction flask, add 1,4-dioxane (10 mL) and water (2 mL) to dissolve, and react at 80°C for 16 hours in a nitrogen atmosphere. The reaction solution was cooled to room temperature, diluted with water (50 mL), and extracted with ethyl acetate (50 mL×3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L008-1 (386 mg, yield 88%). LC-MS: [M-tBu+H] + = 316.00. 8.2 Synthesis of compound L008-2 Add L008-1 (386 mg, 1.04 mmol) and lithium hydroxide monohydrate (16 mg, 16.86 mmol) into the reaction flask, add tetrahydrofuran (4 mL), methanol (2 mL) and water (2 mL) to dissolve, Stir at room temperature for 2 hours. The pH value of the reaction solution was adjusted to 5~6 with dilute hydrochloric acid (1 M). Dilute with water (10 mL) and extract with ethyl acetate (20 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L008-2 (310 mg, yield 83%). LC-MS: [M-tBu+H] + = 302.00. 8.3 Synthesis of compound L008-3 Add L008-2 (310 mg, 0.87 mmol), tris(triphenylphosphine)rhodium chloride (81 mg, 0.09 mmol) and triethylamine (88 mg, 0.87 mmol) into the reaction flask, and add methanol (15 mL) and tetrahydrofuran (15 mL) were dissolved, and the mixture was stirred at room temperature under a hydrogen atmosphere for 4 days. The reaction solution was filtered, and the pH value of the filtrate was adjusted to pH=10 with sodium hydroxide aqueous solution (1M), extracted with ethyl acetate (40 mL), and the organic phase was washed once with saturated sodium bicarbonate aqueous solution (20 mL) and discarded. Combine all aqueous phases, adjust the pH of the aqueous phase to 5-6 with dilute hydrochloric acid (0.5M), and extract with ethyl acetate (20 mL×3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L008-3 (crude product), which can be directly used in the next step. LC-MS: [M-tBu+H] + = 304.00. 8.4 Synthesis of compound L008-4 Combine L008-3 (100 mg, 0.28 mmol), 1-hydroxybenzotriazole (42.2 mg, 0.31 mmol), N,N-dimethylformamide (2 mL), N,N-diisopropyl Ethylamine (143.7 mg, 1.11 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (58.5 mg, 0.31 mmol) were added to the reaction flask and stirred at room temperature. 0.5 hours, then add L001-7 (73.5 mg, 0.33 mmol), and continue the reaction at room temperature for 1 hour. The reaction solution was diluted with water (50 mL), and extracted with ethyl acetate (30 mL×3). The combined organic phases were washed with saturated sodium chloride aqueous solution (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by high-performance liquid phase preparative column chromatography (acidic conditions) to obtain compound L008-4 (35.2 mg). LC-MS: [M+H] + =562.05. 8.5 Synthesis of compound L008 hydrochloride Dissolve L008-4 (35.2 mg, 0.063 mmol) in dichloromethane (2 mL), add hydrogen chloride in ethyl acetate solution (1 mL, 4 M), and stir at room temperature for 1 hour. If a solid precipitates, the reaction solution is filtered, and the filter cake is washed with ethyl acetate (5 mL). The filter cake was dissolved in deionized water (5 mL) and freeze-dried to obtain compound L008 hydrochloride (23.7 mg). 1 H NMR (400 MHz, CH 3 OH- d 4 ): δ 7.87 - 7.77(m, 1H), 7.68(d, J= 8.0 Hz, 2H), 7.56(t, J= 8.0 Hz, 2H), 6.85 - 6.80(m, 1H), 5.35 - 5.28(m, 1H), 4.55 - 4.49(m, 1H), 4.40 - 4.28(m, 1H), 3.88 - 3.78(m, 2H), 3.42 - 3.37(m, 1H), 3.17 - 3.09(m, 1H), 3.05 - 2.89(m, 2H), 2.67 - 2.63(m, 1H), 2.29 - 2.02(m, 2H), 1.44 - 1.40(m, 3H); LC-MS: [M+H] + = 462.05. Example 9, (2R,4S)-N-((2S)-1-((2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amine Synthesis of methyl)-1-pentanoxypropan-2-yl)-4-(1-phenylethyl)pyrrolidine-2-methamide (compound L009) hydrochloride 9.1 Synthesis of compound L009-1 L006-1 (600 mg, 1.6 mmol), L009-a (442 mg, 1.92 mmol), tetrakis(triphenylphosphine)palladium (185 mg, 0.16 mmol) and potassium carbonate (661.9 mg, 4.8 mmol) were added to In the reaction bottle, under nitrogen atmosphere, add 1,4-dioxane (10 mL) and water (2 mL) to dissolve, and react at 80°C for 16 hours. The reaction solution was cooled to room temperature, diluted with water (50 mL), and extracted with ethyl acetate (50 mL×3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L009-1 (480 mg, yield 91%). LC-MS: [M+H] + = 330.10. 9.2 Synthesis of compound L009-2 Add L009-1 (120 mg, 0.4 mmol) into the reaction flask, and add methanol (10 mL) to dissolve. Then wet palladium on carbon (30 mg, 10% palladium content) was added, and the reaction was carried out at room temperature in a hydrogen environment for 3 hours. The reaction solution was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure to obtain compound L009-2 (crude product), which was directly used in the next step. LC-MS: [M+H] + = 334.10. 9.3 Synthesis of compound L009-3 Add L009-2 (122.7 mg, crude product) and lithium hydroxide monohydrate (129.7 mg, 5.4 mmol) into the reaction flask, add tetrahydrofuran (4 mL), methanol (2 mL) and water (2 mL) to dissolve, chamber Stir at room temperature for 2 hours. The pH value of the reaction solution was adjusted to 5~6 with dilute hydrochloric acid (1 M). Dilute with water (10 mL) and extract with ethyl acetate (20 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L009-3 (100 mg), a colorless oily liquid. LC-MS: [M-tBu+H] + = 264.10. 9.4 Synthesis of compound L009-4 Combine L009-3 (100 mg, 0.31 mmol), 1-hydroxybenzotriazole (48 mg, 0.35 mmol), N,N-dimethylformamide (2 mL), N,N-diisopropyl Ethylamine (162 mg, 1.25 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (66 mg, 0.35 mmol) were added to the reaction flask, and the reaction was carried out at room temperature for 0.5 Hour. Then add L001-7 (83 mg, 0.38 mmol), and continue the reaction at room temperature for 1 hour. The reaction solution was diluted with water (40 mL) and extracted with ethyl acetate (30 mL×3). The combined organic phases were washed with saturated aqueous sodium chloride solution (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by high-performance liquid phase preparative column chromatography (acidic conditions) to obtain compound L009-4 (51.7 mg, yield 36.7%). LC-MS: [M+H] + =522.05. 9.5 Synthesis of Compound L009 Hydrochloride Dissolve L009-4 (51.7 mg, 0.1 mmol) in dichloromethane (2 mL), add hydrogen chloride in ethyl acetate solution (1 mL, 4 M) at room temperature, stir for 0.5 hours, and a solid precipitates. The reaction solution was filtered, and the filter cake was washed with ethyl acetate (5 mL). The filter cake was dissolved in deionized water (2 mL) and freeze-dried to obtain compound L009 hydrochloride (35.9 mg, yield 73.1%) hydrochloride. 1 H NMR (400 MHz, CH 3 OH- d 4 ): δ 7.71 - 7.59(m, 1H), 7.17(t, J= 7.2 Hz, 2H), 7.11 - 7.07(m, 3H), 6.72 - 6.67(m, 1H), 5.18 - 5.09(m, 1H), 4.23 - 4.19(m, 1H), 4.16 - 4.07(m, 1H), 3.52 - 3.48(m, 0.5H), 3.03 - 2.96(m, 1.5H), 2.89 - 2.60(m, 3H), 2.53 - 2.46(m, 3H), 2.05 - 1.87(m, 2H), 1.28(d, J= 7.2 Hz, 2H), 1.21 - 1.15(m, 4H); LC-MS: [M+H] + = 422.15. Example 10, (2R,4S)-N-((2S)-1-((2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amine Synthesis of pyrrolidine-2-carboxamide (compound L010) hydrochloride 10.1 Synthesis of compound L010-1 Dissolve L001-e (5.1 g, 16.0 mmol) in tetrahydrofuran (40 mL) under nitrogen protection, cool to -78°C, and slowly add lithium bis(trimethylsilyl)amide (24 mL, 24.0 mmol, 1 M tetrahydrofuran solution) and stir at this temperature for 0.5 hours. Then L010-a (4.0 g, 16.0 mmol) was slowly added, and the reaction was continued at -78°C for 2 hours. At -78°C, the reaction solution was quenched with saturated ammonium chloride solution (30 mL). The reaction system was raised to room temperature and then extracted with ethyl acetate (30 mL×3). The combined organic phases were washed with saturated sodium chloride (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L010-1 (2.8 g, yield 35.8%). LC-MS: [M-Boc+H] + = 387.90. 10.2 Synthesis of compound L010-2 Dissolve L010-1 (2.0 g, 4.1 mmol) in tetrahydrofuran (25 mL) under nitrogen protection, cool to -78°C, slowly add lithium triethylborohydride (4.5 mL, 4.5 mmol, 1 M tetrahydrofuran solution), The temperature was controlled at -78°C and the reaction was stirred for 2 hours. Add water (15 mL) to quench, extract with ethyl acetate (20 mL×3), wash the combined organic phases with saturated aqueous sodium chloride solution (20 mL), dry over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L010-2 (1.1 g, yield 54.77%). LC-MS: [M-OH] + = 473.95. 10.3 Synthesis of compound L010-3 Dissolve L010-2 (1.0 g, 2.1 mmol) in dichloromethane (10 mL), protect with nitrogen, and cool to -78°C. Slowly add triethylsilane (360 mg, 3.1 mmol), and then slowly add dropwise Boron trifluoride etherate complex (436 mg, 3.1 mmol), continue to stir the reaction at -78°C for 2 hours. At this temperature, add water (15 mL) to quench the reaction. After the reaction system warms to room temperature, extract with dichloromethane (15 mL×3). The combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L010-3 (400 mg, yield 41.35%). LC-MS: [M-Boc+H] + = 375.95. 10.4 Synthesis of compound L010-4 L010-4 (400 mg, 0.84 mmol), L010-b (181.6 mg, 0.89 mmol), cesium carbonate (550 mg, 1.69 mmol) and tetrakis(triphenylphosphine)palladium (107 mg, 0.08 mmol) were added in sequence. Add to 1,4-dioxane (5 mL) and water (1 mL), and stir at 100°C for 2 hours under nitrogen protection. The reaction solution is cooled to room temperature, and any solid remains undissolved. After the reaction solution was filtered, water (10 mL) was added to the filtrate, and extracted with ethyl acetate (10 mL×3). The combined organic phases were washed with saturated sodium chloride aqueous solution (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L010-4 (300 mg, yield 75.29%). 10.5 Synthesis of compound L010-5 Dissolve L010-4 (300 mg, 0.63 mmol) in methanol (2 mL), add wet palladium on carbon (100 mg, 10% palladium content), and stir at 20°C for 1 hour in a hydrogen atmosphere. The reaction solution was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L010-5 (140 mg, yield 57.66%). LC-MS: [M+H] + = 383.05. 10.6 Synthesis of compound L010-6 Dissolve L010-5 (130 mg, 0.34 mmol) in N,N-dimethylformamide (2 mL), add 1-hydroxybenzotriazole (50.5 mg, 0.37 mmol) and 1-(3-bis Methylaminopropyl)-3-ethylcarbodiimide hydrochloride (70.1 mg, 0.37 mmol), stir at room temperature for 10 minutes, then add L001-7 (74.9 mg, 0.34 mmol) and N,N-diiso A solution of propylethylamine (175.4 mg, 1.36 mmol) in N,N-dimethylformamide (2 mL) was stirred at room temperature for 1.5 hours. The reaction solution was poured directly into water (10 mL), extracted with ethyl acetate (15 mL×3), the combined organic phases were washed with saturated aqueous ammonium chloride solution (10 mL×3), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by high-performance liquid phase preparative column chromatography (alkaline conditions) and freeze-dried to obtain compound L010-6 (49 mg, yield 24.65%). LC-MS: [M+H] + = 585.15. 10.7 Synthesis of Compound L010 Hydrochloride Dissolve L010-6 (49 mg, 0.084 mmol) in dichloromethane (2 mL), add hydrogen chloride in ethyl acetate (1 mL, 4 M) at room temperature, stir for 0.5 hours, and a solid precipitates. The reaction solution was filtered, and the filter cake was washed with ethyl acetate (10 mL). The filter cake was dissolved in deionized water (10 mL) and freeze-dried to obtain compound L010 hydrochloride (18.5 mg, yield 45.6%). 1 H NMR (400 MHz, DMSO- d 6 ): δ 10.70(s, 1H), 9.24(s, 1H), 8.99(t, J= 7.2 Hz, 1H), 8.85(d, J= 6.0 Hz, 2H), 8.70(t, J= 7.6 Hz, 1H), 8.61(s, 1H), 8.33 - 7.98(m, 3H), 7.85(d, J= 8.0 Hz, 2H), 7.68(d, J= 8.8 Hz, 1H), 7.48(d, J= 8.0 Hz, 2H), 6.87(d, J= 8.8 Hz, 1H), 5.14(q, J= 7.2 Hz, 1H), 4.43(s, 1H), 4.1 - 4.19(m, 1H), 3.30(s, 1H), 3.12 - 2.99(m, 1H), 2.98 - 2.73(m, 4H), 2.61 - 2.51(m, 1H), 2.48 - 2.38(m, 1H), 2.16 - 2.07(m, 1H), 2.01 - 1.90(m, 2H), 1.23(d, J= 7.2 Hz, 3H); LC-MS: [M+H] + = 485.10. Example 11, (2R,4S)-N-((2S)-1-((2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amine Synthesis of ((2-methylpyridin-4-yl)methyl)pyrrolidine-2-methamide (compound L011) hydrochloride 11.1 Synthesis of compound L011-1 L011-a (3.0 g, 21.90 mmol) was added to tetrahydrofuran (40 mL), and L011-b (3.6 g, 26.30 mmol) was added dropwise at 0°C. After the dropwise addition was completed, the temperature was raised to 20°C and stirred for 0.5 hours. A large amount of white solid precipitated, filter the solid, cool the filtrate to 0°C, add sodium borohydride (1.25 g, 32.90 mmol) in water (5 mL), and stir the reaction solution at 0°C for 0.5 hours. The pH of the reaction solution was adjusted to 5-6 with dilute hydrochloric acid (1 M), and extracted with ethyl acetate (20 mL×3). The organic phase was discarded, the pH of the aqueous phase was adjusted to 8 with sodium carbonate, and extracted with ethyl acetate (20 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L011-1 (1.0 g, yield 38.5%). LC-MS: [M+H] + = 124.20. 11.2 Synthesis of compound L011-2 L011-1 (1.3 g, 10.60 mmol) and triphenylphosphine (3.6 g, 13.70 mmol) were added to dichloromethane (20 mL), and carbon tetrabromide (4.5 g, 13.70 mmol) was added dropwise at 0°C. of dichloromethane (5 mL). After the addition was complete, the reaction was stirred at 20°C for 0.5 hours. The reaction solution was diluted with water (20 mL), and extracted with ethyl acetate (20 mL×3). The organic phase was dried over anhydrous sodium sulfate and filtered. Toluene (20 mL) was added to the filtrate and concentrated to 10 mL under reduced pressure. Toluene (20 mL) was added again and continued to be concentrated under reduced pressure to 5 mL to obtain toluene of compound L011-2. solution. This solution was used directly in the next step. LC-MS: [M+H] + = 188.00. 11.3 Synthesis of compound L011-3 L001-e (2.2 g, 7.00 mmol) was added to tetrahydrofuran (20 mL) and cooled to -78°C. Lithium bis(trimethylsilyl)amide (7.7 mL, 7.70 mmol, 1 M tetrahydrofuran solution) was added dropwise under nitrogen protection. After the dropwise addition was completed, the mixture was stirred at -78°C for 0.5 hours. Then add the toluene solution of L011-2 (~5 mL, crude solution obtained in the previous step) dropwise. The reaction was stirred at -78°C for 1 hour. An aqueous ammonium chloride solution (10 mL) was added to the reaction solution at -78°C to quench the reaction. After the system temperature rose to room temperature, it was extracted with ethyl acetate (10 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L011-3 (1.28 g, yield 43.1%). LC-MS: [M+H] + = 425.10. 11.4 Synthesis of compound L011-4 L011-3 (1.28 g, 3.00 mmol) was added to tetrahydrofuran (15 mL) at room temperature and cooled to -78°C. Lithium triethylborohydride (3.6 mL, 3.6 mmol, 1M tetrahydrofuran solution) was added dropwise under nitrogen protection. After the dropwise addition was completed, the mixture was stirred at -78°C for 0.5 hours. Saturated aqueous sodium bicarbonate solution (10 mL) was added to the reaction solution at -78°C to quench it. After the reaction system warmed to room temperature, it was extracted with ethyl acetate (10 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L011-4 (crude product), which was used directly in the next step. LC-MS: [M+H] + = 427.10. 11.5 Synthesis of compound L011-5 Dissolve L011-4 (1.3 g, 3.00 mmol) in dichloromethane (20 mL) at room temperature, and cool to -78°C. Triethylsilane (650 mg, 4.50 mmol) and boron trifluoride etherate complex (522 mg, 4.50 mmol) were added dropwise under nitrogen protection. The reaction solution was reacted at -78°C for 1 hour. Add saturated aqueous sodium bicarbonate solution (10 mL) at -78°C to quench, wait until the system warms to room temperature, and then extract with ethyl acetate (10 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L011-5 (crude product), which was used directly in the next step. LC-MS: [M+H] + = 411.10. 11.6 Synthesis of compound L011-6 L011-5 (400 mg, 0.98 mmol) and wet palladium on carbon (200 mg, 10% palladium content) were added to methanol (4 mL), and stirred at room temperature under a hydrogen atmosphere for 0.5 hours. The reaction solution was filtered, and the filtrate was concentrated under reduced pressure to obtain L011-6 (crude product), which was directly used in the next step. LC-MS: [M+H] + =321.10. 11.7 Synthesis of compound L011-7 L011-6 (110 mg, crude product), L001-7 (100 mg, 0.34 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (97 mg, 0.51 mmol), 1-hydroxybenzotriazole (77 mg, 0.51 mmol) and triethylamine (104 mg, 1.02 mmol) were added to dichloromethane (3 mL), and stirred at room temperature for 0.5 hours. The reaction solution was diluted with water (20 mL), and extracted with dichloromethane (10 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by high-performance liquid phase preparative column chromatography (acidic conditions) to obtain compound L011-7 (70 mg, yield 38.5%). LC-MS: [M+H] + = 523.10. 11.8 Synthesis of Compound L011 Hydrochloride Dissolve L011-7 (70 mg, 0.13 mmol) in dichloromethane (2 mL), add hydrogen chloride in 1,4-dioxane solution (2 mL, 4M) dropwise at room temperature, and stir for 0.5 hours. If a solid precipitates, the reaction solution is filtered, and the filter cake is washed with dichloromethane (5 mL). The filter cake was dissolved in deionized water (10 mL) and freeze-dried to obtain compound L011 hydrochloride (39.0 mg, yield 63.8%). 1 H NMR (400 MHz, DMSO- d 6 ): δ 10.75 - 10.69(m, 1H), 8.93(t, J= 6.8 Hz, 1H), 8.71 - 8.58(m, 3H), 8.05(s, 2H), 7.86(s, 1H), 7.80(d, J= 5.6 Hz, 1H), 7.85 - 7.63(m, 1H), 6.83(d, J= 8.8 Hz, 1H), 5.13(m, 1H), 4.41(s, 1H), 4.33 - 4.16(m, 1H), 3.29(d, J= 4.4 Hz, 2H), 3.10 - 2.97(m, 1H), 2.96 - 2.84(m, 3H), 2.70(s, 3H), 2.62(s, 1H), 2.46 - 2.32(m, 1H), 2.15 - 2.04(m, 1H), 2.02 - 1.87(m, 2H), 1.22(d, J= 7.2 Hz, 3H); LC-MS: [M+H] + = 423.10. Example 12, (2R,4S)-N-((2S)-1-((2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amine Synthesis of methyl)-1-pentanoxypropan-2-yl)-4-(3-chloro-4-fluorobenzyl)pyrrolidine-2-formamide (compound L012) hydrochloride 12.1 Synthesis of compound L012-1 Dissolve L001-e (1.5 g, 4.69 mmol) in tetrahydrofuran (15 mL) at room temperature, cool to -78°C, and add lithium bis(trimethylsilyl)amide (5.16 mL, 5.16 mmol, 1M solution in tetrahydrofuran). After the dropwise addition was completed, the mixture was stirred at -78°C for 0.5 hours. A solution of L012-a (1.15 g, 5.16 mmol) in tetrahydrofuran (10 mL) was added, and stirring was continued at -78°C for 2 hours. At this temperature, an aqueous solution of ammonium chloride (10 mL) was added to the reaction solution to quench it. After the system warmed to room temperature, it was extracted with ethyl acetate (50 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L012-1 (1.5 g, yield 69.1%). LC-MS: [M-Boc+H] + = 361.95. 12.2 Synthesis of compound L012-2 Dissolve L012-1 (1.5 g, 3.20 mmol) in tetrahydrofuran (25 mL) at room temperature and cool to -78°C. Lithium triethylborohydride (3.5 mL, 3.5 mmol, 1 M tetrahydrofuran solution) was added dropwise under nitrogen protection. After the dropwise addition was completed, the mixture was stirred at -78°C for 0.5 hours. At this temperature, saturated aqueous sodium bicarbonate solution (10 mL) was added to the reaction solution to quench it. After the system warmed to room temperature, it was extracted with ethyl acetate (50 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L012-2 (crude product), which was used directly in the next step. 12.3 Synthesis of compound L012-3 L012-2 (1.5 g, crude product) was dissolved in dichloromethane (15 mL) at room temperature, and the reaction solution was cooled to -78°C. After adding triethylsilane (487 mg, 4.20 mmol) under nitrogen protection, boron trifluoride etherate complex (600 mg, 4.20 mmol) was added dropwise. After the dropwise addition, stir at -78°C for 1 hour. At this temperature, saturated aqueous sodium bicarbonate solution (10 mL) was added to the reaction solution to quench it. After the system warmed to room temperature, it was extracted with ethyl acetate (50 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L012-3 (crude product), which was used directly in the next step. LC-MS: [M+H] + = 447.95. 12.4 Synthesis of compound L012-4 Dissolve L012-3 (500 mg, 1.16 mmol) in tetrahydrofuran (4 mL) and water (2 mL) at room temperature, add lithium hydroxide monohydrate (180 mg, 4.46 mmol), and stir at room temperature for 16 hours. The reaction solution was directly concentrated under reduced pressure, and the residue was dissolved in water (10 mL). The pH value of the aqueous phase was adjusted to 5-6 with dilute hydrochloric acid (1 M), and then extracted with ethyl acetate (20 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L012-4 (crude product), which was used directly in the next step. LC-MS: [M-tBu+H] + = 301.95. 12.5 Synthesis of compound L012-5 L012-4 (170 mg, crude product), L001-7 (140 mg, 0.48 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (137 mg, 0.72 mmol), 1-hydroxybenzotriazole (109 mg, 0.72 mmol) and triethylamine (146 mg, 1.44 mmol) were added to dichloromethane (3 mL), and stirred at room temperature for 0.5 hours. The reaction solution was diluted with water (20 mL), and extracted with dichloromethane (10 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by high-performance liquid phase preparative column chromatography to obtain compound L012-5 (100 mg, yield 37.5%). LC-MS: [M+H] + = 560.00. 12.6 Synthesis of Compound L012 Hydrochloride Dissolve L012-5 (100 mg, 0.18 mmol) in dichloromethane (1 mL), add hydrogen chloride in 1,4-dioxane solution (1 mL, 4M), and stir at room temperature for 1 hour. If a solid precipitates, the reaction solution is filtered, and the filter cake is dissolved in deionized water (10 mL) and freeze-dried to obtain compound L012 hydrochloride (69.7 mg, yield 78.7%). 1 H NMR (400 MHz, DMSO- d 6 ): δ 10.29 - 10.19(m, 1H), 8.82 - 8.78(m, 1 H), 8.54 - 8.52(m, 2H), 7.94(s, 2H), 7.66 - 7.65(m, 1H), 7.48 - 7.45 (m, 1H), 7.34(t, J= 8.8 Hz, 1H), 7.29 - 7.17(m, 1H), 6.80( d, J= 8.8 Hz, 1H), 5.14 - 5.12(m, 1H), 4.35 - 4.18(m, 2H), 3.26 - 3.24(m, 1H), 2.94 - 2.84(m, 3H), 2.78 - 2.59(m, 2H), 2.46 - 2.40(m, 1H), 2.10 - 1.83(m, 3H), 1.24 - 1.21(m, 4H); LC-MS: [M+H] + =459.95. Example 13, (2R,4R)-N-((2S)-1-((2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amine yl)-1-Pendant oxypropan-2-yl)-4-((5-chlorobenzo[d]thiazol-2-yl)methyl)pyrrolidine-2-carboxamide (Compound L013) hydrochloride Synthesis 13.1 Synthesis of compound L013-1 L013-a (2 g, 12.50 mmol) was added to toluene (15 mL), and L013-b (2.8 g, 25.00 mmol) was added dropwise at room temperature. After completion of the dropwise addition, stir at 100°C for 2 hours. The reaction solution was cooled to room temperature and concentrated under reduced pressure to remove toluene. Petroleum ether (100 mL) was added to the residue, stirred at room temperature for 1 hour, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L013-1 (1.5 g, yield 55.5%). LC-MS: [M+H] + = 217.95. 13.2 Synthesis of compound L013-2 L013-1 (1.5 g, 6.88 mmol) and sodium iodide (2.1 g, 13.76 mmol) were added to tetrahydrofuran (20 mL), and stirred at 40°C for 2 hours. The reaction solution was cooled to room temperature, then diluted with water (20 mL), and extracted with ethyl acetate (20 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L013-2 (2.05 g, yield 96.2%). LC-MS: [M+H] + = 309.80. 13.3 Synthesis of compound L013-3 L001-e (2.11 g, 6.60 mmol) was dissolved in tetrahydrofuran (20 mL) at room temperature and cooled to -78°C. Under nitrogen protection, lithium bis(trimethylsilyl)amide (7.3 mL, 7.3 mmol, 1 M tetrahydrofuran solution) was added dropwise. After the dropwise addition was completed, stirring was continued for 0.5 hours. Then a tetrahydrofuran solution (10 mL) of L013-2 (2.05 g, 6.6 mmol) was added dropwise. After the dropwise addition was completed, the reaction solution was continued to stir at -78°C for 1 hour. At this temperature, an aqueous solution of ammonium chloride (10 mL) was added to the reaction solution to quench it. After the system temperature rose to room temperature, it was extracted with ethyl acetate (10 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L013-3 (2 g, yield 60.6%). LC-MS: [M+H] + = 500.90. 13.4 Synthesis of compound L013-4 Dissolve L013-3 (1.3 g, 2.60 mmol) in tetrahydrofuran (15 mL) at room temperature, then cool to -78°C, and add lithium triethylborohydride (2.9 mL, 2.90 mmol, 1 M tetrahydrofuran) dropwise under nitrogen protection. solution), after the dropwise addition is completed, stir at -78°C for 0.5 hours. At this temperature, saturated aqueous sodium bicarbonate solution (10 mL) was added to quench the reaction. After the system temperature rose to room temperature, it was extracted with ethyl acetate (10 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L013-4 (crude product), which was used directly in the next step. LC-MS: [M-OH] + = 484.90. 13.5 Synthesis of compound L013-5 Dissolve L013-4 (1.3 g, crude product) in dichloromethane (20 mL) at room temperature, cool to -78°C, add triethylsilane (382 mg, 3.30 mmol) under nitrogen protection, and then add trifluoride dropwise Boron etherate complex (472 mg, 3.30 mmol) was added dropwise and stirred at -78°C for 1 hour. At this temperature, saturated aqueous sodium bicarbonate solution (10 mL) was added to the reaction solution to quench it. After the system temperature rose to room temperature, it was extracted with ethyl acetate (10 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain compound L013-5 (crude product), which was used directly in the next step. LC-MS: [M+H] + = 487.00. 13.6 Synthesis of compound L013-6 L013-5 (300 mg, 0.61 mmol) and lithium hydroxide monohydrate (100 mg, 2.40 mmol) were added to tetrahydrofuran (6 mL) and water (2 mL), and stirred at room temperature for 16 hours. The reaction solution was directly concentrated under reduced pressure, diluted with water (10 mL), and the pH of the aqueous phase was adjusted to 5-6 with hydrochloric acid (1 M), and then extracted with ethyl acetate (10 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L013-6 (150 mg, crude product), which was used directly in the next step. LC-MS: [M+H] + = 396.95. 13.7 Synthesis of compound L013-7 L013-6 (150 mg, crude product), L001-7 (110 mg, 0.37 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (106 mg, 0.55 mmol), 1-hydroxybenzotriazole (84 mg, 0.55 mmol) and triethylamine (112 mg, 1.10 mmol) were added to dichloromethane (3 mL), and the reaction was stirred at room temperature for 0.5 hours. The reaction solution was diluted by adding water (20 mL), and extracted with dichloromethane (10 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by high-performance liquid phase preparative column chromatography (acidic conditions) to obtain compound L013-7 (120 mg, yield 49.6%). LC-MS: [M+H] + =599.00. 13.8 Synthesis of Compound L013 Hydrochloride Dissolve L013-7 (120 mg, 0.20 mmol) in dichloromethane (2 mL). A solution of hydrogen chloride in 1,4-dioxane (4 M, 2 mL) was added dropwise at room temperature and stirred for 0.5 h. Solids precipitated. The reaction solution was filtered, and the filter cake was washed with dichloromethane (3 mL). The filter cake was dissolved in deionized water (10 mL) and freeze-dried to obtain compound L013 hydrochloride (50.4 mg, yield 78.7%). 1 H NMR (400 MHz, DMSO- d 6 ): δ 10.46 - 10.44(m, 1H), 8.87(dd, J 1 = 7.2 Hz, J 2 = 2.8 Hz, 1H), 8.72 - 8.53(m, 2H), 8.11(d, J= 8.8 Hz, 1H), 8.03 - 8. 00(m, 3H), 7.68 - 7.64(m, 1H), 7.47(dd, J 1 = 8.8 Hz, J 2 = 2.0 Hz, 1H), 6.82(dd, J 1 = 8.8 Hz, J 2 = 2.4 Hz, 1H), 5.17 - 5.11(m, 1H), 4.38(s, 1H), 4.26 - 4.22(m, 1H), 3.54 - 3.42(m, 1H), 3.31(d, J= 7.2 Hz, 2H), 3.13 - 2.96(m, 2H), 2.85 - 2.82(m, 2H), 2.47 - 2.37(m, 1H), 2.12(m, 2H), 1.98 - 1.87(m, 1H) , 1.22(d, J= 7.2 Hz, 3H); LC-MS: [M+H] + = 499.00. Example 14, (2R,4S)-N-((2S)-1-((2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amine Synthesis of methyl)-1-side oxypropan-2-yl)-4-(3-chlorobenzyl)pyrrolidine-2-methamide (compound L014) hydrochloride 14.1 Synthesis of compound L014-1 Add L001-e (1.0 g, 3.13 mmol) to the reaction flask, add tetrahydrofuran (10 mL) under nitrogen atmosphere to dissolve, and place it in a -78°C cold bath. Add bis(trimethyl) while maintaining the temperature at -78°C. Silica) lithium amide (3.2 mL, 3.2 mmol, 1M tetrahydrofuran solution), stir for 0.5 hours after addition. Then L014-a (639 mg, 3.13 mmol) was added, and the reaction was continued at -78°C for two hours. A small amount of solid precipitated, and the reaction solution was quenched with saturated aqueous ammonium chloride solution (10 mL) at -78°C. After the system temperature rose to room temperature, it was extracted with ethyl acetate (20 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L014-1 (950 mg, yield 68%). LC-MS: [M-Boc+H] + = 344.00. 14.2 Synthesis of compound L014-2 Add L014-1 (950 mg, 2.14 mmol) to the reaction flask, add tetrahydrofuran (10 mL) under nitrogen atmosphere to dissolve and place it in a -78°C cold bath, and add lithium triethylborohydride (keeping it at -78°C). 3.2 mL, 3.20 mmol, 1M tetrahydrofuran solution), stir for 0.5 hours after addition. At this temperature, water (50 mL) was added to the reaction solution to quench it. After the system temperature rose to room temperature, it was extracted with ethyl acetate (50 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L014-2 (crude product), which can be used directly in the next step. LC-MS: [M-OH] + = 428.05. 14.3 Synthesis of compound L014-3 Add L014-2 (1.1 g crude product) into the reaction bottle, add dichloromethane (10 mL) under nitrogen atmosphere to dissolve, and place it in a -78°C cold bath. Keep it at -78°C and add triethylsilane ( 345 mg, 2.97 mmol) and boron trifluoride etherate complex (421 mg, 2.97 mmol), stir for 0.5 hours after addition. Add additional triethylsilane (345 mg, 2.97 mmol) and boron trifluoride etherate complex (421 mg, 2.97 mmol), and continue stirring at -78°C for two hours. At this temperature, water (50 mL) was added to the reaction solution to quench it. After the system temperature rose to room temperature, it was extracted with ethyl acetate (50 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L014-3 (830 mg, yield 84%). LC-MS: [M+H] + = 430.05. 14.4 Synthesis of compound L014-4 Add L014-3 (830 mg, 1.93 mmol) and sodium hydroxide (154 mg, 3.87 mmol) into the reaction flask, add methanol (10 mL) and water (5 mL) to dissolve, and react at room temperature for 16 hours. The reaction solution was concentrated under reduced pressure to a volume of 2~3 mL, diluted with water (40 mL), adjusted to pH 5~6 with dilute hydrochloric acid (0.5 M), and extracted with ethyl acetate (30 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L014-4 (crude product), which could be used directly in the next step. LC-MS: [M+Na] + = 362.00. 14.5 Synthesis of compound L014-5 Combine L014-4 (100 mg, crude product), 1-hydroxybenzotriazole (78 mg, 0.32 mmol), N,N-dimethylformamide (2 mL), N,N-diisopropylethyl Amine (170 mg, 1.18 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (62 mg, 0.32 mmol) were added to the reaction bottle, and the reaction was carried out at room temperature for 0.5 hours. . Then add L001-7 (78 mg, 0.35 mmol), and continue the reaction at room temperature for 1 hour. The reaction solution was diluted with water (40 mL), and extracted with ethyl acetate (30 mL×3). The combined organic phases were washed with saturated sodium chloride aqueous solution (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by high-performance liquid phase preparative column chromatography (acidic conditions) to obtain compound L014-5 (16 mg). LC-MS: [M+H] + = 542.00. 14.6 Synthesis of compound L014 hydrochloride Dissolve L014-5 (16 mg, 0.03 mmol) in dichloromethane (2 mL), add hydrogen chloride in ethyl acetate solution (1 mL, 4 M) at room temperature, stir for 0.5 hours, and a white solid precipitates. The reaction solution was filtered, and the filter cake was washed with ethyl acetate (10 mL). The filter cake was dissolved in deionized water (2 mL) and freeze-dried to obtain compound L014 hydrochloride (10.5 mg). 1 H NMR (400 MHz, CH 3 OH- d 4 ): δ 7.84 -7.76(m, 1H), 7.33 – 7.16(m, 4H), 6.82(d, J= 9.2 Hz, 1H), 5.34 – 5.27(m, 1H), 4.47 – 4.45(m, 1H), 4.33 – 4.23(m, 1H), 3.51 – 3.45(m, 1H), 3.16 – 2.96(m, 3H), 2.79 – 2.74(m, 2H), 2.66 – 2.62(m, 2H), 2.20 – 1.02(m, 3H), 1.38(d, J= 7.2 Hz, 3H); LC-MS: [M+H] + = 442.05. Example 15, (2R,4S)-N-((2S)-1-((2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amine Synthesis of ((3-methoxynaphthalene-2-yl)methyl)-1-pentanoxypropan-2-yl)-4-((3-methoxynaphthalen-2-yl)methyl)pyrrolidine-2-methamide (compound L015) hydrochloride 15.1 Synthesis of compound L015-1 To a suspension of lithium aluminum tetrahydrofuran (386 mg, 10.17 mmol) in tetrahydrofuran (10 mL) was slowly added dropwise at 0°C. After the dropwise addition is completed, the temperature of the reaction system is raised to 25°C, and stirring is continued for 3 hours. The reaction solution was cooled to 0°C, quenched by adding sodium hydroxide aqueous solution (5 mL, 5 N), diluted with tetrahydrofuran (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L015-1 (crude product) can be used directly in the next step. 15.2 Synthesis of compound L015-2 Dissolve L015-1 (1.7 g, crude product) in tetrahydrofuran (30 mL), cool to 0°C, and slowly add phosphorus tribromide (1.2 g, 4.52 mmol) in tetrahydrofuran (10 mL) dropwise. After the dropwise addition was completed, the reaction system was heated to 25°C and stirred for 2.5 hours. The reaction solution was quenched by adding water (20 mL), and extracted with ethyl acetate (20 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L015-2 (1.3 g, yield 57.3%). 15.3 Synthesis of compound L015-3 Dissolve L001-e (1.3 g, 4.07 mmol) in tetrahydrofuran (20 mL), and slowly add lithium bis(trimethylsilyl)amide (4.5 mL, 4.5 mmol, 1M) at -70°C under nitrogen protection. Tetrahydrofuran solution). After the dropwise addition was completed, the reaction solution was continued to stir at -70°C for 0.5 hours. Then a solution of L015-2 (1.2 g, 4.88 mmol) in tetrahydrofuran (10 mL) was slowly added dropwise. After the dropwise addition was completed, the reaction solution was continued to stir at -70°C for 2 hours. At this temperature, saturated aqueous ammonium chloride solution (20 mL) was added to the reaction solution to quench it. After the system temperature rose to room temperature, it was extracted with ethyl acetate (20 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L015-3 (900 mg, yield 38.5%). LC-MS: [M-Boc+H] + = 390.00. 15.4 Synthesis of compound L015-4 Dissolve L015-3 (900 mg, 1.84 mmol) in tetrahydrofuran (20 mL), and slowly add lithium triethylborohydride (2.1 mL, 2.1 mmol, 1 M tetrahydrofuran solution) dropwise at -70°C under nitrogen protection. After the dropwise addition was completed, the reaction solution was continued to stir at -70°C for 2 hours. At this temperature, saturated aqueous sodium bicarbonate solution (10 mL) was added to the reaction solution to quench it. After the system temperature rose to room temperature, it was extracted with ethyl acetate (15 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L015-4 (400 mg, yield 44.3%). LC-MS: [M-OH] + = 474.00. 15.5 Synthesis of compound L015-5 Dissolve L015-5 (400 mg, 0.81 mmol) in dichloromethane (10 mL), and add triethylsilane (113 mg, 0.98 mmol) and boron trifluoride etherate complex at -70°C under nitrogen protection. (139 mg, 0.98 mmol), stir for 0.5 hours. Then triethylsilane (113 mg, 0.98 mmol) and boron trifluoride etherate complex (139 mg, 0.98 mmol) were added, and stirring was continued at -70°C for 2 hours. At this temperature, saturated sodium bicarbonate aqueous solution (10 mL) was added to the reaction solution to quench it. After the system temperature rose to room temperature, it was extracted with dichloromethane (15 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L015-5 (300 mg, yield 77.5%). LC-MS: [M-tBu+H] + = 420.00. 15.6 Synthesis of compound L015-6 Dissolve L015-5 (300 mg, 0.63 mmol) in methanol (10 mL), add wet palladium on carbon (30 mg, 10% palladium content), and stir at 25°C for 1 hour in a hydrogen atmosphere. The reaction solution was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure to obtain compound L015-6 (crude product), which can be directly used in the next step. LC-MS: [M-tBu +H] + = 330.00. 15.7 Synthesis of compound L015-7 Dissolve L015-6 (100 mg, crude product) in N,N-dimethylformamide (2 mL), add 1-hydroxybenzotriazole (39 mg, 0.29 mmol), 1-(3-bis Methylaminopropyl)-3-ethylcarbodiimide hydrochloride (55 mg, 0.29 mmol), stir at 20°C for 10 minutes. Then add L001-7 (80 mg, 0.31 mmol) and N,N-diisopropylethylamine (167 mg, 1.30 mmol) in N,N-dimethylformamide (2 mL) and continue the reaction for 1.5 Hour. The reaction solution was poured into water (10 mL), and extracted with ethyl acetate (15 mL×3). The combined organic phases were washed with saturated sodium chloride aqueous solution (10 mL×3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by high-performance liquid phase preparative column chromatography (acidic conditions) to obtain compound L015-7 (60 mg, yield 39.4%). LC-MS: [M+H] + =588.05. 15.8 Synthesis of Compound L015 Hydrochloride Dissolve L015-7 (60 mg, 0.05 mmol) in dichloromethane (2 mL), add hydrogen chloride in ethyl acetate solution (2 mL, 4 M), and stir at 25°C for 0.5 hours. A solid precipitated out of the reaction solution. The reaction solution was filtered, and the filter cake was washed with ethyl acetate (5 mL). The filter cake was dissolved in deionized water (15 mL) and freeze-dried to obtain compound L015 hydrochloride (29.2 mg, yield 58%). 1 H NMR (400 MHz, DMSO- d 6 ): δ 10.27 – 10.16(m, 1 H), 8.85(d, J= 8.0 Hz, 1H), 8.56(t, J= 8.0 Hz, 2H), 7.97(s, 1H), 7.89 – 7.65(m, 2H), 7.45 – 7.41(m, 4H), 7.37 – 7.33(m, 2H), 6.82(dd, J 1 =8.8 Hz, J 2 = 2.0 Hz, 1H), 5.18 – 5.12(m, 1H), 4.43 – 4.35(m, 1H), 4.34 – 4.19(m, 1H), 3.92(s, 3H), 3.36 – 3.28(m, 1H), 3.13 – 2.78(m, 5H), 2.66 – 2.63(m, 1H), 2.48 – 2.41(m, 1H), 2.16 – 2.08(m, 1H), 1.97 – 1.88(m, 2H), 1.23(d, J= 8.0 Hz, 3H); LC / MS(ESI+)m / z: [M+H] + =488.10. Example 16, (2R,4S)-N-((2S)-1-((2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amine Synthesis of methyl)-1-side oxypropan-2-yl)-4-(3-methylbenzyl)pyrrolidine-2-methamide (compound L016) hydrochloride 16.1 Synthesis of compound L016-1 Dissolve L001-e (1.0 g, 3.13 mmol) in tetrahydrofuran (10 mL), and add lithium bis(trimethylsilyl)amide (3.2 mL, 3.2 mmol, 1 M tetrahydrofuran) dropwise under nitrogen protection at -78°C. solution), stir at -78°C for 0.5 hours after addition. L016-a (576 mg, 3.13 mmol) was added to the reaction system, and after the addition was completed, the reaction was continued at -78°C for 2 hours. The reaction solution was quenched by adding water (50 mL), and extracted with ethyl acetate (40 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L016-1 (697 mg, yield 53%). LC-MS [M-Boc+H] + =324.0. 16.2 Synthesis of compound L016-2 Dissolve L016-1 (697 mg, 1.65 mmol) in tetrahydrofuran (10 mL), and add lithium triethylborohydride (2.5 mL, 2.5 mmol, 1 M tetrahydrofuran solution) dropwise under nitrogen protection at -78°C. After completion, stir at -78°C for 0.5 hours. At this temperature, the reaction solution was quenched by adding water (50 mL), and extracted with ethyl acetate (40 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L016-2 (crude product), which was used directly in the next step. 16.3 Synthesis of compound L016-3 Dissolve L016-2 (810 mg, crude product) in dichloromethane (10 mL), and add triethylsilane (284 mg, 2.45 mmol) and boron trifluoride ether complex ( 347 mg, 2.45 mmol), stir at -78°C for 0.5 hours after addition. Triethylsilane (284 mg, 2.45 mmol) and boron trifluoride etherate complex (347 mg, 2.45 mmol) were added, and stirring was continued at -78°C for 2 hours. At this temperature, the reaction solution was quenched by adding water (50 mL), and extracted with ethyl acetate (40 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L016-3 (432 mg, yield 56%). LC-MS [M-Boc+H] + = 310.1. 16.4 Synthesis of compound L016-4 Dissolve L016-3 (432 mg, 1.93 mmol) in methanol (10 mL), add wet palladium on carbon (20 mg, 10% palladium content), and stir at room temperature under a hydrogen atmosphere for 3 hours. The reaction solution was filtered through a diatomaceous earth cushion, and the filtrate was concentrated under reduced pressure to obtain compound L016-4 (307 mg, crude product), which was used directly in the next step. 16.5 Synthesis of compound L016-5 Combine L016-4 (100 mg, 0.31 mmol), 1-hydroxybenzotriazole (48 mg, 0.35 mmol), N,N-dimethylformamide (2 mL), N,N-diisopropyl Ethylamine (162 mg, 1.25 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (66 mg, 0.35 mmol) were added to the reaction flask and stirred at room temperature. 0.5 hours. Then L001-7 (83 mg, 0.38 mmol) was added, and the reaction was continued for 1 hour at room temperature. The reaction solution was diluted with water (40 mL), and extracted with ethyl acetate (30 mL×3). The combined organic phases were washed with saturated sodium chloride (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by high-performance liquid phase preparative column chromatography (alkaline conditions) to obtain compound L016-5 (25.2 mg). LC-MS[M+H] + =522.1. 16.6 Synthesis of Compound L016 Hydrochloride Dissolve L016-5 (25.2 mg, 0.05 mmol) in dichloromethane (2 mL), add hydrogen chloride in ethyl acetate solution (1 mL, 4 M), and stir at room temperature for 0.5 hours. A solid precipitates. The reaction system was filtered, and the filter cake was washed with ethyl acetate (5 mL). The filter cake was dissolved in water (15 mL) and freeze-dried to obtain compound L016 hydrochloride (17.1 mg, yield 71.8%). 1 H NMR (400 MHz, CH 3 OH- d 4 ): δ 7.84 - 7.76(m, 1H), 7.19(t, J= 7.2 Hz, 1H), 7.05 – 6.98(m, 3H), 6.83(d, J= 8.8 Hz, 1H), 5.30(m, 1H), 4.48 – 4.23(m, 2H), 3.49 – 3.40(m, 1H), 3.13 – 3.11(m, 1H), 3.06 – 2.96(m, 2H) , 2.78 – 2.73(m, 2H), 2.68 – 2.47(m, 2H), 2.32(s, 3H), 2.21 – 1.97(m, 3H), 1.39 – 1.36(m, 3H); LC-MS [M+ H ] + = 422.2. Example 17, (2R,4R)-N-((2S)-1-((2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amine Synthesis of methyl)-1-side oxypropan-2-yl)-4-(1-phenylcyclopropyl)pyrrolidine-2-methamide (compound L017) 17.1 Synthesis of compound L017-1 At room temperature, add diiodomethane (5.9 g, 21.72 mmol) to dichloromethane (40 mL), cool to 0°C, stir for 5 minutes under nitrogen atmosphere, and then slowly add diethylzinc toluene solution (10.8 mL , 10.8 mmol, 1 M toluene solution), the reaction solution was stirred at 0°C for 0.5 hours. Then, a solution of L017-a (1 g, 4.35 mmol) in dichloromethane (10 mL) was slowly added dropwise, and the reaction solution was continued to stir at 0°C for 0.5 hours, and then the temperature was raised to room temperature and stirred for 16 hours. Add saturated aqueous ammonium chloride solution (50 mL) to the reaction solution to quench, and stir for 3 to 5 minutes. Extract with dichloromethane (50 mL×3), wash the combined organic phases with saturated brine (50 mL), dry over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L017-1 (979 mg, yield 92%). LC-MS: [M+H] + = 245.15. 17.2 Synthesis of compound L017-2 At room temperature, add L017-1 (900 mg, 3.69 mmol), potassium hydrogen fluoride (1.73 g, 22.1 mmol) and methanol (30 mL) into a 100 mL sealed tube, and stir at 80°C for 5 hours. The reaction solution was cooled to room temperature, concentrated under reduced pressure to about 10 mL, and filtered if solid precipitated. Place the filter cake into a round-bottomed flask, add diethyl ether / n-heptane solution (40 mL, 1 / 1 (v / v)), and stir at room temperature for 0.5 hours. The suspension was filtered, and the filter cake was washed with diethyl ether (30 mL). The washed filter cake was then added to acetonitrile (40 mL), stirred at 60°C for 5 minutes, filtered while hot, and the filter cake was dried under reduced pressure to obtain compound L017-2 (471 mg, yield 57%). 17.3 Synthesis of compound L017-3 L017-2 (471 mg, 2.10 mmol), L006-1 (790 mg, 2.10 mmol), methanesulfonic acid [n-butyldi(1-adamantyl)phosphine](2-amino-1,1' -Biphenyl-2-yl)palladium (II) (70 mg, 0.11 mmol) and cesium carbonate (1.37 g, 4.20 mmol) were dissolved in toluene (20 mL) and water (2 mL), and after nitrogen replacement for 15 minutes, React at 95°C for 2 hours. The reaction solution was cooled to room temperature, concentrated under reduced pressure to remove toluene, then diluted with water (40 mL), and extracted with ethyl acetate (30 mL×3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L017-3 (270 mg, yield 37%). LC-MS: [M-tBu+H] + = 288.05. 17.4 Synthesis of compound L017-4 L017-3 (270 mg, 0.79 mmol) and lithium hydroxide monohydrate (485.6 mg, 11.8 mmol) were dissolved in tetrahydrofuran (4 mL), methanol (2 mL) and water (2 mL), and stirred at room temperature for 2 hours. . The pH value of the reaction solution was adjusted to 5~6 with dilute hydrochloric acid (1 M), diluted with water (20 mL), and extracted with ethyl acetate (20 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L017-4 (157 mg). LC-MS: [M-tBu+H] + = 274.05. 17.5 Synthesis of compound L017-5 Dissolve L017-4 (157 mg, 0.48 mmol), tris(triphenylphosphine)rhodium chloride (44.6 mg, 0.05 mmol) and triethylamine (48.6 mg, 0.48 mmol) in methanol (15 mL) at room temperature. and tetrahydrofuran (15 mL), and stirred at room temperature under hydrogen atmosphere for 4 days. The reaction solution was filtered, and the pH value of the filtrate was adjusted to 10 with sodium hydroxide aqueous solution (1 M), and then extracted with ethyl acetate (40 mL). The organic phase was washed with saturated aqueous sodium bicarbonate solution (20 mL), and the organic phase was discarded. . Combine all aqueous phases, adjust the pH to 5~6 with dilute hydrochloric acid (1 M), and then extract with ethyl acetate (20 mL×3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain compound L017-5 (140 mg, crude product), which was used directly in the next step. LC-MS: [M-tBu+H] + = 276.00. 17.6 Synthesis of compound L017-6 Dissolve L017-5 (140 mg, crude product) and 1-hydroxybenzotriazole (59 mg, 0.42 mmol) in N,N-dimethylformamide (2 mL) at room temperature, and add N, N -Diisopropylethylamine (217 mg, 1.68 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (81 mg, 0.42 mmol), stirred at room temperature for 0.5 hours later. Then L001-7 (111 mg, 0.5 mmol) was added, and the reaction was continued for 1 hour at room temperature. The reaction solution was diluted with water (50 mL), and extracted with ethyl acetate (30 mL×3). The combined organic phases were washed with saturated sodium chloride (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by high-performance liquid phase preparative column chromatography (acidic conditions) to obtain compound L017-6 (120 mg, yield 53.6%). LC-MS: [M+H] + = 534.00. 17.7 Synthesis of compound L017 Dissolve L017-6 (120 mg, 0.225 mmol) in dichloromethane (2 mL), add hydrogen chloride in ethyl acetate solution (1 mL, 4 M), and stir at room temperature for 1 hour. If a solid precipitates, the reaction solution is filtered, and the filter cake is washed with ethyl acetate (10 mL). The crude product obtained by filtration was purified by high performance liquid phase preparative grade column chromatography (alkaline conditions) to obtain compound L017 (19.1 mg). 1 H NMR (400 MHz, DMSO- d 6 ): δ 8 8.91- 8.90(m, 1H), 8.58 – 8.51(m, 1H), 7.97(s, 2H), 7.68 – 7.62(m, 1H), 7.35 – 7.23(m, 5H), 6.80(d , J= 8.8 Hz, 1H), 5.30(s, 0.5H), 5.16 – 5.09(m, 1H), 4.97(s, 0.5H), 4.38 – 4.36(m, 1H), 4.23 – 4.17(m, 1H) , 3.83 – 3.81(m, 1H), 3.05 – 2.98(s, 1H), 2.93 – 2.85(m, 1H), 2.45 – 2.42(m, 1H), 2.35(s, 1H), 2.01 – 1.74(m, 2H), 1.33(t, J= 7.2 Hz, 2H), 1.22 – 1.07(m, 6H), 0.80 – 0.72(m, 1H); LC-MS: [M+H] + = 434.10. Example 18, (2R,4S)-N-((2S)-1-((2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amine Synthesis of methyl)-1-pentanoxypropan-2-yl)-4-(3-chloro-4-(trifluoromethoxy)benzyl)pyrrolidine-2-methamide (compound L018) 18.1 Synthesis of compound L018-1 L018-a (2.0 g, 8.52 mmol) was dissolved in dichloromethane (30 mL), and a solution of phosphorus tribromide (1.2 g, 4.52 mmol) in dichloromethane (10 mL) was slowly added dropwise at 0°C. After completion of the dropwise addition, stir at 0°C for 1 hour. The reaction solution was quenched by adding water (20 mL), and extracted with ethyl acetate (20 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L018-1 (1.5 g, yield 59.1%). 18.2 Synthesis of compound L018-2 Dissolve L001-e (1.5 g, 4.70 mmol) in tetrahydrofuran (20 mL) and cool to -70°C. Under nitrogen protection, lithium bis(trimethylsilyl)amide (5.2 mL, 5.2 mmol, 1 M tetrahydrofuran solution) was slowly added dropwise. After the dropwise addition was completed, the reaction solution was stirred at -70°C for 0.5 hours. Then a solution of L018-1 (1.5 g, 5.17 mmol) in tetrahydrofuran (10 mL) was added dropwise. After the dropwise addition, the reaction system continued to stir at -70°C for 2 hours. At this temperature, the reaction was quenched with saturated aqueous ammonium chloride solution (20 mL). After the system temperature rose to room temperature, it was extracted with ethyl acetate (20 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L018-2 (1.2 g, yield 48%). LC-MS: [M-Boc+H] + = 427.90. 18.3 Synthesis of compound L018-3 Dissolve L018-2 (1.2 g, 2.27 mmol) in tetrahydrofuran (20 mL), cool to -70°C, and slowly add lithium triethylborohydride (2.5 mL, 2.5 mmol, 1M tetrahydrofuran solution) dropwise under nitrogen protection. After the addition was completed, the reaction solution was stirred at -70°C for 2 hours. At this temperature, saturated aqueous sodium bicarbonate solution (10 mL) was added to the reaction solution to quench it. After the system temperature rose to room temperature, it was extracted with ethyl acetate (15 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L018-3 (900 mg, yield 49.5%). LC-MS: [M-OH] + =512.00. 18.4 Synthesis of compound L018-4 Dissolve L018-3 (900 mg, 1.71 mmol) in dichloromethane (20 mL), cool to -70°C, and add triethylsilane (237 mg, 2.04 mmol) and boron trifluoride etherate under nitrogen protection. compound (290 mg, 2.04 mmol), stirred at -70°C for 0.5 hours. Triethylsilane (237 mg, 2.04 mmol) and boron trifluoride etherate complex (290 mg, 2.04 mmol) were added, and stirring was continued at -70°C for 2 hours. At this temperature, saturated sodium bicarbonate aqueous solution (10 mL) was added to the reaction solution to quench it. After the system temperature rose to room temperature, it was extracted with dichloromethane (15 mL×3). The combined organic phases were dried with anhydrous sodium sulfate. , filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L018-4 (450 mg, yield 38.8%). LC-MS: [M-tBu+H] + = 457.90. 18.5 Synthesis of compound L018-5 Dissolve L018-4 (450 mg, 0.88 mmol) in methanol (10 mL) and water (10 mL), add lithium hydroxide monohydrate (110 mg, 2.63 mmol), and stir at 25°C for 4 hours. The reaction solution was directly concentrated under reduced pressure, and the residue was diluted with water (10 mL), then washed with ethyl acetate (10 mL×3), and the organic phase was discarded. The pH value of the aqueous phase was adjusted to 4~5 with dilute hydrochloric acid (1 M), and then extracted with dichloromethane (10 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L018-5 (350 mg, crude product), which could be used directly in the next step. LC-MS: [M-tBu+H] + = 367.95. 18.6 Synthesis of compound L018-6 Dissolve L018-5 (150 mg, 0.35 mmol) in N,N-dimethylformamide (2 mL), add 1-hydroxybenzotriazole (57 mg, 0.42 mmol) and 1-(3-bis Methylaminopropyl)-3-ethylcarbodiimide hydrochloride (82 mg, 0.42 mmol), stir at room temperature for 10 minutes, then add L001-7 (91 mg, 0.35 mmol) and N,N-diiso A solution of propylethylamine (129 mg, 1.77 mmol) in N,N-dimethylformamide (2 mL) was stirred at room temperature for 1.5 hours. The reaction solution was poured directly into water (10 mL), and extracted with ethyl acetate (15 mL×3). The combined organic phases were washed with saturated aqueous ammonium chloride solution (10 mL×3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L018-6 (200 mg, crude product). LC-MS: [M+H] + = 626.05. 18.7 Synthesis of compound L018 Dissolve L018-6 (200 mg, 0.32 mmol) in dichloromethane (2 mL), add hydrogen chloride in ethyl acetate (2 mL, 4 M) at room temperature, stir for 0.5 hours, and a solid precipitates. The reaction solution was concentrated under reduced pressure, and the residue was purified by high-performance liquid phase preparative column chromatography (alkaline conditions) and freeze-dried to obtain compound L018 (50.3 mg, yield 29.94%). 1 H NMR (400 MHz, DMSO- d 6 ): δ 8.28 - 8.13(m, 2 H), 7.54 - 7.52(m, 1 H), 7.50 -7.44(m, 1 H), 7.31 - 7.27(m, 1 H), 7.14 -7.09(m, 1 H), 6.24 - 6.22(m, 1 H), 5.83(s, 2 H), 5.14 - 5.02(m, 1 H), 4.26 - 4.15(m, 1 H), 3.62(dd, J 1 = 8.0, J 2 = 4.0 Hz, 1 H), 2.89 - 2.51(m, 7 H), 2.39 - 2.26(m, 1 H), 2.20 - 2.11(m, 1 H), 1.78 - 1.62(m, 3 H), 1.24 - 1.18(m, 3 H); LC-MS: [M+H] + =526.00. Example 19, (2R)-N-((2S)-1-((2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino) Synthesis of -1-Pendant oxypropan-2-yl)-4-phenyl-2,5-dihydro-1H-pyrrole-2-methamide (compound L019) hydrochloride 19.1 Synthesis of compound L019-1 Combine L006-3 (100 mg, 0.35 mmol), 1-hydroxybenzotriazole (53 mg, 0.38 mmol), N,N-dimethylformamide (3 mL), N,N-diisopropyl Ethylamine (178 mg, 1.38 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (73 mg, 0.38 mmol) were added to the reaction flask and stirred at room temperature. 0.5 hours. Then add L001-7 (92 mg, 0.42 mmol), and continue the reaction at room temperature for 1 hour. The reaction solution was diluted with water (40 mL) and extracted with ethyl acetate (30 mL×3). The combined organic phases were washed with saturated aqueous sodium chloride solution (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was reduced to pressure concentrate. The residue was purified by high-performance liquid phase preparative column chromatography to obtain compound L019-1 (68 mg, yield 40.1%). LC-MS: [M+H] + = 492.10. 19.2 Synthesis of Compound L019 Hydrochloride Dissolve L019-1 (68 mg, 0.14 mmol) in dichloromethane (2 mL), add hydrogen chloride in ethyl acetate solution (1 mL, 4 M), and stir at room temperature for 0.5 hours. A solid precipitated out of the reaction solution. The reaction solution was filtered, and the filter cake was washed with ethyl acetate (10 mL). The filter cake was dissolved in deionized water (10 mL) and freeze-dried to obtain compound L019 hydrochloride (24.0 mg, yield 37.4%). 1 H NMR (400 MHz, DMSO- d 6 ): δ 7.85 - 7.79(m, 1H), 7.57 - 7.46(m, 2H), 7.46 - 7.37(m, 3H), 6.95 - 6.74(m, 1H), 6.50 - 6.28(m, 1H), 5.33( m, 2H), 4.57 - 4.52(m, 2H), 4.39 - 4.24(m, 1H), 3.22 - 3.07(m, 1H), 3.06 - 2.95(m, 1H), 2.77 - 2.56(m, 1H), 2.25 - 1.98(m, 1H), 1.46 - 1.44(m, 3H); LC-MS: [M+H] + = 392.10. Example 20, N-((2S)-1-((2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)-1-side Oxypropan-2-yl)-4-phenyl-1H-pyrrole-2-methamide (compound L020) and N-((S)-1-((R)-2-amino-6, 7-Dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)-1-pentanoxypropan-2-yl)-4-phenyl-1H-pyrrole-2-methane Amine (compound L020-IS-01 or L020-IS-02) and N-((S)-1-(((S)-2-amino-6,7-dihydro-5H-cyclopenta [b]pyridin-5-yl)amino)-1-side oxypropan-2-yl)-4-phenyl-1H-pyrrole-2-methamide (compound L020-IS-02 or L020-IS -01) synthesis 20.1 Synthesis of compound L020-1 Dissolve L020-a (2 g, 9.85 mmol) in N,N-dimethylformamide (20 mL), add potassium tert-butoxide (1.3 g, 11.76 mmol), and stir at 0°C for 0.5 hours. Then 2-(trimethylsilyl)ethoxymethyl chloride (1.8 g, 10.77 mmol) was added, and the reaction was continued at 0°C for 2 hours. A small amount of insoluble matter precipitated from the reaction solution. The reaction solution was filtered. The filtrate was diluted with water (50 mL) and extracted with ethyl acetate (50 mL×3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L020-1 (2.4 g, yield 73%). . LC-MS: [M+H] + = 334.28. 20.2 Synthesis of compound L020-2 L020-1 (1.7 g, 5.01 mmol), tetrakis(triphenylphosphine)palladium (576 mg, 0.50 mmol), phenylboronic acid (917 mg, 7.52 mmol) and cesium carbonate (3.3 g, 10.02 mmol) were added to the reaction In the bottle, replace with nitrogen, add 1,4-dioxane (24 mL) and water (6 mL) to dissolve, and reflux at 90°C for 5 hours. The reaction solution was cooled to room temperature, diluted with (50 mL), and extracted with ethyl acetate (50 mL × 3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was reduced to The mixture was concentrated under pressure, and the residue was purified by silica gel column chromatography to obtain compound L020-2 (1.45 g, yield 87%). LC-MS: [M+H] + = 332.05. 20.3 Synthesis of compound L020-3 Add L020-2 (1.45 g, 4.38 mmol) and tetrabutylammonium fluoride (2.29 g, 8.76 mmol) into the reaction flask, add tetrahydrofuran (10 mL) to dissolve, and stir at 80°C for 6 hours. The reaction solution was cooled to room temperature, diluted with water (50 mL), and extracted with ethyl acetate (50 mL×3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was reduced to The mixture was concentrated under pressure, and the residue was purified by silica gel column chromatography to obtain compound L020-3 (570 mg, yield 65%). LC-MS: [M+H] + = 202.10. 20.4 Synthesis of compound L020-4 Add L020-3 (570 mg, 2.83 mmol) into the reaction flask, add tetrahydrofuran (2 mL), methanol (2 mL) and water (1 mL) to dissolve, and add lithium hydroxide monohydrate (357 mg, 8.49 mmol), stir at 80°C for 3 hours. The reaction solution was cooled to room temperature and concentrated under reduced pressure to obtain crude product. Add water (30 mL) to the crude product to dilute, adjust the pH of the solution to 5~6 with hydrochloric acid aqueous solution (1 M), extract with ethyl acetate (50 mL×3), and use saturated brine (50 mL) to combine the organic phases. ), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L020-4 (511 mg, yield 96.3%). LC-MS: [M+H] + = 188.10. 20.5 Synthesis of compound L020 Combine L020-4 (100 mg, 0.53 mmol), 1-hydroxybenzotriazole (81 mg, 0.58 mmol), N,N-dimethylformamide (2 mL), N,N-diisopropyl Ethylamine (290 mg, 2.12 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (111 mg, 0.58 mmol) were added to the reaction flask, and the reaction was carried out at room temperature for 0.5 Hour. Then compound L001-7 (141 mg, 0.64 mmol) was added, and the reaction was continued for 1 hour at room temperature. The reaction solution was diluted with water (40 mL) and extracted with ethyl acetate (30 mL×3). The combined organic phases were washed with saturated sodium chloride (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. . The residue was purified by high-performance liquid phase preparative column chromatography to obtain compound L020 (50.8 mg, yield 24.4%). 1 H NMR (400 MHz, DMSO- d 6 ): δ 11.67(s, 1H), 8.32-8.26(m, 1H), 8.17 - 8.02(m, 1H), 7.55(d, J= 8.0 Hz, 2H), 7.39 - 7.27(m, 4H), 7.25(s, 1H), 7.18 - 7.07(m, 2H), 6.83(s, 1H), 6.51(d, J= 8.8 Hz, 1H), 5.15(d, J= 6.8 Hz, 1H), 4.61 - 4.24(m, 1H), 2.99 - 2.82(m, 1H), 2.81 - 2.65(m, 1H), 2.48 - 2.29(m, 1H), 1.96 -1.72(m, 1H), 1.34(d, J= 7.2 Hz, 3H); LC-MS: [M+H] + = 390.05. 20.6 Preparation of compound L020-IS-01 or L020-IS-02 Compound L020 (50.8 mg) was subjected to supercritical fluid column chromatography (SFC) (Method: Cellulose-2-3-MeOH+CAN(DEA)-40-3 mL-35T, column chromatography: Lux Cellulose-2, 50×25 mm, 10 μm, mobile phase, A: carbon dioxide, B: methanol, flow rate: 75g / min), the compounds L020-IS-01 (retention time Rt =0.952min, 14.9 mg) and L020-IS-02 (retention time Rt=1.418min, 8.5 mg). L020-IS-01: 1 H NMR (400 MHz, DMSO- d 6 ): δ 11.63(s, 1H), 8.14(d, J= 8.2 Hz, 1H), 8.00(d, J= 7.6 Hz, 1H), 7.54(d, J= 7.2 Hz, 2H), 7.37 - 7.24(m, 4H), 7.18(d, J= 8.0 Hz, 1H), 7.12(t, J= 7.2 Hz, 1H), 6.21(d, J= 8.4 Hz, 1H), 5.79(s, 2H), 5.11(q, J= 7.6 Hz, 1H), 4.44 - 4.36(m, 1H), 2.73 - 2.68(m, 1H), 2.65 - 2.57(m, 1H), 2.35 - 2.27(m, 1H), 1.76 -1.67(m, 1H), 1.31(d, J= 7.2 Hz, 3H); LC-MS: [M+H] + = 390.05. L020-IS-02: 1 H NMR (400 MHz, DMSO- d 6 ): δ 11.64(s, 1H), 8.13(d, J= 8.4 Hz, 1H), 8.02(d, J= 7.6 Hz, 1H), 7.55(d, J= 7.4 Hz, 2H), 7.35 - 7.29(m, 4H), 7.16 - 7.13(m, 2H), 6.24(d, J= 8.4 Hz, 1H), 5.81(s, 2H), 5.13(q, J= 7.6 Hz, 1H), 4.47- 4.40(m, 1H), 2.77 - 2.69(m, 1H), 2.67 - 2.59(m, 1H), 2.38 - 2.30(m, 1H), 1.81 - 1.72(m, 1H), 1.33(d, J= 7.2 Hz, 3H); LC-MS: [M+H] + = 390.05. Example 21, N-((2S)-1-((2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)-1-side Synthesis of oxypropan-2-yl)-4-phenylpiperidine-2-methamide (compound L021) hydrochloride 21.1 Synthesis of compound L021-1 Dissolve L021-a (100 mg, 0.33 mmol) in N,N-dimethylformamide (2 mL), and add 1-(3-dimethylaminopropyl)-3-ethylcarbodioxide Amine hydrochloride (69 mg, 0.36 mmol) and 1-hydroxybenzotriazole (49 mg, 0.36 mmol) were stirred at 20°C for 10 minutes, then N,N-diisopropylethylamine (211 mg, 1.64 mmol) and L001-7 (106 mg, 0.36 mmol) in N,N-dimethylformamide (2 mL), and the reaction was continued at 20°C for 30 minutes. The reaction solution was poured into water (10 mL), extracted with ethyl acetate (15 mL×3), the combined organic phases were washed with saturated aqueous ammonium chloride solution (10 mL×3), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by high-performance liquid phase preparative column chromatography (acidic conditions) and then freeze-dried to obtain compound L021-1 (60 mg, yield 36.09%). LC-MS: [M+H] + =508.15. 21.2 Synthesis of compound L021 hydrochloride Dissolve L021-1 (60 mg, 0.12 mmol) in dichloromethane (2 mL), add hydrogen chloride in ethyl acetate solution (2 mL, 4M), and react at 25°C for 1 hour. A solid is formed. The reaction solution was filtered, and the filter cake was dissolved in deionized water (10 mL) and then freeze-dried to obtain compound L021 hydrochloride (38.7 mg, yield 68.3%). 1 H NMR (400 MHz, DMSO- d 6 ): δ 9.93 - 9.38(m, 1H), 9.02 - 8.69(m, 2H), 8.59 - 8.48(m, 1H), 8.04(s, 2H), 7.74 - 7.61(m, 1H), 7.55 - 7.09( m, 6H), 6.87 - 6.81(m, 1H), 5.24 - 4.97(m, 1H), 4.36 - 4.17(m, 1H), 3.95(t, J= 12.0 Hz, 1H), 3.34(d, J= 12.0 Hz, 1H), 3.21 - 2.78(m, 4H), 2.49 - 2.21(m, 2H), 2.01 - 1.98(m, 3H), 1.80 - 1.55(m, 1H), 1.27 - 1.23(m, 3H); LC-MS: [M+H] + = 408.10. Example 22, (2R)-N-((2S)-1-((2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino) Synthesis of -1-Pendant oxypropan-2-yl)-4-(naphthyl-1-yl)piperidine-2-methamide (compound L022) hydrochloride 22.1 Synthesis of compound L022-1 L022-a (1.0 g, 3.85 mmol) was added to tetrahydrofuran (10 mL) at room temperature, the reaction solution was cooled to -78°C, and lithium bis(trimethylsilyl)amide (4.2 mL) was added dropwise under nitrogen protection. 4.2 mmol, 1 M tetrahydrofuran solution), after the dropwise addition is completed, stir at -78°C for 10 minutes. Then add N-(5-chloro-2-pyridyl)bis(trifluoromethanesulfonamide) (1.58 g, 4.04 mmol) in tetrahydrofuran (5 mL) at this temperature. After the addition is completed, the temperature is raised to room temperature and continued stirring. 1.5 hours. Saturated ammonium chloride aqueous solution (20 mL) was added to the reaction solution to quench, and the mixture was extracted with ethyl acetate (20 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L022-1 (600 mg, crude product, the product was a double bond isomer mixture). 22.2 Synthesis of compound L022-2 L022-1 (440 mg, 1.13 mmol), L022-b (233 mg, 1.36 mmol)), tetrakis(triphenylphosphine)palladium (130 mg, 0.11 mmol) and potassium carbonate (311 mg, 2.26 mmol) were added into 1,4-dioxane (10 mL) and water (1 mL), and stirred at 75°C for 16 hours under nitrogen protection. The reaction solution was cooled to room temperature, diluted with water (20 mL), and extracted with ethyl acetate (20 mL×3). After combining, the organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the double bond isomeric mixture L022-2 (430 mg, crude product). LC-MS: [M-Boc+H] + = 268.05. 22.3 Synthesis of compound L022-3 Dissolve L022-2 (430 mg, 1.17 mmol) in tetrahydrofuran (5 mL), methanol (1 mL) and water (1 mL), add lithium hydroxide monohydrate (147 mg, 3.50 mmol), and stir at room temperature for 3 hours . Add water (10 mL) to the reaction solution to dilute, extract with ethyl acetate (20 mL×3), and discard the organic phase. The aqueous phase was adjusted to pH 5~6 with dilute hydrochloric acid (1 M), and then extracted with ethyl acetate (20 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain double bond isomeric mixture L022-3 (260 mg, crude product). LC-MS: [M-Boc +H] + = 254.10. 22.4 Synthesis of compound L022-4 L022-3 (200 mg, 0.56 mmol), tris(triphenylphosphine)rhodium chloride (92 mg, 0.10 mmol) and triethylamine (57 mg, 0.56 mmol) were dissolved in tetrahydrofuran (2.5 mL) and methanol ( 2.5 mL) and stirred at room temperature for 3 days in a hydrogen atmosphere. The reaction solution was filtered, and the filtrate was directly concentrated under reduced pressure to obtain compound L022-4 (200 mg, crude product). LC-MS: [M-Boc+H] + = 256.10. 22.5 Synthesis of compound L022-5 L022-4 (120 mg, 0.34 mmol), L001-7 (100 mg, 0.34 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (88 mg , 0.46 mmol), 1-hydroxybenzotriazole (69 mg, 0.46 mmol) and triethylamine (93 mg, 0.92 mmol) were added to dichloromethane (2 mL), and stirred at room temperature for 0.5 hours. The reaction solution was diluted with water (20 mL), and extracted with dichloromethane (10 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by high-performance liquid phase preparative column chromatography to obtain compound L022-5 (150 mg, yield 79%), LC-MS : [M+H] + = 558.10. 22.6 Synthesis of Compound L022 Hydrochloride Dissolve L022-5 (50 mg, 0.09 mmol) in dichloromethane (1 mL), add hydrogen chloride in 1,4-dioxane solution (1 mL, 4 M) dropwise, and stir at room temperature for 1 hour. If a solid precipitates, the reaction solution is filtered, and the filter cake is washed with dichloromethane (3 mL). The filter cake was dissolved in deionized water (15 mL) and freeze-dried to obtain compound L022 hydrochloride (11.1 mg, yield 25.1%). 1 H NMR (400 MHz, DMSO- d 6 ): δ 9.91(s, 1H), 9.05 - 9.04(m, 1H), 8.94 - 8.70(m, 1H), 8.55(d, J= 8.0 Hz, 1H), 8.34 - 7.98(m, 1H), 7.92 - 7.80(m, 1H), 7.85 - 7.78(m, 1H), 7.67 - 7.45(m, 5H), 7.38(d, J= 7.2 Hz, 1H), 6.78 - 6.57(m, 1H), 5.26 - 5.09(m, 1H), 4.48 - 4.24(m, 2H), 3.58(m, 2H), 2.97 - 2.87(m, 2H) , 2.44 - 2.34(m, 1H), 2.13(s, 2H), 2.06 - 1.88(m, 2H), 1.42 - 1.21(m, 4H); LC-MS: [M+H] + = 458.10. Example 23, (2R)-N-((2S)-1-((2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino) -1-Pendant oxypropan-2-yl)-4-phenyl-1,2,5,6-tetrahydropyridine-2-methamide (L023-IS-01 or L023-IS-02) and ( 2R)-N-((2S)-1-((2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amine)-1-side oxygen Synthesis of propan-2-yl)-4-phenyl-1,2,3,6-tetrahydropyridine-2-methamide (L023-IS-02 or L023-IS-01) hydrochloride 23.1 Synthesis of compound L023-1 L022-1 (2.5 g, 6.42 mmol), L006-b (1.17 g, 9.63 mmol), tetrakis(triphenylphosphine)palladium (226 mg, 0.32 mmol) and sodium carbonate (1.36 g, 12.84 mmol) were mixed at room temperature. Dissolve in tetrahydrofuran (75 mL) and water (15 mL), stir at 40°C for 4 hours. The reaction solution was cooled to room temperature, diluted with water (50 mL), and extracted with ethyl acetate (50 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L023-1 (2.1 g, a double bond isomer mixture). LC-MS: [M-Boc+H] + = 218.10. 23.2 Synthesis of compound L023-2 Dissolve L023-1 (1.5 g, 4.73 mmol) in tetrahydrofuran (20 mL), methanol (10 mL) and water (10 mL), add lithium hydroxide monohydrate (600 mg, 14.2 mmol) at room temperature, and stir 2 hours. The reaction solution was directly concentrated under reduced pressure, the residue was diluted with water (30 mL), washed with ethyl acetate (30 mL×3), and the organic phase was discarded. The pH of the aqueous phase was adjusted to 5~6 with dilute hydrochloric acid (1 M), and then extracted with ethyl acetate (30 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L023-2 (1.2 g, a double bond isomer mixture). LC-MS: [M-Boc+H] + =204.10. 23.3 Synthesis of compounds L023-2-IS-01 and L023-2-IS-02 Compound L023-2 (1.2 g, 3.96 mmol) was separated by high-performance liquid phase column chromatography (Prep-HPLC) (column chromatography: CHIRAL ART Amylose-C NEO, 30*250 mm, 10 μm, mobile phase, A: n-hexane (0.1% acetic acid), B: isopropyl alcohol, flow rate: 30 mL / min) to obtain compounds L023-2-IS-01 (retention time Rt = 10.854min, 400 mg) and L023-2-IS-02 ( Retention time Rt = 17.612min, 540 mg). L023-2-IS-01: 1 H NMR (400 MHz, CH 3 OH- d 4 ): δ 7.45 – 7.28(m, 5H), 6.34 – 6.07(m, 1H), 5.04 – 4.98(m, 1H), 4.26 – 4.21(m, 1H), 3.31 – 3.15(m, 1H), 2.67 – 2.46(m, 2H), 1.53 – 1.49(m, 9H); LC-MS: [M-Boc+H] + = 204.10. L023-2-IS-02: 1 H NMR (400 MHz, CH 3 OH- d 4 ): δ 7.58 – 7.16(m, 5H), 6.41 – 6.19(m, 1H), 5.06 – 4.94(m, 1H), 4.27 – 4.21(m, 1H), 3.23 – 3.11(m, 1H), 2.59 – 2.47(m, 2H), 1.53 – 1.49(m, 9H); LC-MS: [M-Boc+H] + = 204.10. 23.4 Synthesis of compounds L023-3-IS-01 and L023-3-IS-02 Dissolve L023-2-IS-01 (100 mg, 0.33 mmol) in dichloromethane (3 mL) at room temperature, and add 1-propyl phosphoric acid cyclic anhydride (315 mg, 0.49 mmol, 50% ethyl acetate solution) , N,N-diisopropylethylamine (213 mg, 1.65 mmol) and L001-7 (85 mg, 0.33 mmol), stir at 20°C for 1 hour. The reaction solution was diluted with water (10 mL), and extracted with dichloromethane (10 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by high-performance liquid phase column chromatography (acidic conditions) and freeze-dried to obtain compound L023-3-IS-01 (60 mg, Yield 36%). LC-MS: [M-Boc+H] += 406.10. Dissolve L023-2-IS-02 (100 mg, 0.33 mmol) in dichloromethane (3 mL) at room temperature, and add 1-propyl phosphoric acid cyclic anhydride (315 mg, 0.49 mmol, 50% ethyl acetate solution) , N,N-diisopropylethylamine (213 mg, 1.65 mmol) and L001-7 (85 mg, 0.33 mmol), stir at 20°C for 1 hour. The reaction solution was diluted with water (10 mL), and extracted with dichloromethane (10 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by high-performance liquid phase column chromatography (acidic conditions) and freeze-dried to obtain compound L023-3-IS-02 (75 mg , yield 45%). LC-MS: [M-Boc+H] + = 406.10. 23.5 Synthesis of compounds L023-IS-01 hydrochloride and L023-IS-02 hydrochloride Dissolve L023-3-IS-01 (60 mg, 0.12 mmol) in ethyl acetate (2 mL), add hydrogen chloride in ethyl acetate solution (2 mL, 4 M), react at room temperature for 2 hours, and a white solid precipitates. The reaction solution was directly concentrated under reduced pressure, and the residue was dissolved in deionized water (10 mL) and then freeze-dried to obtain compound L023-IS-01 hydrochloride (48.6 mg, yield 92.66%). Dissolve L023-3-IS-02 (75 mg, 0.15 mmol) in ethyl acetate (2 mL), add hydrogen chloride in ethyl acetate solution (2 mL, 4 M), and react at room temperature for 2 hours. A white solid precipitates. The reaction solution was directly concentrated under reduced pressure. The residue was dissolved in deionized water (10 mL) and then freeze-dried to obtain compound L023-IS-02 hydrochloride (43.2 mg, yield 65.89%). L023-IS-01 hydrochloride: 1 H NMR (400 MHz, DMSO- d 6 ): δ 10.09(s, 1 H), 9.07(dd, J= 7.2, 3.6 Hz, 1 H), 8.94(s, 1 H), 8.54(dd, J= 24.4, 8.0 Hz, 1 H), 7.83(d, J= 24.4 Hz, 2 H), 7.59(dd, J= 32.0, 8.8 Hz, 1 H), 7.50 – 7.31(m, 5 H), 6.71(t, J= 9.6 Hz, 1 H), 6.34(d, J= 8.8 Hz, 1 H), 5.20 – 5.09(m, 1 H), 4.77(s, 1 H), 4.33 – 4.26(m, 1 H), 3.43(s, 2 H), 3.05 – 2.81(m , 2 H), 2.69(s, 2 H), 2.48 – 2.37(m, 1 H), 2.04 – 1.79(m, 1 H), 1.35-1.32(m, 3 H); LC-MS: [M+ H ] + = 406.10. L023-IS-02 hydrochloride: 1 H NMR (400 MHz, DMSO- d 6 ): δ 10.09(d, J= 38.4 Hz, 1 H), 9.08(dd, J= 7.2, 4.4 Hz, 1 H), 8.96 – 8.94(m, 1 H), 8.61 – 8.48(m, 1 H), 7.93 – 7.52(m, 3 H), 7.51 – 7.44(m, 2 H) , 7.43 – 7.30(m, 3 H), 6.75(d, J= 8.0 Hz, 1 H), 6.30(s, 1 H), 5.17(q, J= 7.6 Hz, 1 H), 4.78(s, 1 H), 4.35 – 4.22(m, 1 H), 3.44 – 3.38(m, 2 H), 3.16 – 2.96(m, 1 H), 2.94 – 2.81 (m, 1 H), 2.81 – 2.54(m, 2 H), 2.46 – 2.39(m, 1 H), 2.00 – 1.93(m, 1 H), 1.31(d, J= 7.2 Hz, 3 H); LC-MS: [M+H] + = 406.10. Example 24, (2R)-N-((2S)-1-((2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino) Synthesis of -1-Pendant oxypropan-2-yl)-4-benzylpiperazine-2-carboxamide (compound L024) hydrochloride 24.1 Synthesis of compound L024-1 Dissolve L024-a (300 mg, 1.23 mmol) in N,N-dimethylformamide (3 mL), and add N,N-diisopropylethylamine (239 mg, 1.85 mmol) to the system. and benzyl bromide (221 mg, 1.29 mmol), stirred at room temperature for 1 hour. The reaction solution was diluted with water (10 mL), and extracted with ethyl acetate (20 mL×3). The combined organic phases were washed with saturated aqueous ammonium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L024-1 (344 mg, yield 83.7 %). LC-MS: [M+H] + = 335.10. 24.2 Synthesis of compound L024-2 L024-1 (344 mg, 1.03 mmol) was dissolved in tetrahydrofuran (4 mL) and water (4 mL), lithium hydroxide monohydrate (169 mg, 4.12 mmol) was added, and the mixture was stirred at room temperature for 16 hours. Water (5 mL) was added to the reaction solution, and extracted with ethyl acetate (10 mL). The organic phase was discarded, and the pH value of the aqueous phase was adjusted to about 5-6 with formic acid, and then extracted with ethyl acetate (15 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the compound. L024-2 (343 mg, crude product), can be used directly in the next step. LC-MS: [M+H] + = 321.10. 24.3 Synthesis of compound L024-3 Dissolve L024-2 (90 mg, 0.28 mmol) in N,N-dimethylformamide (2 mL), add 1-hydroxybenzotriazole (41.6 mg, 0.31 mmol) and 1-(3- Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (59.1 mg, 0.31 mmol), react at room temperature for 0.5 hours. At the same time, dissolve L001-7 (100 mg, 0.34 mmol) and N,N-diisopropylethylamine (145 mg, 1.12 mmol) in N,N-dimethylformamide (2 mL) and stir at room temperature. 0.5 hours, then add this solution to the aforementioned reaction solution, and stir at room temperature for 0.5 hours. The reaction solution was diluted with water (10 mL) and extracted with ethyl acetate (20 mL×3). The combined organic phases were washed with saturated aqueous ammonium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. , the residue was purified by high-performance liquid phase preparative column chromatography (acidic conditions) to obtain compound L024-3 (61.0 mg, yield 41.5%). LC-MS: [M+H] + = 523.10. 24.4 Synthesis of Compound L024 Hydrochloride Dissolve L024-3 (61.0 mg, 0.12 mmol) in dichloromethane (2 mL), add hydrogen chloride in ethyl acetate (2 mL, 4 M) at room temperature, stir for 0.5 hours, and a solid precipitates. The reaction solution was filtered, and the filter cake was washed with dichloromethane (15 mL). The filter cake was dissolved in deionized water (15 mL) and freeze-dried to obtain compound L024 hydrochloride (46 mg, yield 93.1%). LC-MS: [M+H] + = 423.15. 1 H NMR (400 MHz, DMSO- d 6 ): δ 10.63(s, 1H), 9.50 – 9.27(m, 2H), 8.63 – 8.38(m, 1H), 8.03(s, 2H), 7.73 – 7.52(m, 3H), 7.45 – 7.41(m, 4H), 6.83(d, J= 4.0 Hz, 1H), 5.16 – 5.14(m, 1H), 4.48 – 4.14(m, 4H), 4.10 – 3.80(m, 5H), 3.11 – 2.84(m, 4H), 2.50 – 2.43(m, 1H), 2.02 - 2.00(m, 1H), 1.23(d, J= 4.0 Hz, 3H); LC-MS: [M+H] + = 423.15. Example 25, (2R)-N-(2S)-1-(2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)-1 -Synthesis of pendant oxyacetone-2-yl)-4-(naphthyl-1-yl)piperazine-2-methamide (compound L025) hydrochloride 25.1 Synthesis of compound L025-1 Dissolve L024-a (600 mg, 2.46 mmol) in dichloromethane (6 mL), add copper acetate (489 mg, 2.70 mmol), L022-b (847 mg, 4.92 mmol), 4Å molecular sieve (300 mg) and pyridine (389 mg, 4.92 mmol), stirred for 16 hours under oxygen atmosphere (room temperature). The reaction solution was directly concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain compound L025-1 (167 mg, yield 18.3%). LC-MS: [M+H] + =371.05. 25.2 Synthesis of compound L025-2 Dissolve L025-1 (167 mg, 0.45 mmol) in tetrahydrofuran (2 mL) and water (2 mL), add lithium hydroxide monohydrate (74 mg, 1.81 mmol), and stir at room temperature for 16 hours. Add water (5 mL) to the reaction solution, extract with ethyl acetate (10 mL), discard the organic phase, adjust the pH value of the aqueous phase to 5-6 with formic acid, and then use ethyl acetate (15 mL×3) extraction. The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L025-2 (50 mg, yield 30.5%). LC-MS: [M+H] + = 357.05. 25.3 Synthesis of compound L025-3 Dissolve L025-2 (50 mg, 0.14 mmol) in N,N-dimethylformamide (1 mL), add 1-hydroxybenzotriazole (21 mg, 0.15 mmol) and 1-(3- Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (30 mg, 0.15 mmol), react at room temperature for 0.5 hours. At the same time, L001-7 (49 mg, 0.17 mmol) and N,N-diisopropylethylamine (72.3 mg, 0.56 mmol) were dissolved in N,N-dimethylformamide (1 mL), and stirred at room temperature for 0.5 hours, then add this solution to the aforementioned reaction solution and stir for 0.5 hours. The reaction solution was diluted with water (5 mL) and extracted with ethyl acetate (15 mL×3). The combined organic phases were washed with saturated aqueous ammonium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. , the residue was purified by high-performance liquid phase preparative column chromatography (acidic conditions) to obtain compound L025-3 (38.0 mg, yield 48.5%). LC-MS: [M+H] + =559.05. 25.4 Synthesis of Compound L025 Hydrochloride Dissolve L025-3 (38 mg, 0.07 mmol) in dichloromethane (2 mL), add hydrogen chloride in ethyl acetate (2 mL, 4 M) at room temperature, and stir for 0.5 hours. If a solid precipitates, the reaction solution is filtered, and the filter cake is washed with dichloromethane (15 mL). The filter cake was dissolved in deionized water (15 mL) and freeze-dried to obtain compound L025 hydrochloride (9 mg, yield 28.9%). 1 H NMR (400 MHz, DMSO- d 6 ): δ 10.10(m, 1H), 9.17 – 9.04(m, 2H), 8.53(dd, J= 8.0, 4.0 Hz, 1H), 8.23(s, 1H), 8.02 – 7.76(m, 3H), 7.69(d, J= 8.0 Hz, 2H), 7.64 – 7.54(m, 2H), 7.46(m, 1H), 7.40 – 7.12(m, 2H), 6.80 – 6.76(m, 1H), 5.33 – 5.16(m, 1H) , 4.34 – 4.24(m, 2H), 3.60(m, 1H), 3.09(s, 2H), 2.93 – 2.85(m, 1H), 2.47 – 2.40(m, 1H), 2.07 – 1.93(m, 2H) , 1.24(m, 7H); LC-MS: [M+H] + = 459.05. Example 26, (2R)-N-(2S)-1-(2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)-1 Synthesis of -Pendant oxypropan-2-yl)-4-(4-fluorophenyl)piperazine-2-carboxamide (compound L026) hydrochloride 26.1 Synthesis of compound L026-1 Dissolve L024-a (400 mg, 1.64 mmol) and L007-a (459 mg, 3.28 mmol) in dichloromethane (3 mL), add copper acetate (327 mg, 1.81 mmol) and 4Å molecular sieve ( 200 mg) and pyridine (259 mg, 3.28 mmol), stirred at room temperature under oxygen atmosphere for 16 hours. The reaction solution was directly concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain compound L026-1 (424 mg, yield 76.5%). LC-MS: [M+H] + = 339.05. 26.2 Synthesis of compound L026-2 Dissolve L026-1 (424 mg, 1.25 mmol) in tetrahydrofuran (4 mL) and water (4 mL), add lithium hydroxide monohydrate (154 mg, 3.76 mmol), and stir at room temperature for 16 hours. Add water (5 mL) to the reaction solution to dilute, extract with ethyl acetate (10 mL), discard the organic phase, adjust the pH of the aqueous phase to 5-6 with formic acid, and then extract with ethyl acetate (15 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L026-2 (325 mg). LC-MS: [M+H] + = 325.05. 26.3 Synthesis of compound L026-3 Dissolve L026-2 (81 mg, 0.25 mmol) in N,N-dimethylformamide (2 mL), add 1-hydroxybenzotriazole (37 mg, 0.27 mmol) and 1-(3- Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (53 mg, 0.27 mmol), stirred at room temperature for 0.5 hours. At the same time, L001-7 (80 mg, 0.27 mmol) and N,N-diisopropylethylamine (160.0 mg, 1.24 mmol) were dissolved in N,N-dimethylformamide (2 mL), and stirred at room temperature for 0.5 Hour. This solution was then added to the aforementioned reaction solution and stirred at room temperature for 0.5 hours. The reaction solution was diluted with water (10 mL), and extracted with ethyl acetate (20 mL×3). The combined organic phases were washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by high-performance liquid phase preparative column chromatography (acidic conditions) to obtain compound L026-3. (50 mg, yield 38.2%). LC-MS: [M+H] + =527.05. 26.4 Synthesis of Compound L026 Hydrochloride Dissolve L026-3 (50 mg, 0.10 mmol) in dichloromethane (2 mL), add hydrogen chloride in ethyl acetate solution (2 mL, 4 M) at room temperature, stir for 0.5 hours, and a solid precipitates. The solid was filtered and the filter cake was washed with dichloromethane (15 mL). The filter cake was dissolved in deionized water (15 mL) and freeze-dried to obtain compound L026 hydrochloride (36.0 mg, yield 88.8%). 1 H NMR (400 MHz, DMSO- d 6 ): δ 10.08 - 9.95(m, 1H), 9.14(d, J= 4.0 Hz, 2H), 8.58(dd, J 1 = 8.0 Hz, J 2 = 2.0 Hz, 1H), 8.04(s, 1H), 7.74 - 7.67(m, 1H), 7.46 - 7.17(m, 1H), 7.15 - 7.03(m, 4H), 6.84(dd, J 1 = 12.0 Hz, J 2 = 4.0 Hz, 1H), 5.20 - 5.15(m, 1H), 4.35 - 4.23(m, 1H), 4.01-3.98(m, 2H), 3.58(d, J= 12.0 Hz, 1H), 3.32(d, J= 12.0 Hz, 1H), 3.20-2.78(m, 6H), 2.48-2.41(m, 1H), 2.03-1.99(m, 1H), 1.30-1.23(m, 4H); LC-MS: [M +H] + = 427.05. Example 27, (2S)-1-(2R,4S)-4-([1,1'-biphenyl]-4-(4-methyl)pyrrolidine-2-carbonyl)-N-(2 -Synthesis of amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)azetidine-2-carboxamide (compound L027) hydrochloride 27.1 Synthesis of compound L027-1 Combine L027-a (91 mg, 0.45 mmol), 1-hydroxybenzotriazole (67 mg, 0.50 mmol), N,N-dimethylformamide (2 mL) and 1-(3-dimethylamine Propyl)-3-ethylcarbodiimide hydrochloride (95 mg, 0.50 mmol) was added to the reaction bottle and reacted at room temperature for 0.5 hours. At the same time, a solution of L001-6 (150 mg, 0.68 mmol), N,N-diisopropylethylamine (232 mg, 1.80 mmol) in N,N-dimethylformamide (2 mL) was stirred at room temperature for 0.5 Hour. Then this solution was added to the aforementioned reaction solution at room temperature, and stirring was continued for 0.5 hours. The reaction solution was diluted with water (10 mL) and extracted with ethyl acetate (15 mL×3). The combined organic phases were washed with saturated sodium chloride (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the compound. L027-1 (160 mg, crude product). LC-MS: [M+H] + = 333.10. 27.2 Synthesis of compound L027-2 Dissolve L027-1 (160 mg, crude product) in dichloromethane (4 mL), add hydrogen chloride in ethyl acetate solution (4 mL, 4 M), stir at room temperature for 0.5 hours, and solid will precipitate. The reaction solution was filtered, the filter cake was washed with dichloromethane (5 mL), and the filter cake was dried under reduced pressure to obtain compound L027-2 hydrochloride (130 mg, crude product). LC-MS: [M+H] + = 233.15. 27.3 Synthesis of compound L027-3 L002-3 (141 mg, 0.37 mmol), 1-hydroxybenzotriazole (55 mg, 0.41 mmol), N,N-dimethylformamide (2 mL) and 1-(3- Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (78 mg, 0.41 mmol) was added to the reaction flask, and stirred at room temperature for 0.5 hours. At the same time, L027-2 (130 mg, crude product) and N,N-diisopropylethylamine (191 mg, 1.48 mmol) were dissolved in N,N-dimethylformamide (2 mL), and stirred at room temperature for 0.5 Hour. Then this solution was added to the aforementioned reaction solution, and stirring was continued for 0.5 hours. Water (10 mL) was added to the reaction solution, and extracted with ethyl acetate (15 mL×3). The combined organic phases were washed with saturated sodium chloride (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the compound. L027-3 (260 mg, crude product). LC-MS: [M+H] + = 596.10. 27.4 Synthesis of Compound L027 Hydrochloride Dissolve L027-3 (260 mg, crude product) in dichloromethane (5 mL), add hydrogen chloride in ethyl acetate solution (5 mL, 4 M) at room temperature, and stir for 0.5 hours. A solid precipitates. The reaction solution was filtered, and the filter cake was washed with dichloromethane (5 mL) to obtain crude product. The crude product was purified by high-performance liquid phase column chromatography (acidic conditions) to obtain compound L027 hydrochloride (10 mg). 1 H NMR (400 MHz, DMSO- d 6 ): δ 10.43(s, 1H), 9.03 – 8.60(m, 2H), 8.12 – 7.81(m, 2H), 7.74 – 7.60(m, 5H), 7.45(t, J= 8.0 Hz, 2H), 7.35 – 7.29(m, 3H), 6.84(t, J= 8.0 Hz, 1H), 5.21 – 5.08(m, 1H), 4.66 – 4.39(m, 1H), 4.28 – 4.09(m, 2H), 3.96 – 3.80(m, 1H), 3.29(s, 1H) , 3.07 – 3.02(m, 1H), 2.98 – 2.52(m, 6H), 2.48 – 2.39(m, 1H), 2.18 – 1.74(m, 4H); LC-MS: [M+H] + = 496.15. Example 28, (2S)-1-(2R,4S)-4-([1,1'-biphenyl]-4-(4-ylmethyl)pyrrolidine-2-carbonyl)-N-( Synthesis of 2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)pyrrolidine-2-methamide (compound L028) hydrochloride 28.1 Synthesis of compound L028-1 Combine L028-a (97 mg, 0.45 mmol), 1-hydroxybenzotriazole (67 mg, 0.50 mmol), N,N-dimethylformamide (2 mL) and 1-(3-dimethylamine Propyl)-3-ethylcarbodiimide hydrochloride (95 mg, 0.50 mmol) was added to the reaction flask, and stirred at room temperature for 0.5 hours. At the same time, L001-6 (150 mg, 0.68 mmol) and N,N-diisopropylethylamine (232.2 mg, 1.80 mmol) were dissolved in N,N-dimethylformamide (2 mL), and stirred at room temperature for 0.5 Hour. Then this solution was added to the aforementioned reaction solution, and stirring was continued for 0.5 hours. The reaction solution was diluted with water (10 mL) and extracted with ethyl acetate (15 mL×3). The combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Compound L028-1 (210 mg, crude product) was obtained. LCMS:[M+H] + = 347.15. 28.2 Synthesis of compound L028-2 Dissolve L028-1 (210 mg, 0.61 mmol) in dichloromethane (4 mL), add hydrogen chloride in ethyl acetate solution (4 mL, 4 M), and stir at room temperature for 0.5 hours. A solid precipitates. The reaction solution was filtered, the filter cake was washed with dichloromethane (5 mL), and the solid was dried under reduced pressure to obtain compound L028-2 (120 mg, crude product). LC-MS: [M+H] + = 247.15. 28.3 Synthesis of compound L028-3 Combine L002-3 (125.7 mg, 0.33 mmol), 1-hydroxybenzotriazole (49 mg, 0.36 mmol), N,N-dimethylformamide (2 mL) and 1-(3-dimethylamine Propyl)-3-ethylcarbodiimide hydrochloride (69.7 mg, 0.36 mmol) was added to the reaction flask, and stirred at room temperature for 0.5 hours. At the same time, L028-2 (120 mg, crude product) and N,N-diisopropylethylamine (170 mg, 1.32 mmol) were dissolved in N,N-dimethylformamide (2 mL) and stirred at room temperature. 0.5 hours. Then this solution was added to the aforementioned reaction solution, and stirring was continued for 0.5 hours. The reaction solution was diluted with water (10 mL) and extracted with ethyl acetate (15 mL×3). The combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Compound L028-3 (240 mg, crude product) was obtained. LC-MS: [M+H] + = 610.10. 28.4 Synthesis of Compound L028 Hydrochloride Dissolve L028-3 (240 mg, crude product) in dichloromethane (5 mL) at room temperature, add hydrogen chloride in ethyl acetate solution (5 mL, 4 M), stir at room temperature for 0.5 hours, and a solid will precipitate. The reaction solution was filtered, the filter cake was washed with dichloromethane (5 mL), and the filter cake was dried under reduced pressure to obtain crude product. The crude product was purified by high-performance liquid phase column chromatography (acidic conditions) to obtain compound L028 hydrochloride (27 mg). 1 H NMR (400 MHz, DMSO- d 6 ): δ 10.53 – 10.50(m, 1H), 8.93 – 8.58(m, 2H), 8.09(s, 2H), 7.77 – 7.58(m, 5H), 7.45(t, J= 8.0 Hz, 2H), 7.35 – 7.31(m, 3H), 6.87 – 6.83(m, 1H), 5.23 – 4.99(m, 1H), 4.71 – 4.51(m, 1H), 4.26 – 4.23(m, 1H), 3.50 – 3.32(m, 3H), 3.09 – 2.74(m, 5H), 2.64 – 2.52(m, 1H), 2.46 – 2.30(m, 1H), 2.17 – 1.82(m, 7H); LC- MS: [M+H] + =510.15. Example 29, (2S)-1-(2R,4S)-4-([1,1'-biphenyl]-4-(4-ylmethyl)pyrrolidine-2-carbonyl)-N-( Synthesis of 2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)pyrrolidine-2-methamide (compound L029) hydrochloride 29.1 Synthesis of compound L029-1 Combine L029-a (103 mg, 0.45 mmol), 1-hydroxybenzotriazole (67 mg, 0.50 mmol), N,N-dimethylformamide (2 mL) and 1-(3-dimethylamine Propyl)-3-ethylcarbodiimide hydrochloride (95 mg, 0.50 mmol) was added to the reaction bottle and reacted at room temperature for 0.5 hours. At the same time, dissolve L001-6 (150 mg, 0.68 mmol) and N,N-diisopropylethylamine (232 mg, 1.80 mmol) in N,N-dimethylformamide (2 mL) and stir at room temperature. 0.5 hours. Then this solution was added to the aforementioned reaction solution, and stirring was continued for 0.5 hours. The reaction solution was diluted with water (10 mL) and extracted with ethyl acetate (15 mL×3). The combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Compound L029-1 (300 mg, crude product) was obtained. LCMS:[M+H] + = 361.10. 29.2 Synthesis of compound L029-2 Dissolve L029-1 (300 mg, crude product) in dichloromethane (5 mL), add hydrogen chloride in ethyl acetate solution (5 mL, 4 M) at room temperature, stir for 0.5 hours, and solid precipitates. The reaction solution was filtered, and the filter cake was washed with dichloromethane (5 mL). The filter cake was dried under reduced pressure to obtain compound L029-2 (140 mg, crude product). LC-MS: [M+H] + = 261.15. 29.3 Synthesis of compound L029-3 Combine L002-3 (137 mg, 0.36 mmol), 1-hydroxybenzotriazole (54 mg, 0.40 mmol), N,N-dimethylformamide (2 mL) and 1-(3-dimethylamine Propyl)-3-ethylcarbodiimide hydrochloride (76 mg, 0.40 mmol) was added to the reaction flask, and stirred at room temperature for 0.5 hours. At the same time, L029-2 (140 mg, 0.54 mmol) and N,N-diisopropylethylamine (185.7 mg, 1.44 mmol) were dissolved in N,N-dimethylformamide (2 mL), and stirred at room temperature for 0.5 hours, then add this solution to the aforementioned reaction solution, and continue stirring for 0.5 hours. The reaction solution was diluted with water (10 mL), extracted with ethyl acetate (15 mL×3), the combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain Compound L029-3 (230 mg, crude). LC-MS: [M+H] + = 624.10. 29.4 Synthesis of Compound L029 Hydrochloride Dissolve L029-3 (230 mg, 0.37 mmol) in dichloromethane (5 mL), add hydrogen chloride in ethyl acetate solution (5 mL, 4 M), and stir at room temperature for 0.5 hours. A solid precipitates. The reaction solution was filtered, and the filter cake was washed with dichloromethane (5 mL). The filter cake was purified by high-performance liquid phase column chromatography (acidic conditions) to obtain compound L029 hydrochloride (65 mg). 1 H NMR (400 MHz, DMSO- d 6 ): δ 10.50(s, 1H), 8.61 – 8.54(m, 2H), 8.08(s, 2H), 7.72 – 7.53(m, 5H), 7.45(t, J=8.0 Hz, 2H), 7.40 – 7.30(m, 3H), 6.88 – 6.80(m, 1H), 5.34 – 5.07(m, 1H), 4.97 – 4.80(m, 1H), 4.77 – 4.28(m, 1H), 3.54 – 3.00(m, 3H), 2.97 – 2.53(m, 5H), 2.47 – 2.31(m, 1H), 2.30 – 2.06(m, 2H), 2.03 – 1.92(m, 2H), 1.81 – 1.12(m, 6H); LC-MS: [M+H] + = 524.10. Example 30, (2S)-N-(2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)-1-((2R,4S)-4 Synthesis of -(4-fluorobenzyl)pyrrolidine-2-carbonyl)azetidine-2-methamide (compound L030) hydrochloride 30.1 Synthesis of compound L030-1 Dissolve L001-11 (150 mg, 0.46 mmol) in N,N-dimethylformamide (3 mL), add 1-hydroxybenzotriazole (75 mg, 0.56 mmol) and 1-(3-bis Methylaminopropyl)-3-ethylcarbodiimide hydrochloride (107 mg, 0.56 mmol), stir at room temperature for 10 minutes, then add L027-2 (162 mg, 0.60 mmol) and N,N-diiso A solution of propylethylamine (299 mg, 2.32 mmol) in N,N-dimethylformamide (2 mL) was allowed to react at room temperature for 0.5 hours. The reaction solution was poured into water (10 mL), extracted with ethyl acetate (15 mL×3), the combined organic phases were washed with saturated aqueous sodium chloride solution (10 mL×3), dried over anhydrous sodium sulfate, filtered, and the filtrate Concentrate under reduced pressure to obtain compound L030-1 (180 mg, yield 72.18%). LCMS:[M+H] + = 538.10. 30.2 Synthesis of compound L030 hydrochloride Dissolve L030-1 (180 mg, 0.33 mmol) in dichloromethane (3 mL), add hydrogen chloride in ethyl acetate solution (2 mL, 4 M), and stir at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure, and the residue was purified by high-performance liquid phase preparative column chromatography (acidic conditions). After freeze-drying, compound L030 hydrochloride (43.1 mg, yield 27.10%) was obtained. 1 H NMR (400 MHz, DMSO- d 6 ): δ 10.31(s, 1H), 8.99 – 8.52(m, 2H), 8.02(s, 2H), 7.83 – 7.64(m, 1H), 7.31 – 7.24(m, 2H), 7.17 – 7.08(m, 2H), 6.82(dd, J= 8.0, 4.0 Hz, 1H), 5.27 – 4.84(m, 2H), 4.62(dd, J= 8.0, 4.0 Hz, 1H), 4.39(dd, J= 12.0, 4.0 Hz, 1H), 4.27 – 4.22(m, 1H), 4.08(dd, J= 12.0, 8.0 Hz, 1H), 3.94 – 3.84(m, 1H), 3.30 – 3.19(m, 1H), 3.08 – 3.02(m, 1H), 2.98 – 2.90(m, 1H), 2.88 – 2.79( m, 1H), 2.79 – 2.51(m, 3H), 2.47 – 2.38(m, 2H), 2.20 – 2.09(m, 1H), 2.05 – 1.67(m, 3H); LC-MS: [M+H] + = 438.10. Example 31, (2S)-N-(2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)-1-((2R,4S)-4 Synthesis of -(4-fluorobenzyl)pyrrolidine-2-carbonyl)pyrrolidine-2-carboxamide (compound L031) hydrochloride 31.1 Synthesis of compound L031-1 Dissolve L001-11 (150 mg, 0.46 mmol) in N,N-dimethylformamide (3 mL), add 1-hydroxybenzotriazole (75 mg, 0.56 mmol) and 1-(3-bis Methylaminopropyl)-3-ethylcarbodiimide hydrochloride (107 mg, 0.56 mmol), stir at room temperature for 10 minutes, add L028-2 (171 mg, 0.60 mmol) and N,N-diisopropyl A solution of ethylamine (299 mg, 2.32 mmol) in N,N-dimethylformamide (2 mL) was stirred at room temperature for 0.5 hours. The reaction solution was poured into water (10 mL), extracted with ethyl acetate (15 mL×3), the combined organic phases were washed with saturated sodium chloride aqueous solution (10 mL×3), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain compound L031-1 (200 mg, yield 78.16%). LCMS:[M+H] + = 552.10. 31.2 Synthesis of compound L031 hydrochloride Dissolve L031-1 (200 mg, 0.36 mmol) in dichloromethane (3 mL), add hydrogen chloride in ethyl acetate solution (2 mL, 4M), and stir at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure, and the residue was purified by high-performance liquid phase preparative column chromatography (acidic conditions). After freeze-drying, compound L031 hydrochloride (45.7 mg, yield 25.83%) was obtained. 1 H NMR (400 MHz, DMSO- d 6 ): δ 10.37–10.35(m, 1H), 8.88 – 8, 51(m, 2H), 8.03(s, 2H), 7.79 – 7.49(m, 1H), 7.31 – 7.24(m, 2H), 7.15 – 7.08(m, 2H), 6.85 – 6.78(m, 1H), 5.23 – 4.99(m, 1H), 4.61 – 4.46(m, 1H), 4.23(td, J= 8.0, 4.0 Hz, 1H), 3.76 – 3.64(m, 1H), 3.53 – 3.37(m, 2H), 3.07 – 2.99(m, 1H), 2.95 – 2.83(m, 2H), 2.79 – 2.55( m, 2H), 2.47 – 2.31(m, 2H), 2.24 – 1.77(m, 7H); LC-MS: [M+H] + = 452.10. Example 32, (2S)-N-(2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)-1-((2R,4S)-4 Synthesis of -(4-fluorobenzyl)pyrrolidine-2-carbonyl)piperidine-2-carboxamide (compound L032) hydrochloride 32.1 Synthesis of compound L032-1 Dissolve L001-11 (150 mg, 0.46 mmol) in N,N-dimethylformamide (3 mL), add 1-hydroxybenzotriazole (75 mg, 0.56 mmol) and 1-(3-bis Methylaminopropyl)-3-ethylcarbodiimide hydrochloride (107 mg, 0.56 mmol), stir at room temperature for 10 minutes, add L029-2 (179 mg, 0.60 mmol) and N,N-diisopropyl A solution of ethylamine (299 mg, 2.32 mmol) in N,N-dimethylformamide (2 mL) was stirred at room temperature for 0.5 hours. The reaction solution was poured into water (10 mL), extracted with ethyl acetate (15 mL×3), the combined organic phases were washed with saturated aqueous sodium chloride solution (10 mL×3), dried over anhydrous sodium sulfate, filtered, and the filtrate Concentrate under reduced pressure to obtain compound L032-1 (160 mg, crude product), which was directly used in the next reaction. LCMS:[M+H] + = 566.10. 32.2 Synthesis of compound L032 hydrochloride Dissolve L032-1 (160 mg, 0.28 mmol) in dichloromethane (3 mL), add hydrogen chloride in ethyl acetate solution (2 mL, 4 M), and stir at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure, and the residue was purified by high-performance liquid phase preparative column chromatography (acidic conditions). After freeze-drying, compound L032 hydrochloride (29.0 mg, yield 27.47%) was obtained as a white solid. 1 H NMR (400 MHz, DMSO- d 6 ): δ 10.41(s, 1H), 8.62 – 8.44(m, 2H), 8.05(s, 2H), 7.72 – 7.56(m, 1H), 7.35 – 7.24(m, 2H), 7.17 – 7.06(m, 2H), 6.86 – 6.79(m, 1H), 5.27 – 5.09(m, 1H), 4.91 – 4.65(m, 2H), 4.33 – 3.65(m, 1H), 3.38 – 2.79(m, 5H), 2.76 – 2.54(m, 2H), 2.49 – 2.40(m, 2H), 2.38 – 2.12(m, 2H), 2.07 – 1.56(m, 5H), 1.55 – 1.20(m, 3H); LC-MS: [M+ H ] + = 466.10. Example 33, (2R,4S)-N-((S)-1-(((R)-2-amino-6,7-dihydro-5H-cyclopenta[b]pyridine-5 Synthesis of -(yl)amino)-1-side oxypropan-2-yl)-4-(4-fluorobenzyl)pyrrolidine-2-methamide (compound L001-IS-01) 33.1 Synthesis of compound L001-IS-01-1 Dissolve L001-g (500.0 g, 4.67 mol) and L001-h (393.0 g, 4.67 mol) in toluene (2750 mL), add anhydrous magnesium sulfate (589.5 g, 5.0 mol) at room temperature, raise the temperature to 30°C and stir 16 hours. The reaction solution was filtered directly, and the filter cake was washed with toluene (500 mL). The filtrates were combined to obtain a toluene solution of compound L001-IS-01-1, which was used directly in the next step. LC-MS: [M+H] + = 174.10. 33.2 Synthesis of compound L001-IS-01-2 Add the toluene solution of L001-IS-01-1 into a 10 L reaction kettle, slowly add triethylamine (491g, 4.85 mol) at 0°C, control the temperature within 5°C, and then add acetic anhydride (485g, 4.85 mol) dropwise ), continue stirring for 16 hours after the reaction solution rises to room temperature. After adding water (3 L) to the reaction solution, stir for 10 minutes, then separate the organic phase, wash the organic phase with brine (2 L), dry over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 20 / 1) to obtain compound L001-IS-01-2 (580 g). LC-MS: [M+H] + = 216.10. 33.3 Synthesis of compound L001-IS-01-3 At room temperature, dissolve L001-IS-01-2 (550 g, 2.6 mol) in N,N-dimethylformamide (2.2 L) and add it to a 10 L reaction kettle. Slowly add phosphorus oxychloride (980 g, 6.4 mol), the temperature was raised to 30°C and stirred for 1.5 hours. Then the temperature was raised to 60°C and stirred for 1 hour, then the temperature was raised to 70°C and stirred for 1 hour, then the temperature was raised to 80°C and stirred for 1 hour, and then the temperature was raised to 95°C and stirred for 16 hours. The reaction solution was cooled to room temperature, and water (2.2 L) and sodium hydroxide solution (1.8 L, 30% aq.) were added to adjust the pH of the solution to 9. After adding methyl tert-butyl ether (4.8 L), stir for 0.5 hours. Then the organic phase was separated, washed with water (2.2 L×2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product. Dissolve the crude product in n-heptane (2.2 L), then add water (2.2 L) and concentrated hydrochloric acid (1.1 L, 36%), separate the organic phase, and extract the aqueous phase once more with n-heptane (2.2 L), discard Remove the organic phase and keep the aqueous phase. The pH value of the aqueous phase was adjusted to pH=9 with sodium hydroxide solution (30% aq.) (control the system temperature below 25°C), and then stirred at room temperature for 1 hour. If solid precipitates, filter and wash the filter cake with water (500 mL). The filter cake was dried under reduced pressure to obtain crude product. The crude product was added to n-heptane (4.4 L), and the temperature was raised to 80°C. After refluxing for 2 hours, the temperature was lowered to 50°C, and then filtered while hot to remove a small amount of insoluble matter. The filtrate was concentrated under reduced pressure to obtain compound L001-IS-01-3 (224.3 g, yield 66.9%). LC-MS: [M+H] + = 154.10. 33.4 Synthesis of compound L001-IS-01-4 At room temperature, add L001-IS-01-3 (50 g, 325.5 mmol), anhydrous magnesium sulfate (78 g, 325.5 mmol) and tert-butanol (1 L) into a 10 L reaction kettle. Cool the temperature to 0°C, add potassium permanganate (103 g, 325.5 mmol) in water (2.8 L) dropwise to the reaction solution, and control the system temperature within 15°C. After the dropwise addition was completed, the reaction solution was heated to room temperature and stirred for 4 hours. Water (1 L) and ethyl acetate (2 L) were added to the reaction solution, and then stirred at room temperature for 0.5 hours. The organic phase was separated, the aqueous phase was extracted with ethyl acetate (1.5L×2), the organic phases were combined and washed with brine (2 L). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 3 / 1) to obtain compound L001-IS-01-4 (30.3 g, yield 55.6%). LC-MS: [M+H] + = 168.05. 33.5 Synthesis of compound L001-IS-01-5 At room temperature, combine L001-IS-01-4 (40 g, 0.24 mol), tert-butyl carbamate (31 g, 0.26 mol), cesium carbonate (156g, 0.48 mol), and palladium acetate (2.2 g, 9.6 mmol). ) and 2-dicyclohexylphosphine-2',4',6'-triisopropylbiphenyl (9.1 g, 19.2 mmol) were added to 1,4-dioxane (400 mL) under nitrogen protection. Stir at 85°C for 3 hours. The reaction solution was cooled to room temperature, ethyl acetate (200 mL) was added, stirred for 10 minutes, filtered through diatomaceous earth, and the filter cake was washed with ethyl acetate (200 mL). The filtrate was directly concentrated, and the residue was stirred in ethanol (100 mL) for 3 hours, filtered, and after the filter cake was dried, petroleum ether (200 mL) and methyl tert-butyl ether (200 mL) were added again, stirring was continued for 3 hours, and filtered. The filter cake was dried to obtain compound L001-IS-01-5 (36 g, yield 55.6%). LC-MS: [M+H] + = 249.10. 33.6 Synthesis of compound L001-IS-01-6 At room temperature, L001-IS-01-5 (62 g, 0.25 mol) and L001-k (32 g, 0.26 mol) were added to N,N-dimethylformamide (600 mL), and acetic acid ( 7.5 g, 0.125 mol), stir at room temperature for 2 hours, add sodium acetate borohydride (159 g, 0.75 mol) into the above reaction system in 3-4 batches (1 hour / time), stir at room temperature for 16 hours after addition. The reaction solution was quenched with saturated ammonium chloride (500 mL), and the pH of the solution was adjusted to 1 with dilute hydrochloric acid (1 M). The solution was extracted once with ethyl acetate (600 mL), the organic phase was discarded, the pH of the aqueous phase was adjusted to 8-9 with saturated sodium carbonate solution, and extracted with ethyl acetate (600 mL×2). The combined organic phases were washed with saturated aqueous sodium chloride solution (800 mL×3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L001-IS-01-6 (75 g, yield 85%) . LC-MS: [M+H] + = 354.05. 33.7 Synthesis of compound L001-IS-01-7 At room temperature, L001-IS-01-6 (75 g, 0.21 mol) and L001-d (48 g, 0.25 mol) were added to methanol (500 mL), and then palladium on carbon (7.5 g, 10%wt) was added , stirred for 20 hours under hydrogen atmosphere. The reaction solution was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure to obtain the carboxylate form of L001-d of compound L001-IS-01-7, which was used directly in the next step. LC-MS: [M+H] + = 250.10. 33.8 Synthesis of compound L001-IS-01-8 At room temperature, the L001-d carboxylate of L001-IS-01-7 obtained in the previous step was added to dichloromethane (500 mL), and N,N-diisopropylethylamine (81 g, 0.63 mol), add 1-propylphosphoric anhydride (203 g, 0.32 mol, 50% ethyl acetate solution) at 0°C, and the reaction solution continues to stir at room temperature for 2 hours. The reaction solution was stirred and diluted with water (500 mL), and extracted with dichloromethane (300 mL×2). The organic phases were combined and washed with dilute hydrochloric acid (400 mL×2, 0.2 M). The organic phase was dried over anhydrous sodium sulfate and filtered. , the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L001-IS-01-8 (71 g, yield 80.5%, chiral purity 85%). Dissolve L001-IS-01-8 (71 g) in isopropyl alcohol (142 mL), then cool the solution to 0°C, and add purified water (142 mL) dropwise while stirring. After the dropwise addition is completed, the solution continues After stirring at 0°C for 2 hours, a large amount of white solid precipitated and was filtered. The resulting solid was dried under reduced pressure to obtain compound L001-IS-01-8 (36.5 g, chiral purity 98.2%, yield 51.4%). LC-MS: [M+H] + = 421.05. 33.9 Synthesis of compound L001-IS-01-9 Dissolve L001-IS-01-8 (32 g, 76.2 mmol) in dichloromethane (200 mL), add hydrogen chloride in 1,4-dioxane solution (200 mL, 4 M) at 0°C, and react The liquid was raised to room temperature and stirring was continued for 16 hours. The reaction solution was concentrated under reduced pressure to obtain compound L001-IS-01-9 hydrochloride (22 g). LC-MS: [M+H] + = 221.10. 33.10 Synthesis of compound L001-IS-01-10 Dissolve L001-IS-01-9 hydrochloride (3.8 g, 14.84 mmol) and diisopropylethylamine (8.0 g, 61.85 mmol) in dichloromethane (50 mL) at room temperature. After stirring for 30 minutes at 0°C, L001-8 (4 g, 12.37 mmol) and 1-propylphosphoric anhydride (15.7 g, 24.74 mmol, 50% ethyl acetate solution) in dichloromethane (50 mL) solution and continued stirring at room temperature for 1 hour. The reaction solution was poured into a saturated sodium chloride aqueous solution (200 mL), extracted with dichloromethane (200 mL×3), the organic phases were combined and dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was added to a mixed solution of petroleum ether (20 mL) and ethyl acetate (10 mL), stirred for 1 hour, filtered, and the filter cake was dried under reduced pressure to obtain compound L001-IS-01-10 (6.15 g, yield 98 %). LC-MS: [M+H] + =526.05. 33.11 Synthesis of compound L001-IS-01 Dissolve L001-IS-01-10 (32 g, 60.88 mmol) in dichloromethane (300 mL) at room temperature, add hydrogen chloride in 1,4-dioxane solution (200 mL, 4 M), and mix at room temperature. The mixture was stirred for 2 hours, and the reaction solution was concentrated under reduced pressure. The residue was purified by high-performance liquid phase column chromatography (0.1% hydrochloric acid condition) and then freeze-dried to obtain the hydrochloride salt of compound L001-IS-01. Dissolve the hydrochloride in deionized water (200 mL), add strong alkaline deionized resin (32 g) and stir to dissociate, and a white solid will precipitate. Filter, wash the filter cake with deionized water (100 mL), add the obtained solid mixture to acetonitrile (200 mL), stir for 0.5 hours, filter, and concentrate the filtrate under reduced pressure to obtain a crude product. The crude product was added to ethyl acetate (100 mL), stirred for 0.5 hours, filtered, and the filter cake was dried to obtain compound L001-IS-01 (15.563 g, yield 60.09%). 1 H NMR (400 MHz, DMSO- d 6 ): δ 8.16(d, J= 8.0 Hz, 2H), 7.22 – 7.18(m, 2H), 7.16 – 7.04(m, 3H), 6.23(d, J= 8.4 Hz, 1H), 5.85(s, 2H), 5.07(dd, J= 14.4, 7.6 Hz, 1H), 4.27 – 4.15(m, 1H), 3.62(dd, J= 9.2, 4.8 Hz, 1H), 2.85(dd, J= 10.0, 6.4 Hz, 1H), 2.77 – 2.69(m, 1H), 2.66 – 2.52(m, 4H), 2.37 – 2.26(m, 1H), 2.16 – 2.07(m, 1H), 1.78 – 1.61( m, 3H), 1.19(d, J = 6.8 Hz, 3H). LC-MS: [M+H] + = 426.00. Example 34, (2R,4S)-N-((S)-1-(((R)-2-amino-6,7-dihydro-5H-cyclopenta[b]pyridine-5 Synthesis of -(yl)amino)-1-side oxypropan-2-yl)-4-(4-chlorobenzyl)pyrrolidine-2-methamide (compound L003-IS-01) The synthesis of compound L003-IS-01 refers to the synthesis method of compound L001-IS-01. Just replace L001-8 with L003-4. The crude product obtained by the reaction is subjected to high performance liquid phase column chromatography (0.1% hydrochloric acid condition) and normal Compound L003-IS-01 (97.2 mg, yield 26.55%) was purified by phase column chromatography (alkaline conditions). 1 H NMR (400 MHz, DMSO- d 6 ): δ 8.18 – 8.15(m, 2H), 7.33(d, J= 8.0 Hz, 2H), 7.21(d, J= 8.0 Hz, 2H), 7.14(d, J= 8.0 Hz, 1H), 6.23(d, J= 8.0 Hz, 1H), 5.84 – 5.83(m, 2H), 5.07(dd, J= 12.0, 8.0 Hz, 1H), 4.24 – 4.17(m, 1H), 3.64(dd, J= 8.0, 4.0 Hz, 1H), 2.88 – 2.84(m, 1H), 2.77 – 2.69(m, 1H), 2.67 – 2.52(m, 4H), 2.36 – 2.27(m, 1H), 2.19 – 2.07( m, 1H), 1.78 – 1.61(m, 3H), 1.19(d, J= 4.0 Hz, 3H); LC-MS [M+H] + = 442.00. Example 35, (2R,4S)-N-((S)-1-(((R)-2-amino-6,7-dihydro-5H-cyclopenta[b]pyridine-5 Synthesis of -(yl)amino)-1-side oxypropan-2-yl)-4-phenylpyrrolidine-2-methamide (compound L006-IS-03) 35.1 Synthesis of compound L006-IS-03-1 Dissolve L006-3 (440 mg, 1.52 mmol) in methanol (10 mL) at room temperature, add palladium on carbon (88 mg, 10%wt), and stir for 2 hours under a hydrogen atmosphere. The reaction solution was filtered through celite, and the filter cake was washed with methanol (10 mL). The filtrate was concentrated under reduced pressure to obtain compound L006-IS-03-1 (360 mg, yield 81.4%). LC-MS: [M-tBu+H] + = 236.05. 35.2 Synthesis of compound L006-IS-03 The synthesis of compound L006-IS-03 refers to the synthesis method of compound L001-IS-01. Just replace L001-8 with L006-IS-03-1. The crude product obtained from the reaction was subjected to high performance liquid phase column chromatography (0.1% Ammonia solution) was purified and freeze-dried to obtain compound L006-IS-03 (184.1 mg). 1 H NMR (400 MHz, DMSO- d 6 ): δ 8.25 – 8.21(m, 2H), 7.29 – 7.15(m, 6H), 6.24 – 6.20(m, 1H), 5.84(s, 2H), 5.13 – 5.07(m, 1H), 4.30 – 4.23( m, 1H), 3.79 – 3.75(m, 1H), 3.32 – 3.27(m, 2H), 3.20 – 3.07(m, 1H), 2.80 – 2.67(m, 1H), 2.68 – 2.56(m, 2H), 2.40 – 2.28(m, 1H), 1.75 – 1.65(m, 2H), 1.24(d, J= 4.0 Hz, 3H); LC-MS [M+H] + = 394.05. Example 36, (2R,4S)-N-((S)-1-(((R)-2-amino-6,7-dihydro-5H-cyclopenta[b]pyridine-5 -(yl)amino)-1-pentanoxypropan-2-yl)-4-(3-chloro-4-fluorobenzyl)pyrrolidine-2-methamide (compound L012-IS-01) salt Synthesis of acid salts The synthesis of compound L012-IS-01 hydrochloride refers to the synthesis method of compound L001-IS-01. Just replace L001-8 with L012-4. The crude product obtained by the reaction is subjected to high performance liquid phase column chromatography (0.1% hydrochloric acid). After purification (conditions), compound L012-IS-01 hydrochloride (61 mg, yield 40.6%) was obtained by freeze-drying. 1 H NMR (400 MHz, DMSO- d 6 ): δ 10.47(s, 1H), 8.86(d, J= 7.2 Hz, 1H), 8.56 –8.53(m, 2H), 8.04(s, 1H), 7.71(d, J= 8.8 Hz, 1H), 7.53(dd, J= 7.2, 2.4 Hz, 1H), 7.39 – 7.26(m, 2H), 6.84(d, J= 8.8 Hz, 1H), 5.18 – 5.14(m, 1H), 4.40 – 4.26(m, 1H), 4.24(p, J= 7.2 Hz, 1H), 3.33 – 3.24(m, 1H), 3.04(m, 1H), 2.91(m, 2H), 2.72(m, 2H), 2.52(s, 1H), 2.44(dd, J= 8.8, 4.4 Hz, 1H), 2.12 – 2.01(m, 1H), 1.93(m, 2H), 1.23(d, J= 7.2 Hz, 3H); LC-MS [M+H] + =460.00. Example 37, (2R,4S)-N-((S)-1-(((R)-2-amino-6,7-dihydro-5H-cyclopenta[b]pyridine-5 Synthesis of -(yl)amino)-1-side oxypropan-2-yl)-4-(3-chlorobenzyl)pyrrolidine-2-methamide (compound L014-IS-01) hydrochloride The synthesis of compound L014-IS-01 hydrochloride refers to the synthesis method of compound L001-IS-01. Just replace L001-8 with L014-4. The crude product obtained by the reaction is subjected to high performance liquid phase column chromatography (0.1% hydrochloric acid After purification (conditions), compound L014-IS-01 hydrochloride (311.2 mg, yield 73.82%) was obtained by freeze-drying. 1 H NMR (400 MHz, DMSO- d 6 ): δ 10.35(s, 1H), 8.85(d, J= 7.2 Hz, 1H), 8.55(t, J= 9.2 Hz, 2H), 8.01(s, 2H), 7.70(d, J= 8.8 Hz, 1H), 7.49 – 7.17(m, 4H), 6.83(d, J= 8.8 Hz, 1H), 5.15(q, J= 7.6 Hz, 1H), 4.55 – 4.33(m, 1H), 4.24(p, J= 7.2 Hz, 1H), 3.28(d, J= 4.4 Hz, 1H), 3.05 – 3.01(m, 1H), 2.93 – 2.89(m, 2H), 2.76 – 2.72(m, 2H), 2.49 – 2.39(m, 2H), 2.16 – 2.02(m, 1H), 1.99 – 1.84(m, 2H), 1.23(d, J= 7.2 Hz, 3H); LC-MS [M+H] + = 442.00. Example 38, (2R,4S)-N-((S)-1-(((R)-2-amino-6,7-dihydro-5H-cyclopenta[b]pyridine-5 -(yl)amino)-1-pentanoxypropan-2-yl)-4-(3-methylbenzyl)pyrrolidine-2-carboxamide (compound L016-IS-01) hydrochloride synthesis The synthesis of compound L016-IS-01 hydrochloride refers to the synthesis method of compound L001-IS-01. Just replace L001-8 with L016-4. The crude product obtained by the reaction is subjected to high performance liquid phase column chromatography (0.1% hydrochloric acid). After purification (conditions), compound L016-IS-01 hydrochloride (140.4 mg, yield 57.92%) was obtained by freeze-drying. 1 H NMR (400 MHz, DMSO- d 6 ): δ 10.39(s, 1H), 8.87(d, J= 7.2 Hz, 1H), 8.57(d, J= 7.6 Hz, 1H), 8.52(d, J= 4.8 Hz, 1H), 8.03(s, 2H), 7.71(d, J= 8.8Hz, 1H), 7.19(t, J= 7.6 Hz, 1H), 7.06 – 7.00(m, 3H), 6.83(d, J= 8.8 Hz, 1H), 5.15(d, J= 6.8 Hz, 1H), 4.39 – 4.34(m, 1H), 4.26 – 4.20(m, 2H), 3.27(d, J= 4.0 Hz, 1H), 3.07 – 3.00(m, 1H), 2.87-2.93(m, 2H), 2.66(t, J= 7.6 Hz, 2H), 2.48 – 2.44(m, 1H), 2.28(s, 3H), 2.03-2.10(m, 1H), 1.89-1.95(m, 2H), 1.23(d, J= 7.2Hz, 3H); LC-MS [M+H] + = 422.05. Example 39, (2R,4S)-N-((2S)-1-((2-amino-6,7-dihydro-5H-cyclopentadieno[b]pyridin-5-yl) Synthesis of amino)-1-side oxypropan-2-yl)-4-phenylpiperidine-2-methamide (compound L021-IS-01) 39.1 Synthesis of compound L021-IS-01-1 Dissolve L021-b (25 g, 86.42 mmol) and L021-c (12.5 g, 86.42 mmol) in dichloromethane (360 mL), and add 1-(3-dimethylaminopropyl)-3 at 0°C. -Ethylcarbodiimide hydrochloride (24.8 g, 129.35 mmol) and 4-dimethylaminopyridine (15.8 g, 129.35 mmol), the reaction solution was stirred at 0°C for 1 hour, then raised to room temperature and continued to stir for 2 Hour. The reaction solution was washed with potassium hydrogen sulfide aqueous solution (1 M) (100 mL × 4), the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was added to toluene (800 mL) and refluxed at 110°C for 16 hours. The reaction solution was cooled to room temperature and concentrated under reduced pressure. Toluene / petroleum ether (100 mL, V / V=1 / 10) was added to the residue and stirred for 2 hours. The solid was filtered and the filter cake was dried to obtain compound L021-IS-01-1 (16 g, yield 59.08%). LC-MS: [M-Boc+H] + = 214.10. 39.2 Synthesis of compound L021-IS-01-2 Dissolve L021-IS-01-1 (1.0 g, 3.19 mmol) and N,N-diisopropylethylamine (825 mg, 6.38 mmol) in dichloromethane (10 mL), and add three drops of Fluoromethanesulfonic anhydride (1.4 g, 4.80 mmol) was added and stirred at room temperature for 1 hour. Saturated aqueous sodium bicarbonate solution (15 mL) was added to quench the reaction, and the mixture was extracted with ethyl acetate (30 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L021-IS-01-2 (1.1 g, yield 77.39%). LC-MS: [M-Boc+H] + = 345.95. 39.3 Synthesis of compound L021-IS-01-3 L021-IS-01-2 (1 g, 2.33 mmol), L006-b (427 mg, 3.50 mmol), potassium carbonate (387 mg, 2.80 mmol) and bis(triphenylphosphine)palladium dichloride (164 mg, 0.23 mmol) was added to tetrahydrofuran (8 mL) and water (1 mL), and stirred at 40°C for 2 hours under nitrogen protection. The reaction solution was diluted with water (10 mL), and extracted with ethyl acetate (20 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L021-IS-01-3 (800 mg, yield 95.41%). LC-MS: [M-Boc+H] + = 274.10. 39.4 Synthesis of compound L021-IS-01-4 L021-IS-01-3 (800 mg, 2.14 mmol) and palladium on carbon (200 mg, 10% palladium content) were added to ethyl acetate (10 mL), and stirred at room temperature in a hydrogen atmosphere for 2 hours. After filtering with diatomaceous earth, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain compound L021-IS-01-4 (600 mg, yield 74.6%). LC-MS: [M-Boc+H] + = 276.10. 39.5 Synthesis of compound L021-IS-01-5 Dissolve L021-IS-01-4 (950 mg, 2.53 mmol) in tetrahydrofuran (5 mL), add borane tetrahydrofuran complex (7.6 mL, 7.6 mmol, 1 M tetrahydrofuran solution) dropwise at 0°C, and complete the addition Then stir at room temperature for 3 hours. The reaction solution was quenched by dropwise addition of methanol (15 mL), and stirred at room temperature for 1 hour. The reaction solution was then concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain compound L021-IS-01-5 (550 mg, yield 60.13%). LC-MS: [M+H] + = 362.10. 39.6 Synthesis of compound L021-IS-01-6 Trifluoroacetic acid / dichloromethane (2 mL / 1 mL) was added to L021-IS-01-5 (300 mg, 0.83 mmol) at 0°C, and the reaction solution was raised to room temperature and stirred for 1 hour. The reaction solution was concentrated under reduced pressure, and the residue was dissolved in dichloromethane (3 mL). Di-tert-butyl dicarbonate (217 mg, 1.0 mmol) and triethylamine (168 mg, 1.66 mmol) were added, and stirred at room temperature for 16 hours. . The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain compound L021-IS-01-6 (100 mg, yield 39.46%). LC-MS: [M-Boc+H] + = 206.10. 39.7 Synthesis of compound L021-IS-01-7 L021-IS-01-6 (80 mg, 0.26 mmol), 1-hydroxybenzotriazole (53 mg, 0.39 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodi Imine hydrochloride (75 mg, 0.39 mmol) was dissolved in N,N-dimethylformamide (2 mL) and stirred at room temperature for 0.5 hours. Dissolve L001-7 (71 mg, 0.27 mmol) and N,N-diisopropylethylamine (135 mg, 1.05 mmol) in N,N-dimethylformamide (2 mL) and stir at room temperature for 0.5 Hour. Add the latter to the former reaction solution and continue stirring for 1 hour. The reaction solution was diluted with water (10 mL) and extracted with ethyl acetate (10 mL×3). The combined organic phases were washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L021-IS-01-7 (80 mg, yield 60.16%). LC-MS: [M+H] + =508.15. 39.8 Synthesis of compound L021-IS-01 Dissolve L021-IS-01-7 (80 mg, 0.16 mmol) in dichloromethane (2 mL), add hydrogen chloride in ethyl acetate solution (2 mL, 4 M), and stir at room temperature for 0.5 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by high-performance liquid phase preparative column chromatography (alkaline conditions) and freeze-dried to obtain compound L021-IS-01 (25.4 mg, yield 39.55%). 1 H NMR (400 MHz, DMSO- d 6 ): δ 8.13(d, J= 8.0 Hz, 1H), 7.72(d, J= 7.6 Hz, 1H), 7.33 – 7.26(m, 2H), 7.24 – 7.09(m, 4H), 6.22(d, J= 8.4 Hz, 1H), 5.83(d, J= 3.6 Hz, 2H), 5.09(q, J= 7.6 Hz, 1H), 4.30 – 4.19(m, 1H), 3.19(d, J= 11.2 Hz, 1H), 3.10(d, J= 12.4 Hz, 1H), 2.74 – 2.59(m, 4H), 2.38 – 2.27(m, 1H), 1.94(d, J= 12.4 Hz, 1H), 1.70(d, J= 12.0 Hz, 2H), 1.54 – 1.41(m, 1H), 1.39 – 1.27(m, 1H), 1.24 – 1.20(m, 3H). LC-MS: [M+H] + = 408.10. Example 40, (2R,4R)-N-((2S)-1-((2-amino-6,7-dihydro-5H-cyclopentadieno[b]pyridin-5-yl) Synthesis of amino)-1-side oxypropan-2-yl)-4-phenylpiperidine-2-methamide (compound L021-IS-02) 40.1 Synthesis of compound L021-IS-02-1 Dissolve L021-IS-01-1 (5 g, 16 mmol) in dichloromethane (40 mL) and acetic acid (4 mL), add sodium borohydride (607 mg, 16 mmol) in batches at 0°C, 0 Stir for 0.5 hours at ℃, then rise to room temperature and stir for 48 hours. The reaction solution was quenched by adding saturated aqueous ammonium chloride solution (30 mL), and extracted with dichloromethane (40 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue Compound L021-IS-02-1 (3 g, yield 59.62%) was purified by silica column chromatography. LC-MS: [M-Boc+H] + = 216.15. 40.2 Synthesis of compound L021-IS-02-2 Dissolve L021-IS-02-1 (3 g, 9.5 mmol) in toluene (20 mL), add triethylamine (2.9 g, 28.5 mmol), and add methylsulfonyl chloride (1.6 g, 14.3 mmol), and the temperature should not exceed 5℃. After the addition is completed, stir at 0°C for 0.5 hours, then rise to room temperature and stir for 1.5 hours. The reaction solution was quenched by adding saturated aqueous sodium bicarbonate (15 mL), and extracted with ethyl acetate (20 mL × 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L021-IS-02-2 (1.7 g, yield 60.10%). LC-MS: [M-Boc+H] + = 198.15. 40.3 Synthesis of compound L021-IS-02-3 (1,5-cyclooctadiene)rhodium(I) chloride dimer (83 mg, 0.17 mmol) and (S)-1,1'-binaphthyl-2,2'-biphenyl were mixed at room temperature. Phosphine (105 mg, 0.17 mmol) was added to the reaction flask. After nitrogen replacement, toluene (5 mL) was added, and nitrogen replacement was performed for 0.5 hours. At room temperature, L021-IS-02-2 (500 mg, 1.68 mmol), L006-b (307 mg, 2.52 mmol) and triethylamine (340 mg, 3.36 mmol) were dissolved in toluene (4 mL) and water ( 1 mL), then add this reaction solution to the above reaction flask containing the catalyst, and stir at 50°C for 1.5 hours under nitrogen protection. The reaction solution was diluted with water (10 mL) and extracted with ethyl acetate (20 mL×3). The combined organic phases were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L021-IS-02-3 (500 mg, yield 79.20%) as a yellow oil. LC-MS: [M+H] + = 376.10. 40.4 Synthesis of compound L021-IS-02 The synthesis of compound L021-IS-02 refers to the synthesis method of compound L021-IS-01. Just replace L021-IS-01-4 with L021-IS-02-3. The crude product obtained by the reaction is passed through the high-performance liquid phase column layer. After purification by chromatography (alkaline conditions), compound L021-IS-02 (71.8 mg, yield 44.72%) was obtained by freeze-drying. 1 H NMR (400 MHz, DMSO- d 6 ): δ 8.27 – 8.06(m, 2H), 7.34 – 7.26(m, 2H), 7.24 – 7.12(m, 4H), 6.23(t, J= 7.6 Hz, 1H), 5.84(s, 2H), 5.17 – 5.07(m, 1H), 4.42 – 4.29(m, 1H), 3.54(d, J= 4.0 Hz, 1H), 2.95 – 2.57(m, 5H), 2.42 – 2.32(m, 1H), 2.29(d, J= 13.6 Hz, 1H), 1.80 – 1.68(m, 1H), 1.63 – 1.49(m, 2H), 1.49 – 1.36(m, 1H), 1.28 – 1.20(m, 4H). LC-MS: [M+H] + = 408.10. Example 41, (2R,4R)-N-((2S)-1-((2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amine Synthesis of methyl)-1-side oxypropan-2-yl)-4-(4-fluorophenyl)piperidine-2-methamide (compound L033-IS-01) hydrochloride The synthesis of compound L033-IS-01 hydrochloride refers to the synthesis method of compound L021-IS-02. Just replace L006-b with L007-a. The crude product obtained by the reaction is subjected to high performance liquid phase column chromatography (acidic conditions) Purification gave compound L033-IS-01 hydrochloride (50.2 mg). 1 H NMR (400 MHz, DMSO- d 6 ): δ 9.93(m, 1H), 9.04(s, 1H), 8.87 - 8.84(m, 1H), 8.57 - 8.53(m, 1H), 8.02(s, 1H), 7.72-7.65(m, 1H) , 7.36 - 7.24(m, 2H), 7.17(t, J= 8.8 Hz, 2H), 6.83(d, J= 8.0 Hz, 1H), 5.17 - 5.16(m, 1H), 4.40 - 4.14(m, 2H), 3.41 - 3.39(m, 1H), 3.15 - 3.03(m, 2H), 2.98 - 2.77(m, 2H), 2.48 - 2.38(m, 1H), 2.36 - 2.13(m, 2H), 2.07 - 1.85(m, 3H), 1.30 - 1.23(m, 4H). LC-MS: [M+H] + =426.15. Example 42, (2R,4S)-N-((2S)-1-((2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amine Synthesis of methyl)-1-side oxypropan-2-yl)-4-(4-fluorophenyl)piperidine-2-methamide (compound L033-IS-02) hydrochloride The synthesis of compound L033-IS-02 hydrochloride refers to the synthesis method of compound L021-IS-01. Just replace L006-b with L007-a. The crude product obtained by the reaction is subjected to high performance liquid phase column chromatography (acidic conditions) After purification, compound L033-IS-02 hydrochloride (37.3 mg, yield 32.5%) was obtained. 1 H NMR (400 MHz, DMSO- d 6 ): δ 9.61 – 9.46(m, 1H), 8.81 – 8.80(m, 2H), 8.54 – 8.50(m, 1H), 7.98(s, 1H), 7.73 – 7.65(m, 1H), 7.31 – 7.22( m, 2H), 7.19 – 7.15(m, 2H), 6.82(t, J= 8.0 Hz, 1H), 5.17 – 5.16(m, 1H), 4.34 – 4.16(m, 1H), 3.93(s, 1H), 3.33 – 3.28(m, 1H), 3.14 – 3.00(m, 2H) , 2.95 – 2.88(m, 2H), 2.46 – 2.44(m, 1H), 2.30(d, J= 12.0 Hz, 1H), 2.02 – 1.81(m, 3H), 1.71 – 1.62(m, 1H), 1.24 – 1.22(m, 4H). LC-MS: [M+H] + =426.05. Example 43, (2R,4S)-N-((2S)-1-((5-amino-2,3-dihydro-1H-inden-1-yl)amino)-1-side oxy group Synthesis of propan-2-yl)-4-(4-fluorobenzyl)pyrrolidine-2-methamide (compound L034) 43.1 Synthesis of compound L034-1 L001-11 (500 mg, 1.55 mmol), 1-hydroxybenzotriazole (231 mg, 1.71 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (328 mg, 1.71 mmol) was dissolved in N,N-dimethylformamide (3 mL) and reacted at room temperature for 0.5 hours. At the same time, L034-a (400 mg, 1.86 mmol) and N,N-diisopropylethylamine (800 mg, 6.2 mmol) were dissolved in N,N-dimethylformamide (2 mL) and reacted at room temperature. 0.5 hours. The latter reaction solution was added to the former reaction solution, and the reaction was continued for 0.5 hours. The reaction solution was diluted with water (20 mL), and extracted with ethyl acetate (30 mL×3). The organic phases were combined and washed with saturated brine (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L034-1 (750 mg), which was used directly in the next step. LC-MS: [M+H] + = 485.05. 43.2 Synthesis of compound L034-2 L034-1 (750 mg, 1.55 mmol) and palladium on carbon (75 mg, 10%wt) were added to methanol (8 mL), and the reaction was carried out in a hydrogen environment for 2 hours. After the reaction solution was filtered through diatomaceous earth, the filtrate was concentrated under reduced pressure to obtain compound L034-2 (520 mg), which could be used directly in the next step. LC-MS: [M+H] + = 395.05. 43.3 Synthesis of compound L034-3 L034-b (2 g, 9.5 mmol) and tert-butyl carbamate (2.2 g, 19.0 mmol) were dissolved in 1,4-dioxane (20 mL) at room temperature, and then palladium acetate (213 mg, 0.95 mmol), 4,5-bisdiphenylphosphine-9,9-dimethylxanthene (549 mg, 0.95 mmol), and cesium carbonate (6.2 g, 19.0 mmol). Nitrogen was replaced three times, and the temperature of the reaction solution was raised to 100°C for 16 hours. The reaction solution was cooled to room temperature, diluted with water (20 mL), and extracted with ethyl acetate (40 mL×3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L034-3 (2 g, yield 85.5%). LCMS: [M+H]+ = 248.10. 43.4 Synthesis of compound L034-4 Dissolve L034-3 (500 mg, 2.02 mmol) in methanol (6 mL) and water (3 mL), add hydroxylamine hydrochloride (281 mg, 4.04 mmol) and potassium carbonate (419 mg, 3.03 mmol), and react at room temperature for 16 Hour. The reaction solution was diluted with water (10 mL), and extracted with ethyl acetate (20 mL×3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L034-4 (500 mg). LC-MS: [M+H] + = 263.10. 43.5 Synthesis of compound L034-5 L034-4 (500 mg, 1.91 mmol) and palladium on carbon (303 mg, 10%wt) were added to methanol (5 mL), and concentrated hydrochloric acid (0.2 mL) was added. React at room temperature under hydrogen atmosphere for 4 hours. After the reaction solution was filtered through diatomaceous earth, the filtrate was diluted with water (10 mL), adjusted to pH 7-8 with sodium bicarbonate aqueous solution, and extracted with ethyl acetate (20 mL×3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L034-5 (350 mg, crude product), which could be used directly in the next step. LC-MS: [M-NH2]+ = 232.10. 43.6 Synthesis of compound L034-6 L034-2 (442 mg, 1.12 mmol), 1-hydroxybenzotriazole (166 mg, 1.23 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (236 mg, 1.23 mmol) was dissolved in N,N-dimethylformamide (3 mL) and reacted at room temperature for 0.5 hours. At the same time, L034-5 (350 mg, 1.4 mmol) and N,N-diisopropylethylamine (578 mg, 4.48 mmol) were dissolved in N,N-dimethylformamide (2 mL) and reacted at room temperature for 0.5 hours. , then add the latter reaction solution to the former reaction solution, and continue the reaction for 0.5 hours. The reaction solution was diluted with water (10 mL), and extracted with ethyl acetate (20 mL×3). The organic phases were combined and washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L034-6 (410 mg, yield 69.8%). LC-MS: [M+H] + =525.05. 43.7 Synthesis of compound L034 Dissolve L034-6 (410 mg, 0.78 mmol) in dichloromethane (5 mL), add hydrogen chloride in ethyl acetate solution (5 mL, 4 M), and react at room temperature for 0.5 hours. The solid was filtered, and the filter cake was washed with dichloromethane (5 mL) and dried under reduced pressure. The residue was purified by high-performance liquid phase column chromatography to obtain compound L034 (89 mg). 1 H NMR (400 MHz, DMSO- d 6 ): δ 8.20 – 8.07(m, 2H), 7.25 – 7.18(m, 2H), 7.12 – 7.07(m, 2H), 6.81 – 6.75(m, 1H), 6.44 – 6.36(m, 2H), 5.12 – 5.04(m, 1H), 4.95(s, 2H), 4.27 – 4.19(m, 1H), 3.64 – 3.61(m, 1H), 2.88 – 2.71(m, 2H), 2.67 – 2.54(m, 4H), 2.30 – 2.28(m, 1H), 2.20 – 1.97(m, 1H), 1.81 – 1.58(m, 3H), 1.24 – 1.16(m, 4H). LC-MS: [M+H] + =425.15. Example 44, (2R,4S)-N-((2S)-1-((2-amino-3-methyl-6,7-dihydro-5H-cyclopenta[b]pyridine- Synthesis of 5-yl)amino)-1-side oxypropan-2-yl)-4-(4-fluorobenzyl)pyrrolidine-2-methamide (compound L035) 44.1 Synthesis of compound L035-1 L035-a (20.0 g, 203.8 mmol), 2-methacrolein (15.7 g, 224.2 mmol) and ammonium acetate (31.4 g, 407.6 mmol) were dissolved in toluene (100 mL) at room temperature. The reaction solution was refluxed for 24 hours. The reaction solution was cooled to room temperature, and then filtered through celite. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain compound L035-1 (1.8 g, yield 6.0%). LC-MS: [M+H] + = 148.10. 44.2 Synthesis of compound L035-2 Dissolve L035-1 (1.7 g, 11.5 mmol) in methanol (20 mL) at room temperature, add sodium borohydride (0.87 g, 23.0 mmol) in batches at 0°C, and control the reaction temperature not to exceed 5°C. At this temperature, the reaction solution continued to react for 2 hours. Methanol (15 mL) was added dropwise to the reaction solution to quench the reaction. The reaction solution was concentrated under reduced pressure, and the residue was separated and purified by silica gel column chromatography to obtain compound L035-2 (1.5 g, yield 88%). LC-MS: [M+H] + = 150.15. 44.3 Synthesis of compound L035-3 Dissolve L035-2 (1.4 g, 9.3 mmol) in tetrahydrofuran (10 mL), add phthalimide (1.37 g, 9.3 mmol) and triphenylphosphine (2.05 g, 12.09 mmol) under ice bath . Diisopropyl azodicarboxylate (2.4 g, 12.09 mmol) was slowly added dropwise under nitrogen protection. After the dropwise addition was completed, the reaction was raised to room temperature and continued for 2 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain compound L035-3 (2.1 g, yield 80.7%). LC-MS: [M+H] + = 279.00. 44.4 Synthesis of compound L035-4 Dissolve L035-3 (2.0 g, 7.0 mmol) in dichloromethane (20 mL) at room temperature, slowly add m-chloroperoxybenzoic acid (1.86 g, 10.6 mmol), and react at room temperature for 2 hours. The reaction solution was quenched by adding saturated sodium bicarbonate (30 mL), extracted with ethyl acetate (40 mL×3), and the combined organic phases were washed with saturated brine (50 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L035-4 (900 mg, yield 42.4%). LC-MS: [M+H] + = 295.05. 44.5 Synthesis of compound L035-5 Dissolve L035-4 (700 mg, 2.5 mmol) in dichloromethane (10 mL) at room temperature, add p-toluenesulfonyl chloride (739 mg, 3.9 mmol), N,N-diisopropylethylamine ( 969 mg, 7.5 mmol) and phthalimide (442 mg, 3.0 mmol), reacted at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain compound L035-5 (780 mg, yield 72.2%). LC-MS: [M+H] + = 423.90. 44.6 Synthesis of compound L035-6 Dissolve L035-5 (700 mg, 4.28 mmol) in ethanol (10 mL) at room temperature, add hydrazine hydrate monohydrate (5 mL, 98%), and react at 80°C for 2 hours. A white solid precipitates. The reaction solution was cooled to room temperature, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by high-performance liquid phase column chromatography and then freeze-dried to obtain compound L035-6 (250 mg, yield 92.6%). LC-MS: [M+H] + = 163.1. 44.7 Synthesis of compound L035-7 Dissolve L035-6 (50 mg, 0.3 mmol) and L034-2 (120 mg, 0.3 mmol) in N,N-dimethylformamide (2 mL), and add triethylamine (121.3 mg, 1.2 mmol) ) and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate (125 mg, 0.33 mmol), react at room temperature for 2 hours. The reaction solution was purified by high-performance liquid phase column chromatography and then freeze-dried to obtain compound L035-7 (18.0 mg, yield 10.9%). LC-MS: [M+H] + = 540.0. 44.8 Synthesis of compound L035 L035-7 (18.0 mg, 0.033 mmol) was added to a solution of hydrogen chloride in 1,4-dioxane (1 mL, 4 M) and reacted at room temperature for 1 hour. After the reaction solution was concentrated, deionized water (5 mL) was added and freeze-dried to obtain compound L035 (11.0 mg, yield 92.3%). 1 H NMR (400 MHz, DMSO- d 6 ): δ 10.46 –10.37(m, 2H), 8.85(t, J= 6.4 Hz, 1H), 8.54(t, J= 8.0 Hz, 2H), 7.65(s, 2H), 7.55(d, J= 18.8 Hz,1H), 7.42(s, 1H), 7.29(t, J= 8.0 Hz, 2H), 7.16 – 7.10(m, 2H), 5.14(d, J= 6.8 Hz, 1H), 4.38(s, 1H), 4.28 – 4.23(m, 1H), 3.48 – 3.38(m, 2H), 3.03-2.97(m, 1H), 2.89 – 2.84(m, 2H) , 2.72 – 2.67(m,2H), 2.50 – 2.43(m,1H)2.14(s, 3H), 2.07 – 2.05(m, 1H), 1.91 – 1.88(m, 2H), 1.23(d, J = 4.4 Hz, 3H). LC-MS: [M+H] + =440.0. Example 45, (2R,4S)-4-(4-fluorobenzyl)-N-((2S)-1-((2-hydroxy-6,7-dihydro-5H-cyclopentaeno) Synthesis of [b]pyridin-5-yl)amino)-1-side oxypropan-2-yl)pyrrolidine-2-methamide (compound L036) 45.1 Synthesis of compound L036-1 Dissolve L001-3 (1 g, 3.6 mmol) in acetic anhydride (10 mL) at room temperature, raise the temperature to 100°C, and react for 2 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain compound L036-1 (800 mg, yield 69.57%). LC-MS: [M+H] + = 323.00. 45.2 Synthesis of compound L036 The synthesis of compound L036 refers to the synthesis method of compound L035. Just replace L035-5 with L036-1. The crude product obtained by the reaction is purified by high-performance liquid phase column chromatography (alkaline conditions) and freeze-dried to obtain compound L036 (18.6 mg, yield 22.97%). 1 H NMR (400 MHz, DMSO- d 6 ): δ 8.47(d, J= 4.0 Hz, 1H), 8.32(d, J= 8.0 Hz, 1H), 8.21 – 8.13(m, 1H), 7.60 – 7.50(m, 1H), 7.30 – 7.16(m, 3H), 7.09(t, J= 8.8 Hz, 2H), 5.48 – 5.36(m, 2H), 5.01(s, 1H), 4.27 – 4.16(m, 1H), 3.62(dd, J= 9.2, 4.8 Hz, 1H), 2.89 – 2.78(m, 1H), 2.63 – 2.52(m, 3H), 2.27 – 2.18(m, 1H), 2.17 – 2.09(m, 1H), 2.09 – 2.01( m, 1H), 1.79 – 1.61 (m, 2H), 1.27 – 1.19 (m, 4H). LC-MS: [M+H] + =427.05. Example 46, (2R,4S)-N-((2S)-1-((2-amino-5,6,7,8-tetrahydroquinolin-5-yl)amino)-1-side Synthesis of oxypropan-2-yl)-4-(4-fluorobenzyl)pyrrolidine-2-carboxamide (compound L037) trifluoroacetate 46.1 Synthesis of compound L037-1 Dissolve L037-a (900 mg, 4.95 mmol) and tert-butyl carbamate (1.2 g, 9.91 mmol) in 1,4-dioxane (10 mL) at room temperature, and add palladium acetate (110.8 mg , 0.50 mmol), 4,5-bisdiphenylphosphine-9,9-dimethylxanthene (286.1 mg, 0.50 mmol) and cesium carbonate (3.2 g, 9.91 mmol), reaction at 90°C under nitrogen protection 3 Hour. The reaction solution was cooled to room temperature, diluted with water (30 mL), and extracted with ethyl acetate (30 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L037-1 (1.3 g, yield 89%). LC-MS: [M+H] + = 263.10. 46.2 Synthesis of compound L037-2 Dissolve L037-1 (200 mg, 0.76 mmol) in ethanol (2 mL) and water (1 mL), add hydroxylamine hydrochloride (105.6 mg, 1.52 mmol) and potassium carbonate (157.6 mg, 1.14 mmol), and react at room temperature 16 hours. The reaction solution was diluted with water (10 mL), and extracted with ethyl acetate (20 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L037-2. LC-MS: [M+H] + = 278.10. 46.3 Synthesis of compound L037-3 L037-2 (190 mg, crude product) was dissolved in methanol (2 mL), and palladium on carbon (73 mg, 10% wt) was added. Replace with hydrogen three times and react at room temperature for 4 hours. The reaction solution was filtered through celite, and the filter cake was washed with methanol (10 mL). The filtrate was concentrated under reduced pressure to obtain compound L037-3 (85 mg, crude product). LC-MS: [M+H] + = 264.15. 46.4 Synthesis of compound L037-4 Dissolve L001-d (60.5 mg, crude product) in N, N-dimethylformamide (1 mL), add 1-hydroxybenzotriazole (47.5 mg, 0.35 mmol) and 1-(3-bis Methylaminopropyl)-3-ethylcarbodiimide hydrochloride (67.6 mg, 0.35 mmol), react at room temperature for 10 minutes. A solution of L037-3 (85 mg, 0.32 mmol) and N,N-diisopropylethylamine (165.1 mg, 1.28 mmol) in N,N-dimethylformamide (1 mL) was then added to the above reaction. In the system, continue the reaction at room temperature for 1 small test. The reaction solution was diluted with water (20 mL), and extracted with ethyl acetate (30 mL×3). The organic phases were combined and washed with saturated brine (40 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L037-4 (70 mg, crude product). LC-MS: [M+H] + = 435.10. 46.5 Synthesis of compound L037-5 Dissolve L037-4 (128 mg, crude product) in dichloromethane (2 mL), add hydrogen chloride in ethyl acetate solution (2 mL, 4 M), and react at room temperature for 0.5 hours. The reaction solution was concentrated under reduced pressure, and the residue was added with dichloromethane (10 mL), stirred for 10 minutes, filtered, and the filter cake was dried under reduced pressure to obtain compound L037-5 (150 mg). LC-MS: [M+H] + = 235.15. 46.6 Synthesis of compound L037 trifluoroacetate For the synthesis of compound L037, refer to the synthesis method of compound L001. Just replace L001-7 with L037-5. The crude product obtained from the reaction is purified by high-performance liquid phase column chromatography (trifluoroacetic acidic conditions) to obtain compound L037 trifluoroacetic acid. Salt (34 mg). 1 H NMR (400 MHz, DMSO- d 6 ): δ 9.61 – 9.56(m, 1H), 8.77(d, J= 8.0 Hz, 1H), 8.54(s, 1H), 8.39(d, J= 12.0 Hz, 1H), 8.00 – 7.89(m, 1H), 7.67 – 7.52(m, 1H), 7.28 – 7.25(m, 2H), 7.14(t, J= 8.0 Hz, 2H), 6.79(t, J= 12.0 Hz, 1H), 4.81(s, 1H), 4.35 – 4.21(m, 2H), 3.31(s, 1H), 2.91(s, 1H), 2.71 – 2.62(m, 4H), 2.49 – 2.40 (m, 2H), 2.08 – 1.63(m, 6H), 1.24(dd, J = 8.0, 4.0 Hz, 3H). LC-MS: [M+H] + =440.05. Example 47, (2R,4R)-N-((2S)-1-((2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amine Synthesis of methyl)-1-side oxypropane-2-yl)-4-(2-fluorophenyl)piperidine-2-methamide (compound L038-IS-01) The synthesis of compound L038-IS-01 refers to the synthesis method of compound L021-IS-02. Just replace L006-b with L038-a. The crude product obtained by the reaction is purified by high-performance liquid phase column chromatography (alkaline conditions). Compound L038-IS-01 (60.6 mg, yield 29.94%) was obtained by freeze-drying. 1 H NMR (400 MHz, DMSO- d 6 ): δ 7.91(s, 1H), 7.38(d, J= 8.0 Hz, 1H), 7.22 – 6.95(m, 4H), 6.73(s, 1H), 6.39 – 6.15(m, 1H), 5.36(s, 1H), 4.59 – 4.50(m, 1H), 4.45 (s, 2 H), 3.74(s, 1H), 3.08 - 2.76(m, 5H), 2.64 - 2.49(m, 2H), 2.06 - 1.50(m, 5H), 1.43(d, J = 7.2 Hz, 3H). LC-MS: [M+H] + =426.10. Example 48, (2R,4S)-N-((2S)-1-((2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amine Synthesis of methyl)-1-side oxypropan-2-yl)-4-(2-fluorophenyl)piperidine-2-methamide (compound L038-IS-02) hydrochloride The synthesis of compound L038-IS-02 hydrochloride refers to the synthesis method of compound L021-IS-01. Just replace L006-b with L038-a. The crude product obtained by the reaction is subjected to high performance liquid phase column chromatography (acidic conditions) Purification and freeze-drying gave compound L038-IS-02 hydrochloride (56.2 mg, yield 29.06%). 1 H NMR (400 MHz, DMSO- d 6 ): δ 9.76 - 9.62(m, 1H), 8.86(d, J = 7.6 Hz, 2H), 8.55(dd, J = 16.0, 8.0 Hz, 1H), 8.03(s, 2H), 7.72 - 7.66(m , 1H), 7.39 – 7.13(m, 4H), 6.84(t, J = 9.2 Hz, 1H), 5.25 – 5.06(m, 1H), 4.36 – 4.13(m, 1H), 3.98(t, J = 10.8 Hz, 1H), 3.33(d, J = 11.6 Hz, 1H), 3.25 – 3.02(m, 3H), 2.96 – 2.81(m, 1H), 2.47 – 2.41(m, 1H), 2.26(d, J = 13.2 Hz, 1H), 2.03 – 1.74(m, 4H), 1.23(d, J = 6.8 Hz, 3H). LC-MS: [M+H] + =426.10. The following compounds in Table A were synthesized with reference to the synthesis method of L021-IS-01 / L021-IS-02, where Examples 49, 51, 52, 53, 55, 57, and 59 refer to the synthesis method of compound L021-IS-01, Example 50 , 54, 56, 58, 60, 61, 62, 63 refer to the synthesis method of compound L021-IS-02. Table A Example 64, N-((2S)-1-((2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)-1-side Synthesis of oxypropan-2-yl)-4-((4,4-dimethylpiperidin-1-yl)methyl)pyrrolidine-2-methamide (compound L049) hydrochloride 64.1 Synthesis of compound L049-1 Dissolve L049-a (1.00 g, 7.19 mmol) in dichloromethane (6 mL) and nitromethane (6 mL) at room temperature, under nitrogen protection, and add aluminum trichloride (1.92 g) in batches at -20°C. , 14.38 mmol), then add L049-b (1.65 g, 14.38 mmol) dropwise, and maintain the reaction at -20°C for 1 hour. The reaction solution was slowly poured into ice water (20 mL) to quench, the organic phase was separated, and the aqueous phase was extracted with dichloromethane (15 mL×3). The organic phases were combined and washed with saturated aqueous sodium bicarbonate solution (30 mL) and saturated sodium chloride solution (30 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L049-1 (1.10 g, crude product), which was used directly in the next step. LC-MS: [M+H] + =168.10. 64.2 Synthesis of compound L049-2 Dissolve L049-1 (1.10 g, crude product) in dichloromethane (10 mL), add di-tert-butyl dicarbonate (2.15 g, 9.87 mmol), 4-dimethylaminopyridine (161 mg, 1.32 mmol) and triethylamine (1.33 g, 13.16 mmol) for 4 hours at room temperature. The reaction solution was diluted with water (20 mL), extracted with dichloromethane (15 mL×3), the organic phases were combined and washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 4 / 1) to obtain compound L049-2 (660 mg). LC-MS: [M+H] + =268.10. 64.3 Synthesis of compound L049-3 Dissolve L049-2 (650 mg, 2.43 mmol) and L049-c (437 mg, 2.92 mmol) in dichloromethane (10 mL), add acetic acid (146 mg, 2.43 mmol), and react at room temperature for 2 hours. Then add sodium triacetylborohydride (1.29 g, 6.08 mmol), and continue the reaction at room temperature for 16 hours. The reaction solution was poured into ice water (20 mL) to quench, and extracted with dichloromethane (15 mL×3). The organic phases were combined and washed with saturated sodium chloride aqueous solution (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 2 / 1) to obtain compound L049-3 (450 mg, yield: 50.3%). LC-MS: [M+H] + =365.05. 64.4 Synthesis of compound L049-4 L049-3 (450 mg, 1.23 mmol) was dissolved in ethanol (10 mL), and palladium on carbon (200 mg, 10%wt) was added. The reaction was carried out at room temperature under hydrogen atmosphere for 16 hours. The reaction solution was filtered through celite, and the filter cake was washed with ethanol (10 mL). The filtrate was concentrated under reduced pressure to obtain compound L049-4 (450 mg, crude product). LC-MS: [M+H] + =369.10. 64.5 Synthesis of compound L049-5 Dissolve L049-4 (450 mg, 1.22 mmol) in tetrahydrofuran (10 mL), methanol (5 mL) and water (5 mL), add lithium hydroxide monohydrate (154 mg, 3.66 mmol), and react at room temperature 5 hours. The reaction solution was concentrated under reduced pressure, and the residue was dissolved in water (10 mL). The aqueous phase was adjusted to pH=6~7 with dilute hydrochloric acid (1 M), and extracted with dichloromethane (15 mL×3). The organic phases were combined and washed with saturated aqueous sodium chloride solution (20 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L049-5 (450 mg, crude product). LC-MS: [M+H] + =341.05. 64.6 Synthesis of compound L049-6 Dissolve L049-5 (450 mg, crude product), L001-7 (407 mg, 1.58 mmol) and N,N-diisopropylethylamine (668 mg, 6.60 mmol) in dichloromethane (5 mL), Add 1-propylphosphoric anhydride (630 mg, 1.98 mmol, 50% ethyl acetate solution) and react at room temperature for 3 hours. The reaction solution was diluted with water (20 mL), extracted with dichloromethane (15 mL×3), the organic phases were combined and washed with saturated aqueous sodium chloride solution (20 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L049-6 (370 mg, crude product). LC-MS: [M+H] + = 543.15. 64.7 Synthesis of Compound L049 Hydrochloride Dissolve L049-6 (370 mg, crude product) in dichloromethane (6 mL), add hydrogen chloride in ethyl acetate solution (4 mL, 4 M), and react at room temperature for 0.5 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by high-performance liquid phase column chromatography (0.1% hydrochloric acid conditions) to obtain compound L049 hydrochloride (23.4 mg). 1 H NMR (400 MHz, DMSO- d 6 ): δ 10.50(s, 1H), 10.13(s, 1H), 8.86(dd, J= 6.8, 3.2 Hz, 1H), 8.78(s, 1H), 8.56(d, J= 7.6 Hz, 1H), 8.01(s, 2H), 7.75 – 7.62(m, 1H), 6.84(t, J= 9.2 Hz, 1H), 5.19 – 5.09(m, 1H), 4.35 – 4.16(m, 2H), 3.55(s, 2H), 3.32 – 3.16(m, 4H), 3.13 – 2.73(m, 6H) , 2.67 – 2.59(m, 1H), 1.92(d, J= 6.7 Hz, 1H), 1.80 – 1.76(m, 2H), 1.73 – 1.57(m, 1H), 1.48 – 1.45(m, 2H), 1.27(t, J= 6.4 Hz, 3H), 0.99 – 0.96(m, 6H). LC-MS: [M+H] + =443.10. Example 65, (2R)-N-((S)-1-(((R)-2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl) Synthesis of )amino)-1-side oxypropan-2-yl)-4-(difluoro(4-fluorophenyl)methyl)pyrrolidine-2-methamide (compound L050) 65.1 Synthesis of compound L050-1 L006-1 (2.70 g, 7.19 mmol) was dissolved in tetrahydrofuran (20 mL) and water (5 mL), and tetrakis triphenylphosphine palladium (1.66 g, 1.44 mmol) was added. After nitrogen replacement, the reaction solution was reacted in a carbon monoxide atmosphere at room temperature for 16 hours. The reaction solution was diluted with water (30 mL) and extracted with ethyl acetate (20 mL×2). The combined organic phases were washed with saturated aqueous sodium bicarbonate solution (20 mL) and the organic phase was discarded. Combine all aqueous phases, adjust the aqueous phase to pH=2 with dilute hydrochloric acid (2M), and extract with ethyl acetate (25 mL×3). The organic phases were combined and washed with saturated aqueous sodium chloride solution (20 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L050-1 (1.42 g, crude product). LC-MS: [M-tBu+H] + =216.00. 65.2 Synthesis of compound L050-2 At room temperature, L050-1 (1.42 g, crude product) was dissolved in methanol (10 mL) and tetrahydrofuran (10 mL), and triethylamine (529 mg, 5.23 mmol) and triphenylphosphine rhodium chloride (968 mg, 1.05 mmol), after nitrogen replacement, and then hydrogen replacement, the reaction solution was reacted in a hydrogen environment for 72 hours. The reaction solution was concentrated under reduced pressure, and the residue was added to saturated aqueous sodium bicarbonate solution (15 mL), adjusted to pH=10 with aqueous sodium hydroxide solution (1 M), and then extracted with ethyl acetate (15 mL). The organic phase was Wash with saturated aqueous sodium bicarbonate solution (15 mL) and discard the organic phase. Combine all the aqueous phases, adjust the pH to =4-5 with dilute hydrochloric acid (1 M), extract with ethyl acetate (30 mL×3), and wash the combined organic phase with saturated aqueous sodium chloride solution (40 mL). After drying over anhydrous sodium sulfate, it was filtered, and the filtrate was concentrated under reduced pressure to obtain compound L050-2 (1.1 g, crude product). LC-MS: [M-Boc+H] + =174.10. 65.3 Synthesis of compound L050-3 Dissolve L050-2 (1.1 g, crude product) and L050-a (588 mg, 6.03 mmol) in N,N-dimethylformamide (10 mL), and add 2-(7-azobenzotris Azole)-N,N,N',N'-tetramethylurea hexafluorophosphate (1.83 g, 4.82 mmol) and N,N-diisopropylethylamine (1.56 g, 12.06 mmol), reaction at room temperature 16 hours. The reaction solution was diluted with water (50 mL), extracted with ethyl acetate (30 mL×3), the combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was reduced to pressure concentrate. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 2 / 1) to obtain compound L050-3 (800 mg). LC-MS: [M+H] + =317.05. 65.4 Synthesis of compound L050-4 Dissolve L050-3 (700 mg, 2.21 mmol) in anhydrous tetrahydrofuran (10 mL), under nitrogen protection, cool the reaction solution to 0°C, add L050-b (3.3 mL, 3.32 mmol, 1 M) dropwise, and then add React at room temperature for 3 hours. The reaction solution was quenched by adding saturated aqueous ammonium chloride solution (15 mL), extracted with ethyl acetate (15 mL×3), and the combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL) and anhydrous sodium sulfate. After drying, it was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 4 / 1) to obtain compound L050-4 (144 mg). LC-MS: [M-Boc+H] + =252.05. 65.5 Synthesis of Compound L050-5 L050-4 (130 mg, 0.37 mmol) was added to bis(2-methoxyethyl)amino sulfur trifluoride (5 mL), and the reaction was carried out at 90°C for 6 hours under nitrogen protection. The reaction solution was cooled to room temperature, quenched by adding dropwise to saturated aqueous sodium bicarbonate solution (20 mL) that had been cooled to 0°C, extracted with ethyl acetate (15 mL×3), and the combined organic phases were quenched with saturated aqueous sodium chloride solution. (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 3 / 1) to obtain compound L050-5 (80 mg). LC-MS: [M-tBu+H] + =317.95. 65.6 Synthesis of compound L050-6 Dissolve L050-5 (80 mg, 0.21 mmol) in methanol (2 mL), tetrahydrofuran (2 mL) and water (1 mL), add lithium hydroxide monohydrate (27 mg, 0.64 mmol), and react at room temperature 5 hours. The reaction solution was concentrated under reduced pressure, and the residue was poured into water (5 mL). The pH was adjusted to 4-5 with dilute hydrochloric acid aqueous solution (1 M), and extracted with ethyl acetate (10 mL×3). The combined organic phases were washed with saturated sodium chloride aqueous solution (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound L050-6 (80 mg, crude product). LC-MS: [M-tBu+H] + =303.95. 65.7 Synthesis of Compound L050 The synthesis of compound L050 hydrochloride refers to the synthesis method of compound L001-IS-01. Just replace L001-8 with L050-6. The crude product obtained by the reaction is purified by high performance liquid phase column chromatography (0.1% hydrochloric acid condition). Lyophilization gave compound L050 hydrochloride (42.5 mg). 1 H NMR (400 MHz, DMSO- d 6 ): δ 10.47(s, 1H), 8.94 – 8.88(m, 2H), 8.55(s, 1H), 8.00(s, 2H), 7.69 – 7.62(m, 3H), 7.38(t, J= 8.8 Hz, 2H), 6.82(d, J= 8.8 Hz, 1H), 5.18 – 5.12(m, 1H), 4.37 – 4.20(m, 2H), 3.26(s, 1H), 3.10 – 2.99(m, 1H), 2.96 – 2.85(m, 1H) , 2.47 – 2.44(m, 1H), 2.41 – 2.39(m, 3H), 2.03 – 1.73(m, 2H), 1.24(t, J = 5.6 Hz, 3H). LC-MS: [M+H] + =462.00. Example 66, (2R,4S)-N-((2S)-1-((3-amino-6,7-dihydro-5H-cyclopenta[c]pyridin-7-yl)amine Synthesis of methyl)-1-side oxypropan-2-yl)-4-(4-fluorobenzyl)pyrrolidine-2-methamide (compound L051) hydrochloride 66.1 Synthesis of compound L051-1 L051-a (5 g, 36.35 mmol) and triphenylphosphine (9.5 g, 36.35 mmol) were dissolved in toluene (100 mL) at room temperature. After nitrogen replacement, the reaction solution was heated to 80°C and reacted for 16 hours, and a large amount of white solid was generated. The reaction solution was cooled to room temperature, filtered, and the filter cake was washed with toluene (20 mL) and dried under reduced pressure to obtain compound L051-1 (6.7 g, yield 50.72%). LC-MS: [M+H] + =363.95. 66.2 Synthesis of compound L051-2 L051-1 (6.7 g, 18.44 mmol) and L051-b (4.1 g, 18.44 mmol) were dissolved in dichloromethane (100 mL) and reacted at room temperature for 16 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 3 / 1) to obtain compound L051-2 (3.5 g, yield 62.17%). LC-MS: [M+H] + = 306.85. 66.3 Synthesis of compound L051-3 Dissolve L051-2 (3.5 g, 11.45 mmol) in ethyl acetate (50 mL), add rhodium / alumina complex (2 g), replace with hydrogen, and react at room temperature under hydrogen atmosphere for 5 days. The reaction solution was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 3 / 1) to obtain compound L051-3 (3.5 g, yield 99.43%). LC-MS: [M+H] + =308.85. 66.4 Synthesis of compound L051-4 Dissolve L051-3 (3.5 g, 11.44 mmol) in tetrahydrofuran (50 mL), cool the reaction system to -70°C, and slowly add n-butyllithium (14 mL, 22.4 mmol, 1.6 M n-hexane solution) dropwise. After the dropwise addition was completed, the reaction solution was continued to react at -70°C for 2 hours. Saturated ammonium chloride aqueous solution (20 mL) was added to the reaction solution to quench, and the mixture was extracted with ethyl acetate (50 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 3 / 1) to obtain compound L051-4 (1.2 g, yield 62.83%). LC-MS: [M+H] + = 168.05. 66.5 Synthesis of Compound L051-5 At room temperature, L051-4 (1.2 g, 7.16 mmol) and tert-butyl carbamate (1.7 g, 14.32 mmol) were dissolved in 1,4-dioxane (50 mL), and palladium acetate (161 mg, 0.72 mmol), 2-dicyclohexylphosphine-2',4',6'-triisopropylbiphenyl (683 mg, 1.43 mmol) and cesium carbonate (4.7 g, 14.32 mmol), reacted at 80°C under nitrogen atmosphere 16 hours. The reaction solution was cooled to room temperature, diluted into water (50 mL), and extracted with ethyl acetate (50 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 3 / 1) to obtain compound L051-5 (1.2 g, yield 67.42%). LC-MS: [M+H] + = 249.05. 66.6 Synthesis of compound L051-6 Dissolve L051-5 (1.17 g, 4.71 mmol) in ethanol (20 mL) and water (10 mL), add sodium acetate (590 mg, 7.07 mmol) and L051-c (580 mg, 7.07 mmol), and keep at room temperature. Reaction time is 16 hours. The reaction solution was poured into water (20 mL) and diluted, extracted with ethyl acetate (20 mL×3), the organic phases were combined and dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 2 / 1) to obtain compound L051-6 (600 mg, yield 45.80%). LC-MS: [M+H] + = 278.05. 66.7 Synthesis of compound L051-7 Dissolve L051-6 (600 mg, 2.16 mmol) in methanol (20 mL) and ammonia (2 mL), add Raney nickel (100 mg), and react under hydrogen atmosphere for 16 hours. The reaction solution was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure to obtain compound L051-7 (450 mg, crude product), which was directly used in the next reaction. LC-MS: [M+H] + = 250.05. 66.8 Synthesis of compound L051-8 Dissolve L051-7 (200 mg, 0.53 mmol) in dichloromethane (8 mL), add N,N-diisopropylethylamine (194 mg, 1.53 mmol), and react at room temperature for 10 minutes. The system was added to a solution of L034-2 (154 mg, 0.61 mmol) and 1-propylphosphonic anhydride (647 mg, 1.0 mmol, 50% in ethyl acetate) in dichloromethane (8 mL). Continue the reaction for 1 hour at room temperature. The reaction solution was diluted with saturated sodium chloride aqueous solution (20 mL), extracted with dichloromethane (20 mL×3), the organic phases were combined and dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 1) to obtain compound L051-8 (250 mg, yield 43.31%). LC-MS: [M+H] + = 626.10. 66.9 Synthesis of Compound L051 Hydrochloride Dissolve L051-8 (230 mg, 0.35 mmol) in dichloromethane (2 mL), add hydrogen chloride in 1,4-dioxane solution (2 mL, 4 M), and react at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure, and the crude product was purified by high-performance liquid phase column chromatography (0.1% hydrochloric acid condition) to obtain compound L051 hydrochloride (98.5 mg, yield 53.37%). LC-MS: [M+H] + = 426.05. 1 H NMR (400 MHz, DMSO- d 6 ): δ 10.42(s, 1H), 8.94 – 8.89(m, 1H), 8.71 – 8.41(m, 2H), 8.05 – 8.02(m, 2H), 7.72 – 7.68(m, 1H), 7.28(dd, J= 8.4, 5.6 Hz, 2H), 7.11(t, J= 8.8 Hz, 2H), 6.85(s, 1H), 5.12(q, J= 7.6 Hz, 1H), 4.40 – 4.35(m, 1H), 4.23 – 4.21(m, 1H), 3.33 – 3.19(m, 1H), 3.03 – 2.96(m, 1H), 2.92 – 2.78(m, 2H), 2.74 – 2.62(m, 2H), 2.47 – 2.39(m, 1H), 2.38 – 2.26(m, 1H), 2.09 – 2.01(m, 1H), 1.95 – 1.83(m, 2H), 1.22( d, J = 7.2 Hz, 3H). LC-MS: [M+H] + =426.05. Example 67, (2R,4S)-N-((2S)-1-((2-amino-3-methyl-6,7-dihydro-5H-cyclopenta[b]pyridine- Synthesis of 5-yl)amino)-1-side oxypropan-2-yl)-4-(4-fluorophenyl)piperidine-2-carboxamide (compound L052) hydrochloride 67.1 Synthesis of compound L052-1 Dissolve L001-d (1.5 g, 8.08 mmol) in N,N-dimethylformamide (20 mL), and add 1-(3-dimethylaminopropyl)-3-ethylcarbodioxide in sequence. Amine hydrochloride (1.7 g, 8.89 mmol), 1-hydroxybenzotriazole (1.2 g, 8.89 mmol), react at 25°C for 10 minutes, then add N,N-diisopropylethylamine (5.2 g, 40.40 mmol) and L001-6 (1.5 g, 8.08 mmol) in N,N-dimethylformamide solution (10 mL), continue the reaction at 25°C for 30 minutes. The reaction solution was poured into water (30 mL), and extracted with ethyl acetate (30 mL×3). The organic phase was washed with saturated aqueous ammonium chloride solution (20 mL×3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L052-1 (1.5 g). 67.2 Synthesis of compound L052-2 Dissolve L052-1 (200 mg, 0.66 mmol) in acetonitrile (5 mL), add N-bromosuccinimide (134 mg, 0.75 mmol), and react at room temperature for 2 hours. The reaction solution was diluted with water (10 mL) and extracted with dichloromethane (10 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (methanol / dichloromethane=1 / 20) to obtain compound L052-2 (160 mg, yield 60%). LC-MS: [M+H] + = 398.95. 67.3 Synthesis of compound L052-3 Dissolve L052-2 (180 mg, 0.45 mmol) and trimethylcyclotriboroxane (282 mg, 2.25 mmol) in N,N-dimethylformamide (5 mL) and water (0.1 mL), add potassium carbonate (187 mg, 1.35 mmol) and [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride (33 mg, 0.045 mmol). Nitrogen was replaced three times, and the reaction solution was reacted at 110°C for 16 hours. The reaction solution was cooled to room temperature, diluted with water (30 mL), and extracted with ethyl acetate (30 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (methanol / dichloromethane=1 / 10) to obtain compound L052-3 (130 mg, yield 86.7%). LC-MS: [M+H] + = 335.10. 67.4 Synthesis of compound L052-4 Dissolve L052-3 (130 mg, 0.39 mmol) in dichloromethane (1 mL), add hydrogen chloride in 1,4-dioxane solution (2 mL, 4 M), and react at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure to obtain compound L052-4 (crude product), which was directly used in the next step. LC-MS: [M+H] + = 235.15. 67.5 Synthesis of Compound L052 Hydrochloride The synthesis of compound L052 refers to the synthesis method of compound L001. Just replace L001-11 with L033-IS-02-4 and L001-7 with L052-4. The crude product obtained by the reaction is subjected to high performance liquid phase column chromatography (0.1 % hydrochloric acid conditions), and then freeze-dried to obtain compound L052 hydrochloride (8.3 mg). 1 H NMR (400 MHz, DMSO- d 6 ): δ 9.59 – 9.42(m, 1H), 8.92 – 8.69(m, 2H), 8.54 – 8.48(m, 1H), 7.70(s, 2H), 7.58(d, J= 8.0 Hz, 1H), 7.27(d, J= 8.0 Hz, 2H), 7.17 – 7.15(m, 2H), 5.19 – 5.14(m, 1H), 4.28(m, 1H), 3.94(s, 1H), 3.08 – 3.03(m, 2H), 2.91 – 2.89(m, 2H), 2.44 – 2.40(m, 1H), 2.32 – 2.30(m, 1H), 2.15(d, J= 8.0 Hz, 2H), 2.04 – 1.61(m, 5H), 1.24(d, J = 8.0 Hz, 4H). LC-MS: [M+H] + =440.05. Example 68, (2R,4S)-N-((2S)-1-((2-amino-3-chloro-6,7-dihydro-5H-cyclopenta[b]pyridine-5 Synthesis of -(yl)amino)-1-side oxypropan-2-yl)-4-(4-fluorobenzyl)pyrrolidine-2-carboxamide (compound L053) hydrochloride 68.1 Synthesis of compound L053-1 Dissolve L052-1 (400 mg, 1.2 mmol) in acetonitrile (10 mL), add N-chlorosuccinimide (250 mg, 1.8 mmol), and react at room temperature for 3 hours. The reaction solution was diluted with water (20 mL), and extracted with dichloromethane (20 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by high-performance liquid phase column chromatography (0.1% ammonia solution) and then freeze-dried to obtain compound L053-1 (90 mg, yield 21%). LC-MS: [M+H] + = 355.05. 68.2 Synthesis of compound L053-2 Dissolve L053-1 (90 mg, 0.23 mmol) in dichloromethane (2 mL), add hydrogen chloride in 1,4-dioxane solution (4 M, 4 mL), and react at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure to obtain compound L053-2 hydrochloride (67 mg), which was used directly in the next step. LC-MS: [M+H] + = 255.05. 68.3 Synthesis of Compound L053 Hydrochloride The synthesis of compound L053 refers to the synthesis method of compound L001. Just replace L001-7 with L053-2. The crude product obtained by the reaction is purified by high performance liquid phase column chromatography (0.1% hydrochloric acid condition) and freeze-dried to obtain compound L053 hydrochloride. (26.3 mg). 1 H NMR (400 MHz, DMSO- d 6 ): δ 10.13(s, 1H), 8.81(d, J= 8.0 Hz, 1H), 8.52(t, J= 8.0 Hz, 2H), 7.66(d, J= 12 Hz, 1H), 7.29 – 7.27(m, 2H), 7.13(t, J= 8.4 Hz, 2H), 5.13(dd, J= 8.0, 4.0 Hz, 1H), 4.41 – 4.32(m, 3H), 4.32 – 4.23(m, 3H), 3.34 – 3.21(m, 1H), 2.98 – 2.61(m, 5H), 2.48 – 2.37( m, 1H), 2.12 – 1.98(m, 1H), 1.92 – 1.90(m, 2H), 1.23(d, J = 4.0 Hz, 3H). LC-MS: [M+H] + =460.00. Example 69, (2R)-N-((S)-1-(((R)-2-amino-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl) Synthesis of )amino)-1-side oxypropan-2-yl)-4-fluoro-4-(4-fluorophenyl)piperidine-2-methamide (compound L054) 69.1 Synthesis of compound L054-1 L022-a (1.0 g, 3.85 mmol) was added to tetrahydrofuran (10 mL) at room temperature, the reaction solution was cooled to -78°C, and lithium bis(trimethylsilyl)amide (4.2 mL) was added dropwise under nitrogen protection. 4.2 mmol, 1 M tetrahydrofuran solution), after the dropwise addition is completed, stir at -78°C for 10 minutes. At this temperature, add N-(5-chloro-2-pyridyl)bis(trifluoromethanesulfonamide) (1.58 g, 4.04 mmol) in tetrahydrofuran (5 mL). After the addition is complete, raise the temperature to room temperature and continue stirring for 1.5 Hour. A saturated aqueous solution of ammonium chloride (20 mL) was added to the reaction solution to quench, and the mixture was extracted with ethyl acetate (20 mL×3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound L054-1 (600 mg, crude product). 69.2 Synthesis of compound L054-2 L054-1 (2.9 g, 7.45 mmol), L007-a (2.1 g, 14.90 mmol), bis(triphenylphosphine)palladium dichloride (523 mg, 0.74 mmol) and potassium carbonate (2.1 g, 14.90 mmol) were combined ) was dissolved in tetrahydrofuran (50 mL) and water (10 mL), and reacted at 40°C for 3 hours under nitrogen protection. The reaction solution was poured into water (30 mL), extracted with ethyl acetate (30 mL × 3), the organic phases were combined and dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was subjected to silica gel column chromatography ( Ethyl acetate / petroleum ether = 1 / 3) was purified to obtain compound L054-2 (2.4 g, yield 95.56%). LC-MS: [M+H] + = 336.05. 69.3 Synthesis of compound L054-3 Dissolve L054-2 (1.0 g, 2.98 mmol) in acetone (10 m) and water (2 mL) at room temperature, and slowly add N-bromosuccinimide (584 mg, 3.28 mmol) in acetone. (10 mL) solution. After the dropwise addition was completed, the reaction was continued at room temperature for 16 hours. Pour the reaction solution into water (10 mL), extract with ethyl acetate (20 mL×3), dry the organic phase with anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure. The residue is subjected to silica gel column chromatography ( Petroleum ether / ethyl acetate = 1 / 2) was purified to obtain compound L054-3 (867 mg, yield 67.18%). LC-MS: [M-Boc+H] + = 331.85. 69.4 Synthesis of compound L054-4 Dissolve L054-3 (1.2 g, 2.78 mmol) in tetrahydrofuran (30 mL), add sodium acetate (685 mg, 8.35 ...

Claims

1. A compound of formula (I'), its racemic derivative, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: (I') wherein: Cy3 is selected from; Z is selected from CR2 or N; R1, R2 and R3 are independently selected from H, halogen, -NH2, -OH, -NO2, -CN, C1-6 alkyl, C1-6 aminoalkyl or C1-6 alkoxy; X is selected from N; Y is selected from -CH2-; m is selected from 1; each R may be the same or different and is independently selected from H, halogen, C1-6 alkyl or C1-6 alkoxy; p is selected from 0, 1, 2, 3 or 4; R5 is selected from H, C1-6 alkyl, C2-6 alkynyl, C1-6 haloalkyl or C3-6 cycloalkyl; R5' is selected from H or C1-6 alkyl; or R5 and R5' together with the carbon atoms to which they are attached form a C3-6 cycloalkyl; R6 is selected from H or C1-6 alkyl; Alternatively, R5 and R6 together with the C and N atoms to which they are attached form a 3-12 member heterocyclic alkyl group, which is unsubstituted or optionally substituted by one, two, or three R5a; each R5a may be the same or different and is independently selected from halogens, C1-6 alkyl groups, -OH, -NO2, -CN, lateral oxy groups (=O), C2-6 alkenyl groups, C2-6 alkynyl groups, C1-6 haloalkyl groups, C1-6 alkoxy groups, or C1-6 haloalkoxy groups; or R5a on the same carbon or on two adjacent carbons together with the carbon atoms to which they are attached form a C3-6 cycloalkyl group, which is unsubstituted or optionally substituted by one, two, or three halogens; Cy1 is selected from the following groups, either unsubstituted or substituted with one or two R7s: tetrahydropyrrolyl, 2,5-dihydro-1H-pyrrolyl, pyrrolyl, piperidinyl, 1,2,3,6-tetrahydropyridinyl, 1,2,5,6-tetrahydropyridinyl, piperazine, 4-azaspiro[2.5]octyl, 1,2-dihydropyridinyl, or 1,4-dihydropyrazine; each R7 may be the same or different, and is independently selected from H, oxy(=O), halogen, or C1-6 alkyl; L is absent or selected from -C(Ra)(Rb)-, Ra and Rb may be the same or different, and are independently selected from H, halogen, or C1-6 alkyl, or Ra and Rb together with the carbon atoms to which they are attached form a C3-6 cycloalkyl group; Cy2 is selected from the following groups that are unsubstituted or optionally substituted with one, two, three or four R8s: C6-10 aryl, 5-9 heteroaryl or 6-11 heterocyclic; each R8 may be the same or different and is independently selected from -CN, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C3-10 cycloalkyl, C6-10 aryl or 5-10 heteroaryl.

2. The compound as claimed in claim 1, its racemate, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein, The compound shown in formula (I') has the structure shown in formula (I) as follows: (I) Wherein: R1, R2 and R3 are independently selected from H, halogen, -NH2, -OH, -NO2, -CN, C1-6 alkyl, C1-6 aminoalkyl or C1-6 alkoxy; X is selected from N; Y is selected from -CH2-; m is selected from 1; Each R is the same or different and is independently selected from H, halogen, C1-6 alkyl or C1-6 alkoxy; p is selected from 0, 1, 2, 3 or 4; R5 is selected from H, C1-6 alkyl, C2-6 alkynyl, C1-6 haloalkyl or C3-6 cycloalkyl; R6 is selected from H or C1-6 alkyl, or R5 and R6 together with the C and N atoms to which they are attached form a 3-12 member heterocyclic alkyl group, which is unsubstituted or optionally substituted by one, two or three R5a; Each R5a may be the same or different and is independently selected from halogens, C1-6 alkyl, -OH, -NO2, -CN, sideoxy (=O), C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 alkoxy or C1-6 haloalkoxy; or R5a on the same carbon or on two adjacent carbons together with the carbon atoms to which they are attached form a C3-6 cycloalkyl group, said C3-6 cycloalkyl group being unsubstituted or optionally substituted by one, two or three halogens; Cy1 is selected from the following groups unsubstituted or optionally substituted by one or two R7s: tetrahydropyrrolithyl, 2,5-dihydro-1H-pyrrolithyl, pyrrolithyl, piperidinyl, 1,2,3,6-tetrahydropyridinyl, 1,2,5,6-tetrahydropyridinyl, piperazine, 4-azaspiro[2.5]octyl, 1,2-dihydropyridinyl or 1,4-dihydropyrazine; Each R7 may be the same or different, and is independently selected from H, oxy (=O), halogen, or C1-6 alkyl; L is absent or selected from -C(Ra)(Rb)-, Ra and Rb may be the same or different, and are independently selected from H, halogen, or C1-6 alkyl, or Ra and Rb together with the carbon atoms to which they are attached form a C3-6 cycloalkyl; Cy2 is selected from the following groups that are unsubstituted or optionally substituted by one, two, three, or four R8s: C6-10 aryl, 5-9 heteroaryl, or 6-11 heterocyclic; Each R8 may be the same or different, and is independently selected from -CN, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C3-10 cycloalkyl, C6-10 aryl, or 5-10 heteroaryl.

3. The compound as claimed in claim 2, its racemic derivatives, stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein, The compound shown in formula (I') has the structure shown in formula (II): (II), wherein R5 is selected from C1-6 alkyl, C2-6 alkynyl, C1-6 haloalkyl or C3-6 cycloalkyl; m, p, X, Y, R, R1, R2, R3, R6, L, Cy1 and Cy2 have the definitions described in claim 2 independently of each other.

4. The compound as claimed in claim 3, its racemic derivatives, stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein, The compound represented by formula (I') has a structure represented by any of the following formulas (Il) to (I-u'): (Il), (Im), (In), (I-o'), (Ip), (Iq), (I-r'), (I-s'), (I-t'), or (I-u'). Wherein, R5 is selected from C1-3 alkyl, C2-3 alkynyl, C1-3 haloalkyl or C3-4 cycloalkyl; R5a is independently selected from halogen, C1-3 alkyl, -OH, -NO2, -CN, lateral oxy (=O), C1-3 haloalkyl, C1-3 alkoxy or C1-3 haloalkoxy; or R5a on the same carbon or on two adjacent carbons together with the carbon atoms to which they are attached form a C3-6 cycloalkyl, wherein the C3-6 cycloalkyl is unsubstituted or optionally substituted by one, two or three halogens; n is 0, 1, 2 or 3; m, X, R1, R2, R3, R7, L and Cy2 are independently selected from each other as defined in claim 2.

5. The compound as claimed in claim 3, its racemic derivatives, stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein, The compound represented by formula (I') has the structure shown in any of the following formulas (Iv) to (I-z'): (Iv), (Iw), (Ix), (Iy), (Iz), (I-v'), (I-w'), (I-x'), (I-y'), or (I-z'), wherein R5 is selected from methyl, ethyl, ethynyl, propynyl, -CH2F, -CHF2, -CF3, or cyclopropyl; R5a is independently selected from halogens, methyl, ethyl, -CH2F, -CHF2, -CF3, or methoxy; or R5a on the same carbon or on two adjacent carbons together with the carbon atoms to which they are attached form cyclopropyl or cyclobutyl, wherein the cyclopropyl and cyclobutyl are unsubstituted or optionally substituted by one, two, or three halogens; n is 0, 1, 2, or 3; m, X, R1, R2, R3, R7, L, and Cy2 are independently defined as described in claim 2.

6. The compound as claimed in claim 1, its racemic derivatives, stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein, Cy3 is selected from the following structures: , or.

7. The compound as claimed in claim 1, its racemate, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein, Cy3 is selected from the following structures: , , , , , , , , or.

8. The compound as claimed in claim 1, its racemate, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein, R1, R2 and R3 are independently selected from H, F, Cl, Br, -NH2, -OH, -CN, methyl, ethyl, -CH2NH2 or methoxy; and / or each R is the same or different and is independently selected from H, halogen, C1-3 alkyl or C1-3 alkoxy; p is selected from 0, 1 or 2.

9. The compound as claimed in claim 1, its racemate, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein, R6 is selected from H, methyl, or ethyl; or, R5 and R6 together with the C and N atoms to which they are attached form a 4-, 5-, or 6-membered heterocyclic alkyl group, wherein the 4-, 5-, or 6-membered heterocyclic alkyl group is unsubstituted or optionally substituted by one, two, or three R5a; R5a are independently selected from F, Cl, Br, methyl, or ethyl; or R5a on the same carbon or on two adjacent carbons together with the carbon atoms to which they are attached form a cyclopropyl or cyclobutyl group, wherein the cyclopropyl or cyclobutyl group is unsubstituted or optionally substituted by one, two, or three halogens.

10. The compound as claimed in claim 1, its racemate, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein, R5 and R6, together with the C and N atoms they are attached to, form the following structures: , , , , , , , , , or.

11. The compound as claimed in claim 1, its racemate, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein, R5 and R6, together with the C and N atoms they are attached to, form the following structures: , , , , , , , , , , , or.

12. The compound as claimed in claim 1, its racemate, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein, Ra and Rb are independently selected from H, halogens, methyl or ethyl, or Ra and Rb together with the carbon atoms to which they are attached form cyclopropyl or cyclobutyl.

13. The compound as claimed in claim 1, its racemate, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein, L does not exist, or is selected from -CH2-, -CH(CH3)-, -CF2-, or.

14. The compound as claimed in claim 1, its racemate, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein, Each R7 may be the same or different, and is independently selected from H, side oxygen (=O), F, Cl or -CH3.

15. The compound as claimed in claim 1, its racemic derivatives, stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein, Cy1 is selected from the following structures: 、 ...

16. The compound as claimed in claim 1, its racemate, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein, Cy1 is selected from the following structures: 、 ...

17. The compound as claimed in claim 1, its racemic derivatives, stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein, Cy2 is selected from the following groups that are unsubstituted or optionally substituted with one, two, three or four R8s: C6-10 aryl or 5-9 heteroaryl; each R8 may be the same or different and is independently selected from -CN, F, Br, Cl, -CH2F, -CHF2, -CF3, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, methoxy, ethoxy, phenyl, pyridyl or trifluoromethoxy.

18. The compound as claimed in claim 1, its racemate, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein, Cy2 is selected from the following groups that are unsubstituted or substituted with one, two, three or four R8s: phenyl, naphthyl, pyrrole, pyridyl or benzothiazolyl; each R8 may be the same or different and is independently selected from -CN, F, Br, Cl, -CH2F, -CHF2, -CF3, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, methoxy, ethoxy, phenyl, pyridyl or trifluoromethoxy.

19. The compound as claimed in claim 1, its racemate, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein, Cy2 is selected from the following structures: 、 ...

20. The compound as claimed in claim 1, its racemate, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein, Cy3 is selected from the following structures: or; R1, R2, and R3 are independently selected from H, F, Cl, Br, -NH2, -OH, -CN, C1-3 alkyl, or C1-3 aminoalkyl; Y is selected from -CH2-; m is selected from 1; Each R may be the same or different and is independently selected from H, halogen, or C1-3 alkyl; p is selected from 0, 1, or 2; R5 is selected from H, C1-3 alkyl, C2-3 alkynyl, C1-3 haloalkyl, or C3-4 cycloalkyl; R5' is selected from H or C1-3 alkyl; or R5 and R5' together with the carbon atoms to which they are attached form a C3-4 cycloalkyl; R6 is selected from H or C1-3 alkyl; Alternatively, R5 and R6 together with the C and N atoms to which they are attached form a 4-, 5-, or 6-membered heterocyclic alkyl group, wherein the 4-, 5-, or 6-membered heterocyclic alkyl group is unsubstituted or optionally substituted with one, two, or three R5a atoms; R5a is independently selected from F, Cl, Br, methyl, or ethyl; or R5a on the same carbon or on two adjacent carbons together with the carbon atoms to which they are attached form a cyclopropyl or cyclobutyl group, wherein the cyclopropyl or cyclobutyl group is unsubstituted or optionally substituted with one, two, or three halogen atoms; L is absent or selected from -C(Ra)(Rb)-, Ra and Rb are independently selected from H, halogens, or C1-3 alkyl groups, or Ra and Rb together with the carbon atoms to which they are attached form a cyclopropyl group; Cy1 is selected from the following groups, either unsubstituted or substituted with one or two R7s: tetrahydropyrrolyl, 2,5-dihydro-1H-pyrrolyl, pyrrolyl, piperidinyl, 1,2,3,6-tetrahydropyridinyl, 1,2,5,6-tetrahydropyridinyl, piperazine, 4-azaspiro[2.5]octyl, 1,2-dihydropyridinyl, or 1,4-dihydropyrazine; each R7 may be the same or different and is independently selected from H, side oxygen (=O), F, or Cl; Cy2 is selected from the following groups, either unsubstituted or substituted with one, two, three, or four R8s: phenyl, naphthyl, pyrrolyl, pyridinyl, or benzothiazolyl; each R8 may be the same or different and is independently selected from -CN, F, Cl, -CH2F, -CHF2, CF3, methyl, ethyl, n-propyl, isopropyl, tert-butyl, methoxy, phenyl, pyridinyl, or trifluoromethoxy.

21. The compound as claimed in claim 1, its racemic derivatives, stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein, Cy3 is selected from the following structures: or; R1 is selected from H, F, Cl, -NH2 or methyl; R2 is selected from H, F, Cl, -CN or methyl; R3 is selected from H, F, -NH2, -OH, -CH2NH2 or methoxy; Y is selected from -CH2-; m is 1; R is selected from H, methyl or ethyl; R5 is selected from H, methyl, ethyl, ethynyl, propynyl, -CH2F, -CHF2, -CF3 or cyclopropyl; R5' is selected from H, methyl or ethyl; or R5 and R5' together with the carbon atoms they are attached to form a cyclopropyl group; R6 is selected from H; or R5 and R6 together with the C and N atoms they are attached to form the following structures: , , , , , , , , , or.

22. The compound as claimed in claim 1, its racemic derivatives, stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein, The compound is selected from the structures shown below: , ...

23. The compound as claimed in claim 1, its racemate, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein, The compound is selected from the structures shown below: , ...

24. A method for preparing a compound, its racemic derivative, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 23, comprising the following steps: reacting compound I-A' with compound I-B' to generate compound I-1', and then deprotecting compound I-1' to obtain the compound represented by formula (I'); or reacting compound I-C' with compound I-D' to generate compound I-1', and then deprotecting compound I-1' to obtain the compound represented by formula (I'); wherein, R5, R5', R6, L, Cy1, Cy2, and Cy3 have the definitions as described in any one of claims 1 to 23; Cy is the group in Cy1 whose active group is protected by PG; PG is the protecting group.

25. A compound, its racemate, stereoisomer, or its hydrochloride salt as shown in formula (IC): (IC), wherein, R1, R2, R3, R5, R6, R, X, Y, m, p each have the definition as described in any one of claims 1 to 23.

26. The compound, its racemate, stereoisomer, or hydrochloride salt as claimed in claim 25, wherein, The compound represented by formula (IC) is selected from the following compounds: or.

27. A pharmaceutical composition comprising a therapeutically effective amount of at least one of the compounds, racemates, stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, as claimed in any one of claims 1 to 23.

28. Use of any one of claims 1 to 23, its racemic, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, and the pharmaceutical composition of claim 27 in the preparation of a medicament for the prevention and / or treatment of diseases associated with the complement lectin pathway.

29. The use as described in claim 28, wherein, The diseases associated with the complement lectin pathway are selected from thrombotic microangiopathy (TMA), kidney disease, acute respiratory distress syndrome due to coronavirus infection, hematologic disorders, complications of type I or type II diabetes, cardiovascular diseases or conditions, inflammatory gastrointestinal diseases, lung diseases, ophthalmic diseases or conditions, disseminated intravascular coagulation (DIC) or other complement-mediated coagulation disorders, angiogenesis-dependent cancers or tumors, peripheral and / or central nervous system diseases or injuries, sepsis or sepsis-related conditions, inflammatory responses to tissue or organ transplantation, ischemia-reperfusion injury, graft-versus-host disease, diffuse alveolar hemorrhage (DAH), venous occlusive disease (VOD), skin diseases, endocrine disorders, atherosclerosis, or autoimmune diseases; the thrombotic microangiopathy is selected from thrombotic thrombocytopenic purpura (TTP), refractory TTP, Upshaw syndrome, etc. Schulman syndrome (USS), hemolytic uremic syndrome (HUS), atypical hemolytic syndrome (aHUS), non-H factor-dependent atypical hemolytic syndrome, infection-related aHUS, plasma therapy-resistant aHUS, cancer-related TMA, chemotherapy-related TMA, transplant-related TMA, or hematopoietic stem cell transplantation-related TMA (HSCT-TMA); the kidney disease is selected from IgA nephropathy, mesangial proliferative glomerulonephritis, membranous glomerulonephritis, membranoproliferative glomerulonephritis, acute post-infectious glomerulonephritis, C3 glomerulonephropathy, cryoglobulinemia glomerulonephritis, oligoimmune necrotizing crescentic glomerulonephritis, lupus nephritis, or Henoch-Schonlein purpuric nephritis; The respiratory distress syndrome caused by coronavirus infection is selected from respiratory distress syndrome caused by influenza A virus, influenza B virus, or influenza C virus, and respiratory distress syndrome caused by SARS-CoV-2, SARS-CoV, or MERS-CoV; the hematologic disorders are selected from paroxysmal nocturnal hemoglobinuria (PNH), cold agglutinin syndrome, disseminated intravascular coagulation, or autoimmune hemolytic anemia; the inflammatory gastrointestinal disorders are selected from pancreatitis, Crohn's disease, ulcerative colitis, irritable bowel syndrome, or inflammatory bowel disease (IBD); The peripheral nervous system and / or central nervous system disorders or injuries are selected from multiple sclerosis (MS), myasthenia gravis (MG), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), Guillain-Barré syndrome, stroke reperfusion, degenerative intervertebral disc, traumatic brain injury, Parkinson's disease (PD), Alzheimer's disease (AD), Miller-Fair syndrome, traumatic brain injury and / or hemorrhage, traumatic brain injury, demyelinating or meningitis; the autoimmune diseases are selected from systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis, polymyositis or psoriasis.

30. The use as described in claim 29, wherein, The ophthalmological diseases or conditions mentioned are selected from ocular angiogenesis diseases or conditions.